Years,Event,Study,Arm,Source,Strata,Indication,ID
0.00833,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.00833,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.016666667,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.016666667,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.016666667,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.025,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.058333333,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.058333333,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.091666667,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.108333333,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.141666667,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.15,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.15,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.158333333,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.158333333,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.158333333,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.166666667,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.166666667,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.175,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.175,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.175,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.175,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.183333333,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.183333333,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.191666667,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.216666667,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.216666667,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.225,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.225,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.225,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.241666667,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.25,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.258333333,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.258333333,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.3,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.308333333,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.316666667,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.316666667,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.316666667,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.316666667,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.316666667,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.325,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.325,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.325,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.333333333,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.341666667,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.341666667,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.35,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.35,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.358333333,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.358333333,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.366666667,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.366666667,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.366666667,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.366666667,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.375,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.375,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.375,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.375,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.4,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.4,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.408333333,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.408333333,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.408333333,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.408333333,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.408333333,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.408333333,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.416666667,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.416666667,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.416666667,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.425,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.425,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.425,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.433333333,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.433333333,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.441666667,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.441666667,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.441666667,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.441666667,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.441666667,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.441666667,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.45,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.45,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.45,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.458333333,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.458333333,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.466666667,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.466666667,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.475,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.475,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.475,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.483333333,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.483333333,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.483333333,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.483333333,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.491666667,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.491666667,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.491666667,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.5,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.5,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.508333333,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.508333333,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.508333333,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.516666667,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.516666667,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.516666667,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.525,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.525,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.525,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.533333333,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.533333333,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.533333333,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.541666667,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.541666667,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.541666667,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.55,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.55,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.558333333,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.558333333,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.558333333,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.566666667,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.566666667,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.566666667,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.575,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.575,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.583333333,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.583333333,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.583333333,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.6,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.6,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.608333333,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.625,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.625,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.633333333,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.633333333,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.641666667,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.641666667,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.641666667,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.65,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.65,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.65,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.65,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.658333333,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.658333333,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.658333333,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.666666667,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.666666667,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.666666667,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.666666667,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.666666667,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.675,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.683333333,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.683333333,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.691666667,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.691666667,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.691666667,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.691666667,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.691666667,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.691666667,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.7,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.7,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.7,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.7,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.733333333,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.733333333,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.733333333,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.733333333,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.733333333,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.741666667,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.741666667,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.75,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.75,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.75,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.75,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.75,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.75,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.758333333,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.758333333,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.758333333,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.766666667,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.766666667,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.766666667,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.775,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.775,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.783333333,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.783333333,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.791666667,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.791666667,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.8,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.8,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.808333333,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.808333333,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.808333333,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.816666667,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.816666667,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.825,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.825,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.833333333,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.833333333,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.833333333,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.833333333,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.841666667,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.841666667,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.841666667,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.841666667,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.841666667,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.85,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.85,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.866666667,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.875,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.875,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.875,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.875,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.875,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.883333333,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.883333333,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.883333333,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.883333333,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.891666667,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.891666667,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.891666667,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.9,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.9,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.9,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.9,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.908333333,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.916666667,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.916666667,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.916666667,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.925,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.925,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.941666667,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.941666667,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.941666667,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.95,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.95,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.95,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.95,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.958333333,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.966666667,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.966666667,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.966666667,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.975,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.975,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.991666667,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.016666667,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.016666667,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.025,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.025,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.025,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.025,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.033333333,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.033333333,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.033333333,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.041666667,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.05,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.05,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.066666667,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.066666667,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.066666667,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.075,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.075,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.075,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.083333333,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.083333333,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.108333333,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.108333333,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.116666667,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.125,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.125,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.133333333,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.133333333,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.15,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.158333333,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.216666667,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.225,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.233333333,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.233333333,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.241666667,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.241666667,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.241666667,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.258333333,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.258333333,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.266666667,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.275,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.275,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.283333333,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.283333333,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.291666667,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.308333333,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.316666667,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.316666667,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.333333333,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.341666667,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.391666667,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.4,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.408333333,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.416666667,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.426158749,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.433333333,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.441666667,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.45,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.5,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.508333333,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.516666667,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.525,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.558333333,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.591666667,1,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.7625,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.7625,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.7625,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.7625,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.7625,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.770833334,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.770833334,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.770833334,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.770833334,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.770833334,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.779166667,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.779166667,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.779166667,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.779166667,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.779166667,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.7875,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.7875,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.7875,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.7875,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.7875,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.795833334,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.795833334,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.795833334,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.795833334,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.795833334,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.804166667,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.804166667,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.804166667,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.804166667,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.804166667,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.8125,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.8125,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.8125,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.8125,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.8125,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.820833334,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.820833334,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.820833334,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.820833334,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.820833334,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.820833334,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.829166667,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.829166667,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.829166667,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.829166667,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.829166667,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.8375,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.8375,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.8375,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.8375,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.8375,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.845833334,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.845833334,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.845833334,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.845833334,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.845833334,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.854166667,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.854166667,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.854166667,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.854166667,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.854166667,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.8625,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.8625,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.8625,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.8625,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.8625,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.870833334,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.870833334,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.870833334,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.870833334,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.870833334,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.879166667,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.879166667,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.879166667,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.879166667,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.879166667,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.879166667,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.8875,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.8875,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.8875,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.8875,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.8875,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.895833334,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.895833334,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.895833334,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.895833334,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.895833334,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.904166667,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.904166667,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.904166667,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.904166667,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.904166667,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.9125,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.9125,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.9125,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.9125,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.9125,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.920833334,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.920833334,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.920833334,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.920833334,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.920833334,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.929166667,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.929166667,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.929166667,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.929166667,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.929166667,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.9375,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.9375,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.9375,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.9375,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.9375,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.945833334,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.945833334,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.945833334,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.945833334,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.945833334,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.945833334,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.954166667,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.954166667,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.954166667,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.954166667,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.954166667,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.9625,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.9625,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.9625,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.9625,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.9625,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.970833334,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.970833334,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.970833334,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.970833334,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.970833334,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.979166667,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.979166667,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.979166667,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.979166667,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.979166667,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.9875,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.9875,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.9875,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.9875,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.9875,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.995833334,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.995833334,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.995833334,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.995833334,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.995833334,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.004166667,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.004166667,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.004166667,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.004166667,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.004166667,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.0125,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.0125,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.0125,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.0125,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.0125,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.020833334,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.020833334,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.020833334,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.020833334,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.020833334,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.029166667,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.029166667,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.029166667,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.029166667,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.029166667,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.0375,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.0375,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.0375,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.0375,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.0375,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.045833334,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.045833334,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.045833334,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.045833334,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.045833334,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.054166667,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.054166667,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.054166667,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.054166667,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.054166667,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.0625,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.0625,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.0625,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.0625,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.0625,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.070833334,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.070833334,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.070833334,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.070833334,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.070833334,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.070833334,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.079166667,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.079166667,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.079166667,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.079166667,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.079166667,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.0875,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.0875,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.0875,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.0875,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.0875,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.095833334,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.095833334,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.095833334,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.095833334,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.095833334,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.104166667,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.104166667,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.104166667,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.104166667,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.104166667,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.1125,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.1125,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.1125,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.1125,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.1125,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.120833334,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.120833334,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.120833334,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.120833334,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.120833334,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.129166667,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.129166667,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.129166667,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.129166667,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.129166667,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.129166667,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.1375,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.1375,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.1375,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.1375,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.1375,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.145833334,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.145833334,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.145833334,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.145833334,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.145833334,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.154166667,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.154166667,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.154166667,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.154166667,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.154166667,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.1625,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.1625,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.1625,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.1625,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.1625,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.170833334,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.170833334,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.170833334,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.170833334,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.170833334,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.179166667,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.179166667,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.179166667,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.179166667,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.179166667,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.1875,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.1875,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.1875,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.1875,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.1875,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.195833334,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.195833334,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.195833334,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.195833334,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.195833334,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.195833334,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.204166667,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.204166667,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.204166667,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.204166667,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.204166667,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.2125,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.2125,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.2125,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.2125,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.2125,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.220833334,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.220833334,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.220833334,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.220833334,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.220833334,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.229166667,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.229166667,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.229166667,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.229166667,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.229166667,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.2375,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.2375,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.2375,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.2375,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.2375,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.245833334,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.245833334,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.245833334,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.245833334,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.245833334,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.254166667,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.254166667,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.254166667,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.254166667,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.254166667,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.2625,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.2625,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.2625,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.270833334,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.270833334,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.270833334,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.270833334,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.279166667,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.279166667,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.279166667,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.279166667,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.2875,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.2875,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.2875,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.2875,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.295833334,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.295833334,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.295833334,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.295833334,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.304166667,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.304166667,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.304166667,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.304166667,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.3125,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.3125,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.3125,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.3125,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.320833334,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.320833334,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.320833334,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.320833334,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.329166667,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.329166667,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.329166667,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.329166667,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.3375,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.3375,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.3375,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.3375,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.345833334,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.345833334,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.345833334,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.345833334,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.354166667,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.354166667,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.354166667,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.354166667,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.3625,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.3625,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.3625,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.3625,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.370833334,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.370833334,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.370833334,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.370833334,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.379166667,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.379166667,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.379166667,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.379166667,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.3875,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.3875,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.3875,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.395833334,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.395833334,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.395833334,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.395833334,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.404166667,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.404166667,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.404166667,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.404166667,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.4125,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.4125,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.4125,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.4125,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.421412708,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.421412708,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.421412708,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.421412708,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.421412708,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.429746041,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.429746041,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.429746041,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.4375,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.4375,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.4375,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.4375,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.445833334,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.445833334,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.445833334,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.445833334,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.454166667,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.454166667,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.454166667,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.454166667,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.4625,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.4625,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.4625,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.4625,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.470833334,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.470833334,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.470833334,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.470833334,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.479166667,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.479166667,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.479166667,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.479166667,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.4875,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.4875,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.4875,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.4875,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.495833334,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.495833334,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.495833334,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.495833334,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.504166667,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.504166667,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.504166667,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.5125,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.5125,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.520833334,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.520833334,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.529166667,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.529166667,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.5375,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.5375,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.545833334,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.545833334,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.554166667,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.554166667,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.5625,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.5625,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.570833334,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.570833334,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.579166667,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.579166667,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.5875,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.5875,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.5875,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.595833334,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.595833334,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.604166667,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.604166667,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.6125,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.6125,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.620833334,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.620833334,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.629166667,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.629166667,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.6375,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.6375,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.645833334,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.645833334,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.654166667,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.654166667,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.6625,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.6625,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.670833334,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.670833334,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.670833334,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.679166667,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.679166667,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.6875,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.6875,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.695833334,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.695833334,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.704166667,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.704166667,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.7125,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.7125,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.720833334,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.720833334,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.729166667,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.729166667,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.7375,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.7375,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.745833334,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.745833334,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.779166667,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.804166667,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.8375,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.8625,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.895833334,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.920833334,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
1.954166667,0,AFFIRM,Enzalutamide,Scher 2012,AFFIRM (Scher 2012) - Enzalutamide,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Enz-Sch
0.016666667,1,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
0.016666667,1,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
0.016666667,1,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
0.058333333,1,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
0.091666667,1,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
0.15,1,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
0.15,1,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
0.158333333,1,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
0.166666667,1,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
0.175,1,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
0.175,1,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
0.183333333,1,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
0.191666667,1,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
0.208333333,1,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
0.216666667,1,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
0.225,1,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
0.233333333,1,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
0.233333333,1,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
0.233333333,1,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
0.233333333,1,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
0.241666667,1,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
0.25,1,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
0.258333333,1,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
0.258333333,1,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
0.266666667,1,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
0.275,1,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
0.283333333,1,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
0.291666667,1,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
0.3,1,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
0.3,1,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
0.3,1,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
0.308333333,1,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
0.316666667,1,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
0.316666667,1,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
0.333333333,1,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
0.341666667,1,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
0.341666667,1,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
0.35,1,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
0.35,1,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
0.35,1,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
0.35,1,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
0.35,1,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
0.358333333,1,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
0.366666667,1,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
0.375,1,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
0.383333333,1,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
0.391666667,1,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
0.391666667,1,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
0.391666667,1,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
0.391666667,1,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
0.391666667,1,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
0.4,1,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
0.408333333,1,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
0.408333333,1,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
0.408333333,1,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
0.408333333,1,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
0.408333333,1,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
0.425,1,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
0.425,1,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
0.425,1,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
0.433333333,1,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
0.433333333,1,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
0.433333333,1,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
0.441666667,1,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
0.45,1,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
0.45,1,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
0.466666667,1,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
0.466666667,1,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
0.475,1,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
0.475,1,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
0.475,1,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
0.475,1,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
0.483333333,1,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
0.483333333,1,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
0.483333333,1,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
0.491666667,1,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
0.491666667,1,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
0.5,1,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
0.5,1,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
0.5,1,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
0.5,1,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
0.5,1,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
0.508333333,1,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
0.508333333,1,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
0.508333333,1,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
0.516666667,1,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
0.516666667,1,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
0.525,1,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
0.525,1,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
0.525,1,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
0.533333333,1,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
0.533333333,1,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
0.55,1,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
0.55,1,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
0.55,1,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
0.55,1,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
0.558333333,1,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
0.566666667,1,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
0.566666667,1,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
0.566666667,1,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
0.575,1,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
0.575,1,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
0.575,1,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
0.583333333,1,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
0.591666667,1,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
0.591666667,1,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
0.6,1,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
0.6,1,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
0.608333333,1,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
0.608333333,1,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
0.608333333,1,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
0.616666667,1,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
0.616666667,1,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
0.616666667,1,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
0.633333333,1,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
0.641666667,1,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
0.65,1,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
0.65,1,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
0.658333333,1,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
0.666666667,1,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
0.666666667,1,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
0.675,1,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
0.683333333,1,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
0.691666667,1,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
0.691666667,1,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
0.7,1,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
0.7,1,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
0.7,1,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
0.708333333,1,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
0.708333333,1,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
0.716666667,1,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
0.725,1,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
0.733333333,1,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
0.733333333,1,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
0.741666667,1,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
0.75,1,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
0.758333333,1,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
0.758333333,1,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
0.766666667,1,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
0.766666667,1,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
0.775,1,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
0.783333333,1,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
0.783333333,1,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
0.783333333,1,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
0.783333333,1,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
0.791666667,1,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
0.791666667,1,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
0.8,1,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
0.8,1,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
0.808333333,1,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
0.808333333,1,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
0.808333333,1,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
0.816666667,1,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
0.816666667,1,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
0.833333333,1,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
0.833333333,1,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
0.841666667,1,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
0.85,1,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
0.85,1,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
0.858333333,1,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
0.858333333,1,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
0.866666667,1,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
0.866666667,1,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
0.866666667,1,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
0.875,1,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
0.875,1,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
0.883333333,1,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
0.883333333,1,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
0.891666667,1,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
0.9,1,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
0.9,1,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
0.908333333,1,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
0.908333333,1,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
0.908333333,1,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
0.925,1,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
0.933333333,1,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
0.941666667,1,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
0.941666667,1,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
0.966666667,1,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
0.983333333,1,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
1.008333333,1,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
1.008333333,1,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
1.016666667,1,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
1.025,1,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
1.033333333,1,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
1.075,1,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
1.091666667,1,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
1.1,1,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
1.116666667,1,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
1.116666667,1,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
1.133333333,1,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
1.133333333,1,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
1.15,1,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
1.166666667,1,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
1.175,1,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
1.191666667,1,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
1.2,1,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
1.216666667,1,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
1.225,1,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
1.233333333,1,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
1.283333333,1,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
1.308333333,1,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
1.333333333,1,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
1.333333333,1,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
1.341666667,1,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
1.366666667,1,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
1.458333333,1,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
1.475,1,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
1.55,1,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
1.575,1,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
1.583333333,1,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
1.6,1,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
1.608333333,1,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
0.079166667,0,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
0.1625,0,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
0.7625,0,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
0.770833334,0,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
0.770833334,0,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
0.779166667,0,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
0.779166667,0,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
0.7875,0,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
0.795833334,0,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
0.795833334,0,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
0.804166667,0,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
0.804166667,0,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
0.8125,0,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
0.820833334,0,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
0.820833334,0,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
0.829166667,0,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
0.829166667,0,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
0.8375,0,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
0.8375,0,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
0.845833334,0,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
0.854166667,0,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
0.854166667,0,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
0.8625,0,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
0.8625,0,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
0.870833334,0,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
0.879166667,0,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
0.879166667,0,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
0.8875,0,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
0.8875,0,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
0.895833334,0,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
0.904166667,0,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
0.904166667,0,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
0.9125,0,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
0.9125,0,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
0.920833334,0,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
0.920833334,0,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
0.929166667,0,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
0.9375,0,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
0.9375,0,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
0.945833334,0,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
0.945833334,0,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
0.954166667,0,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
0.9625,0,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
0.9625,0,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
0.970833334,0,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
0.970833334,0,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
0.979166667,0,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
0.9875,0,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
0.9875,0,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
0.995833334,0,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
0.995833334,0,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
1.004166667,0,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
1.0125,0,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
1.0125,0,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
1.020833334,0,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
1.020833334,0,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
1.029166667,0,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
1.029166667,0,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
1.0375,0,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
1.0375,0,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
1.045833334,0,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
1.045833334,0,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
1.045833334,0,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
1.054166667,0,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
1.054166667,0,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
1.0625,0,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
1.0625,0,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
1.070833334,0,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
1.070833334,0,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
1.079166667,0,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
1.079166667,0,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
1.079166667,0,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
1.0875,0,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
1.0875,0,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
1.095833334,0,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
1.095833334,0,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
1.104166667,0,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
1.104166667,0,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
1.1125,0,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
1.1125,0,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
1.1125,0,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
1.120833334,0,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
1.120833334,0,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
1.129166667,0,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
1.129166667,0,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
1.1375,0,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
1.1375,0,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
1.145833334,0,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
1.145833334,0,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
1.154166667,0,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
1.154166667,0,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
1.154166667,0,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
1.1625,0,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
1.1625,0,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
1.170833334,0,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
1.170833334,0,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
1.180325415,0,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
1.180325415,0,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
1.180325415,0,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
1.188658749,0,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
1.188658749,0,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
1.195833334,0,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
1.195833334,0,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
1.204166667,0,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
1.204166667,0,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
1.2125,0,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
1.2125,0,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
1.220833334,0,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
1.220833334,0,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
1.220833334,0,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
1.229166667,0,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
1.229166667,0,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
1.2375,0,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
1.2375,0,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
1.245833334,0,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
1.245833334,0,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
1.254166667,0,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
1.254166667,0,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
1.2625,0,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
1.270833334,0,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
1.279166667,0,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
1.279166667,0,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
1.2875,0,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
1.295833334,0,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
1.304166667,0,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
1.304166667,0,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
1.3125,0,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
1.320833334,0,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
1.329166667,0,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
1.329166667,0,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
1.3375,0,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
1.345833334,0,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
1.345833334,0,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
1.354166667,0,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
1.3625,0,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
1.370833334,0,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
1.370833334,0,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
1.379166667,0,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
1.3875,0,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
1.395833334,0,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
1.395833334,0,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
1.404166667,0,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
1.4125,0,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
1.420833334,0,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
1.420833334,0,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
1.429166667,0,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
1.4375,0,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
1.4375,0,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
1.445833334,0,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
1.454166667,0,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
1.4625,0,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
1.4625,0,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
1.470833334,0,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
1.479166667,0,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
1.4875,0,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
1.4875,0,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
1.495833334,0,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
1.504166667,0,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
1.520833334,0,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
1.529166667,0,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
1.5375,0,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
1.545833334,0,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
1.554166667,0,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
1.5625,0,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
1.570833334,0,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
1.579166667,0,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
1.595833334,0,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
1.604166667,0,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
1.6125,0,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
1.620833334,0,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
1.645833334,0,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
1.645833334,0,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
1.645833334,0,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
1.645833334,0,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
1.645833334,0,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
1.708333334,0,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
1.708333334,0,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
1.708333334,0,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
1.708333334,0,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
1.708333334,0,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
1.708333334,0,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
1.708333334,0,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
1.708333334,0,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
1.791666667,0,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
1.875,0,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
1.945833334,0,AFFIRM,Placebo,Scher 2012,AFFIRM (Scher 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,AFF-Pla-Sch
0.048875856,1,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
0.074939515,1,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
0.075,1,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
0.1,1,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
0.108333333,1,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
0.108333333,1,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
0.116666667,1,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
0.125,1,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
0.141666667,1,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
0.158333333,1,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
0.175,1,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
0.175,1,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
0.183333333,1,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
0.2,1,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
0.216666667,1,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
0.225,1,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
0.225,1,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
0.233333333,1,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
0.241666667,1,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
0.241666667,1,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
0.258333333,1,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
0.258333333,1,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
0.258333333,1,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
0.266666667,1,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
0.282406245,1,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
0.282406245,1,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
0.282406245,1,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
0.283333333,1,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
0.294916802,1,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
0.294916802,1,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
0.3,1,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
0.319937915,1,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
0.321358125,1,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
0.321358125,1,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
0.325,1,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
0.333333333,1,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
0.333333333,1,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
0.335576111,1,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
0.335576111,1,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
0.340788843,1,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
0.341666667,1,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
0.341666667,1,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
0.35,1,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
0.358333333,1,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
0.358333333,1,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
0.358333333,1,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
0.375,1,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
0.375,1,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
0.375,1,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
0.383333333,1,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
0.383333333,1,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
0.391666667,1,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
0.391666667,1,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
0.4,1,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
0.4,1,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
0.4,1,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
0.408333333,1,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
0.416666667,1,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
0.416666667,1,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
0.416666667,1,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
0.416666667,1,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
0.425,1,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
0.441666667,1,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
0.441666667,1,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
0.441666667,1,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
0.475,1,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
0.475,1,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
0.491666667,1,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
0.491666667,1,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
0.491666667,1,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
0.491666667,1,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
0.491666667,1,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
0.491666667,1,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
0.508333333,1,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
0.508333333,1,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
0.508333333,1,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
0.525,1,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
0.525,1,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
0.533333333,1,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
0.533333333,1,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
0.533333333,1,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
0.541666667,1,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
0.541666667,1,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
0.55,1,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
0.558333333,1,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
0.558333333,1,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
0.566666667,1,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
0.566666667,1,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
0.566666667,1,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
0.583333333,1,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
0.583333333,1,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
0.583333333,1,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
0.591666667,1,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
0.591666667,1,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
0.608333333,1,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
0.608333333,1,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
0.616666667,1,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
0.616666667,1,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
0.633333333,1,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
0.641666667,1,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
0.641666667,1,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
0.658333333,1,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
0.658333333,1,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
0.658333333,1,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
0.675,1,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
0.683333333,1,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
0.691666667,1,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
0.691666667,1,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
0.7,1,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
0.716666667,1,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
0.716666667,1,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
0.716666667,1,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
0.725,1,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
0.741666667,1,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
0.741666667,1,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
0.75,1,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
0.75,1,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
0.75,1,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
0.766666667,1,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
0.775,1,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
0.775,1,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
0.791666667,1,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
0.791666667,1,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
0.808333333,1,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
0.808333333,1,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
0.816666667,1,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
0.825,1,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
0.841666667,1,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
0.85,1,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
0.858333333,1,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
0.866666667,1,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
0.875,1,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
0.883333333,1,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
0.883333333,1,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
0.891666667,1,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
0.9,1,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
0.908333333,1,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
0.908333333,1,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
0.916666667,1,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
0.925,1,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
0.925,1,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
0.941666667,1,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
0.95,1,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
0.958333333,1,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
0.958333333,1,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
0.966666667,1,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
0.983333333,1,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
0.983333333,1,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
1,1,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
1.025,1,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
1.025,1,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
1.041666667,1,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
1.058333333,1,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
1.064316033,1,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
1.066666667,1,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
1.066666667,1,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
1.069528765,1,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
1.075,1,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
1.075,1,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
1.083333333,1,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
1.1,1,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
1.116666667,1,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
1.133333333,1,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
1.141666667,1,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
1.158333333,1,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
1.166666667,1,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
1.175,1,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
1.2,1,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
1.225,1,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
1.317654804,1,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
1.317654804,1,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
1.317654804,1,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
1.317654804,1,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
1.339548278,1,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
1.339548278,1,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
1.339548278,1,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
1.366666667,1,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
1.375,1,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
1.417739257,1,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
1.427122174,1,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
1.433333333,1,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
1.491666667,1,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
1.508333333,1,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
1.525,1,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
1.566666667,1,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
1.583333333,1,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
1.6,1,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
1.65,1,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
1.775,1,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
1.8,1,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
1.957778283,1,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
1.957778283,1,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
1.957778283,1,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
1.975,1,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
2.043267087,1,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
2.043267087,1,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
2.415456146,1,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
0.2875,0,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
0.323179063,0,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
0.3625,0,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
0.395833334,0,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
0.4375,0,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
0.470833334,0,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
0.520833334,0,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
0.529166667,0,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
0.5375,0,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
0.545833334,0,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
0.554166667,0,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
0.5625,0,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
0.570833334,0,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
0.579166667,0,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
0.5875,0,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
0.604166667,0,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
0.6125,0,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
0.620833334,0,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
0.629166667,0,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
0.6375,0,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
0.645833334,0,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
0.654166667,0,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
0.6625,0,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
0.670833334,0,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
0.6875,0,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
0.695833334,0,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
0.704166667,0,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
0.7125,0,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
0.720833334,0,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
0.729166667,0,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
0.7375,0,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
0.745833334,0,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
0.770833334,0,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
0.779166667,0,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
0.7875,0,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
0.795833334,0,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
0.8125,0,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
0.820833334,0,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
0.829166667,0,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
0.8375,0,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
0.854166667,0,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
0.8625,0,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
0.870833334,0,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
0.879166667,0,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
0.895833334,0,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
0.904166667,0,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
0.9125,0,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
0.920833334,0,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
0.9375,0,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
0.945833334,0,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
0.954166667,0,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
0.9625,0,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
0.979166667,0,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
0.9875,0,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
0.995833334,0,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
1.020833334,0,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
1.0375,0,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
1.054166667,0,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
1.068097716,0,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
1.079166667,0,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
1.095833334,0,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
1.1125,0,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
1.129166667,0,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
1.1375,0,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
1.154166667,0,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
1.170833334,0,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
1.1875,0,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
1.195833334,0,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
1.2125,0,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
1.229166667,0,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
1.245833334,0,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
1.270833334,0,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
1.2875,0,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
1.304135944,0,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
1.322346263,0,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
1.336420639,0,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
1.355720876,0,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
1.370833334,0,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
1.379166667,0,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
1.395833334,0,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
1.413036295,0,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
1.430227754,0,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
1.445833334,0,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
1.4625,0,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
1.479166667,0,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
1.495833334,0,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
1.529166667,0,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
1.554166667,0,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
1.579166667,0,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
1.604166667,0,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
1.629166667,0,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
1.654166667,0,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
1.679166667,0,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
1.704166667,0,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
1.729166667,0,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
1.795833334,0,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
1.845833334,0,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
1.895833334,0,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
1.952044278,0,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
2.037533082,0,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
2.079166667,0,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
2.120833334,0,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
2.1625,0,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
2.204166667,0,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
2.329166667,0,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
2.419105058,0,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
2.579166667,0,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
2.6625,0,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
2.870833334,0,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
3.020833334,0,ALSYMPCA,Placebo,Parker 2013,ALSYMPCA (Parker 2013) - Placebo,hormone-relapsed prostate cancer with bone metastases,ALS-Pla-Par
0.041666667,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.058333333,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.091666667,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.1,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.1,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.116666667,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.125,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.125,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.133333333,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.15,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.15,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.15,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.166666667,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.166666667,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.175,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.191666667,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.191666667,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.191666667,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.191666667,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.216666667,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.216666667,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.225,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.225,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.225,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.233333333,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.233333333,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.241666667,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.241666667,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.25,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.258333333,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.258333333,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.258333333,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.258333333,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.266666667,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.291666667,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.291666667,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.291666667,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.291666667,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.291666667,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.316666667,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.316666667,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.325,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.325,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.325,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.325,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.333333333,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.341666667,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.341666667,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.35,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.35,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.35,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.35,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.366666667,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.366666667,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.366666667,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.366666667,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.375,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.391666667,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.391666667,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.4,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.4,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.4,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.4,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.416666667,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.416666667,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.416666667,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.425,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.425,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.425,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.441666667,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.441666667,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.45,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.45,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.45,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.45,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.45,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.466666667,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.466666667,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.466666667,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.466666667,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.466666667,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.466666667,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.475,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.475,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.475,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.483333333,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.483333333,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.483333333,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.491666667,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.491666667,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.491666667,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.491666667,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.491666667,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.491666667,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.508333333,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.508333333,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.508333333,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.508333333,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.508333333,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.516666667,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.516666667,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.516666667,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.525,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.525,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.533333333,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.541666667,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.541666667,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.541666667,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.541666667,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.541666667,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.541666667,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.558333333,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.566666667,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.566666667,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.575,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.591666667,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.591666667,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.591666667,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.591666667,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.591666667,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.608333333,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.608333333,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.608333333,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.616666667,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.616666667,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.616666667,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.616666667,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.616666667,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.616666667,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.616666667,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.616666667,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.616666667,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.625,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.633333333,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.633333333,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.633333333,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.641666667,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.641666667,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.641666667,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.641666667,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.65,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.65,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.65,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.65,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.65,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.666666667,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.666666667,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.666666667,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.666666667,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.666666667,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.675,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.675,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.675,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.683333333,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.683333333,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.683333333,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.683333333,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.691666667,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.691666667,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.7,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.7,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.7,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.716666667,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.716666667,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.716666667,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.733333333,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.75,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.75,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.75,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.75,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.75,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.758333333,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.758333333,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.758333333,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.775,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.775,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.775,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.775,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.775,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.775,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.783333333,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.783333333,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.791666667,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.791666667,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.791666667,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.791666667,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.791666667,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.808333333,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.816666667,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.825,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.825,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.825,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.841666667,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.841666667,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.841666667,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.85,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.85,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.85,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.866666667,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.866666667,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.875,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.875,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.875,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.891666667,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.891666667,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.9,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.933333333,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.933333333,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.95,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.95,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.95,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.95,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.95,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.966666667,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.966666667,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.966666667,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.966666667,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.975,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.975,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.975,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.983333333,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.991666667,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.991666667,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.991666667,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
1,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
1,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
1.025,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
1.025,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
1.033333333,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
1.033333333,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
1.041666667,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
1.05,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
1.05,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
1.058333333,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
1.058333333,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
1.075,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
1.075,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
1.083333333,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
1.091666667,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
1.108333333,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
1.116666667,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
1.116666667,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
1.133333333,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
1.133333333,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
1.141666667,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
1.141666667,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
1.158333333,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
1.158333333,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
1.158333333,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
1.158333333,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
1.166666667,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
1.166666667,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
1.166666667,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
1.166666667,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
1.175,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
1.183333333,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
1.183333333,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
1.191666667,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
1.2,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
1.2,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
1.216666667,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
1.216666667,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
1.225,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
1.225,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
1.233333333,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
1.241666667,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
1.241666667,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
1.25,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
1.25,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
1.266666667,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
1.283333333,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
1.283333333,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
1.283333333,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
1.283333333,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
1.3,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
1.3,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
1.308333333,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
1.308333333,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
1.325,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
1.325,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
1.333333333,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
1.333333333,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
1.333333333,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
1.35,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
1.35,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
1.35,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
1.366666667,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
1.366666667,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
1.383333333,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
1.391666667,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
1.4,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
1.416666667,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
1.425,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
1.433333333,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
1.45,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
1.45,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
1.45,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
1.466666667,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
1.483333333,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
1.483333333,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
1.483333333,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
1.5,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
1.508333333,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
1.508333333,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
1.541666667,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
1.558333333,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
1.6,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
1.608333333,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
1.616666667,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
1.625,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
1.633333333,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
1.716666667,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
1.733333333,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
1.8,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
1.825,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
1.916666667,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
1.933333333,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
1.983333333,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
2.008333333,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
2.017954061,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
2.025,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
2.033333333,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
2.05,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
2.083333333,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
2.236388379,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
2.243894713,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
2.279925116,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
2.284428916,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
2.353487189,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
2.353487189,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
2.425547995,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
2.514122735,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
2.710788685,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
2.710788685,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
2.814376094,1,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.029166667,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.054166667,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.079166667,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.1125,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.1375,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.1625,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.195833334,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.220833334,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.279166667,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.304166667,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.3375,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.3625,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.395833334,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.420833334,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.454166667,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.479166667,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.5125,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.520833334,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.520833334,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.529166667,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.529166667,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.5375,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.5375,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.545833334,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.545833334,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.554166667,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.554166667,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.5625,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.5625,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.570833334,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.570833334,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.579166667,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.579166667,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.5875,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.5875,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.595833334,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.595833334,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.604166667,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.604166667,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.6125,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.6125,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.620833334,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.620833334,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.629166667,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.629166667,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.6375,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.6375,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.645833334,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.645833334,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.654166667,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.654166667,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.6625,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.6625,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.670833334,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.670833334,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.679166667,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.679166667,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.6875,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.6875,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.695833334,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.695833334,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.704166667,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.704166667,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.7125,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.7125,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.720833334,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.720833334,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.729166667,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.729166667,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.7375,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.7375,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.745833334,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.745833334,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.754166667,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.7625,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.770833334,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.779166667,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.779166667,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.7875,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.795833334,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.804166667,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.804166667,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.8125,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.820833334,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.829166667,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.829166667,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.8375,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.845833334,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.845833334,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.854166667,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.8625,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.870833334,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.870833334,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.879166667,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.8875,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.895833334,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.895833334,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.904166667,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.9125,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.920833334,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.920833334,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.929166667,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.9375,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.9375,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.945833334,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.954166667,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.9625,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.9625,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.970833334,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.979166667,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.9875,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.9875,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.995833334,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
1.004166667,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
1.0125,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
1.020833334,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
1.020833334,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
1.029166667,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
1.029166667,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
1.0375,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
1.0375,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
1.045833334,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
1.045833334,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
1.054166667,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
1.0625,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
1.0625,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
1.070833334,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
1.070833334,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
1.079166667,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
1.079166667,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
1.0875,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
1.0875,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
1.095833334,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
1.104166667,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
1.104166667,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
1.1125,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
1.1125,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
1.120833334,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
1.120833334,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
1.129166667,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
1.129166667,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
1.1375,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
1.145833334,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
1.145833334,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
1.154166667,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
1.154166667,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
1.1625,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
1.1625,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
1.170833334,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
1.170833334,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
1.179166667,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
1.1875,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
1.1875,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
1.195833334,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
1.195833334,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
1.204166667,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
1.204166667,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
1.2125,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
1.2125,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
1.220833334,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
1.229166667,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
1.229166667,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
1.2375,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
1.2375,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
1.245833334,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
1.245833334,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
1.254166667,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
1.2625,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
1.270833334,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
1.279166667,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
1.279166667,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
1.2875,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
1.295833334,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
1.304166667,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
1.304166667,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
1.3125,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
1.320833334,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
1.329166667,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
1.329166667,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
1.3375,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
1.345833334,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
1.345833334,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
1.354166667,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
1.3625,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
1.370833334,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
1.370833334,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
1.379166667,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
1.3875,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
1.395833334,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
1.395833334,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
1.404166667,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
1.4125,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
1.420833334,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
1.420833334,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
1.429166667,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
1.4375,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
1.4375,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
1.445833334,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
1.454166667,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
1.4625,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
1.4625,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
1.470833334,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
1.479166667,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
1.4875,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
1.4875,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
1.495833334,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
1.504166667,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
1.5125,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
1.520833334,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
1.529166667,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
1.5375,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
1.545833334,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
1.545833334,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
1.554166667,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
1.5625,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
1.570833334,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
1.579166667,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
1.5875,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
1.5875,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
1.595833334,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
1.604166667,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
1.6125,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
1.620833334,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
1.629166667,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
1.629166667,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
1.6375,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
1.645833334,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
1.654166667,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
1.6625,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
1.670833334,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
1.670833334,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
1.679166667,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
1.6875,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
1.695833334,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
1.704166667,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
1.7125,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
1.7125,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
1.720833334,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
1.729166667,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
1.7375,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
1.745833334,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
1.7625,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
1.779166667,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
1.795833334,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
1.8125,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
1.829166667,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
1.845833334,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
1.8625,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
1.879166667,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
1.895833334,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
1.9125,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
1.929166667,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
1.945833334,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
1.9625,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
1.979166667,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
2.013143697,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
2.029166667,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
2.045833334,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
2.0625,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
2.079166667,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
2.095833334,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
2.1125,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
2.129166667,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
2.145833334,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
2.154166667,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
2.170833334,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
2.1875,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
2.204166667,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
2.222774356,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
2.240141546,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
2.28743145,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
2.320833334,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
2.360242889,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
2.395833334,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
2.427799895,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
2.4625,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
2.61245571,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
2.61245571,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
2.76258239,0,ALSYMPCA,Radium-223,Parker 2013,ALSYMPCA (Parker 2013) - Radium-223,hormone-relapsed prostate cancer with bone metastases,ALS-Rad-Par
0.058333333,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.058333333,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.058333333,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.083333333,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.083333333,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.083333333,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.091666667,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.091666667,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.091666667,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.1,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.1,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.1,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.1,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.1,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.1,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.108333333,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.108333333,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.116666667,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.141672357,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.149997724,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.158345851,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.158345851,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.166673495,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.166673495,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.166673495,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.166673495,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.175007966,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.175007966,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.175007966,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.175007966,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.175007966,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.183333333,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.183333333,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.191666667,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.191666667,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.208333333,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.208333333,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.216666667,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.216666667,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.216666667,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.216666667,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.225,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.225,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.233333333,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.233333333,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.233333333,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.233333333,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.241666667,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.241666667,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.25,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.25,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.258333333,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.258333333,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.258333333,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.266666667,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.275,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.275,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.275,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.283333333,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.283333333,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.291666667,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.291666667,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.291666667,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.291666667,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.3,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.308333333,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.316666667,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.325,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.325,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.333333333,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.333333333,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.341666667,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.35,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.35,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.35,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.358333333,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.358333333,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.366666667,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.366666667,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.366666667,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.375,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.383333333,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.383333333,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.391666667,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.391666667,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.391666667,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.4,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.4,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.4,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.4,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.408333333,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.408333333,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.408333333,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.408333333,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.416666667,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.416666667,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.425,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.425,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.425,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.425,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.433333333,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.433333333,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.433333333,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.433333333,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.441666667,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.441666667,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.45,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.45,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.458333333,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.458333333,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.458333333,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.458333333,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.466666667,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.466666667,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.466666667,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.475,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.475,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.483333333,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.483333333,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.491666667,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.491666667,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.491666667,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.491666667,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.5,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.5,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.508333333,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.508333333,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.508333333,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.508333333,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.508333333,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.516666667,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.516666667,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.516666667,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.516666667,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.525,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.525,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.525,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.525,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.533333333,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.533333333,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.533333333,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.533333333,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.541666667,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.541666667,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.541666667,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.55,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.55,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.55,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.558333333,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.558333333,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.558333333,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.558333333,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.566666667,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.566666667,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.566666667,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.575,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.575,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.575,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.575,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.591666667,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.591666667,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.591666667,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.6,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.6,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.608333333,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.616666667,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.616666667,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.616666667,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.616666667,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.616666667,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.616666667,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.625,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.625,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.625,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.633333333,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.633333333,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.633333333,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.633333333,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.633333333,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.633333333,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.633333333,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.633333333,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.641666667,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.641666667,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.658333333,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.658333333,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.658333333,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.658333333,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.658333333,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.666666667,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.675,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.683333333,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.683333333,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.691666667,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.7,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.7,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.7,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.708333333,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.708333333,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.708333333,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.708333333,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.716666667,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.716666667,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.716666667,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.716666667,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.716666667,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.716666667,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.725,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.725,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.733333333,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.733333333,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.733333333,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.733333333,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.741666667,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.741666667,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.75,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.758333333,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.758333333,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.766666667,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.766666667,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.766666667,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.775,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.775,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.775,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.783333333,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.783333333,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.783333333,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.791666667,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.8,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.808333333,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.825,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.825,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.825,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.833333333,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.833333333,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.833333333,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.833333333,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.833333333,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.833333333,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.841666667,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.85,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.85,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.85,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.85,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.85,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.85,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.875,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.875,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.875,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.875,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.883333333,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.891666667,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.891666667,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.9,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.9,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.908333333,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.908333333,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.908333333,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.916666667,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.916666667,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.916666667,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.925,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.925,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.933333333,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.933333333,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.933333333,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.933333333,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.941666667,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.941666667,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.941666667,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.941666667,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.941666667,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.95,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.958333333,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.958333333,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.966666667,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.966666667,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.966666667,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.975,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.975,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.983333333,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.983333333,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.991666667,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.991666667,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.991666667,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.991666667,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.991666667,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.025,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.033333333,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.033333333,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.05,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.058333333,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.058333333,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.075,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.075,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.108333333,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.108333333,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.116666667,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.133333333,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.141666667,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.15,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.158333333,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.158333333,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.175,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.183333333,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.183333333,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.183333333,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.191666667,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.191666667,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.2,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.2,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.2,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.225,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.233333333,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.241666667,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.258333333,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.266666667,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.275,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.281171926,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.283333333,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.28785188,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.28785188,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.291666667,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.341666667,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.341666667,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.345923098,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.35,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.358333333,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.412932027,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.412932027,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.631736365,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.631736365,1,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.020836748,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.037503414,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.054168374,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.079166667,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.095833334,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.1125,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.137503983,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.154171788,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.170840731,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.195833334,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.2125,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.229166667,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.3125,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.379166667,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.445833334,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.5125,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.520833334,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.520833334,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.529166667,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.5375,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.5375,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.545833334,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.554166667,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.554166667,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.5625,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.570833334,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.570833334,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.579166667,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.579166667,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.5875,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.595833334,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.595833334,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.604166667,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.6125,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.6125,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.620833334,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.629166667,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.629166667,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.6375,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.6375,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.645833334,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.654166667,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.654166667,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.6625,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.670833334,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.670833334,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.679166667,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.6875,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.6875,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.695833334,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.695833334,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.704166667,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.7125,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.7125,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.720833334,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.729166667,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.729166667,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.7375,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.745833334,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.745833334,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.754166667,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.7625,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.7625,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.7625,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.7625,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.7625,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.770833334,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.770833334,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.770833334,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.770833334,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.770833334,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.770833334,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.779166667,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.779166667,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.779166667,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.779166667,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.779166667,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.7875,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.7875,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.7875,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.7875,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.7875,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.7875,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.795833334,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.795833334,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.795833334,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.795833334,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.795833334,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.804166667,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.804166667,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.804166667,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.804166667,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.804166667,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.804166667,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.8125,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.8125,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.8125,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.8125,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.8125,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.820833334,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.820833334,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.820833334,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.820833334,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.820833334,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.820833334,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.829166667,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.829166667,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.829166667,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.829166667,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.829166667,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.8375,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.8375,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.8375,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.8375,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.8375,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.8375,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.845833334,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.845833334,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.845833334,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.845833334,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.845833334,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.854166667,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.854166667,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.854166667,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.854166667,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.854166667,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.854166667,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.8625,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.8625,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.8625,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.8625,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.8625,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.870833334,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.870833334,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.870833334,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.870833334,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.870833334,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.870833334,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.879166667,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.879166667,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.879166667,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.879166667,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.879166667,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.879166667,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.8875,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.8875,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.8875,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.8875,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.8875,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.895833334,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.895833334,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.895833334,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.895833334,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.895833334,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.895833334,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.904166667,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.904166667,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.904166667,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.904166667,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.904166667,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.9125,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.9125,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.9125,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.9125,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.9125,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.9125,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.920833334,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.920833334,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.920833334,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.920833334,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.920833334,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.929166667,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.929166667,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.929166667,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.929166667,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.929166667,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.929166667,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.9375,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.9375,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.9375,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.9375,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.9375,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.945833334,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.945833334,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.945833334,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.945833334,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.945833334,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.945833334,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.954166667,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.954166667,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.954166667,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.954166667,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.954166667,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.9625,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.9625,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.9625,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.9625,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.9625,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.9625,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.970833334,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.970833334,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.970833334,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.970833334,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.970833334,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.979166667,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.979166667,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.979166667,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.979166667,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.979166667,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.979166667,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.9875,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.9875,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.9875,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.9875,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.9875,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.995833334,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.995833334,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.995833334,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.995833334,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.995833334,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.995833334,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.004166667,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.004166667,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.004166667,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.004166667,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.004166667,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.0125,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.0125,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.0125,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.0125,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.0125,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.0125,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.020833334,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.020833334,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.020833334,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.020833334,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.020833334,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.020833334,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.029166667,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.029166667,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.029166667,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.029166667,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.029166667,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.029166667,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.0375,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.0375,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.0375,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.0375,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.0375,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.0375,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.045833334,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.045833334,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.045833334,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.045833334,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.045833334,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.045833334,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.045833334,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.054166667,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.054166667,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.054166667,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.054166667,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.054166667,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.054166667,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.0625,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.0625,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.0625,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.0625,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.0625,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.0625,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.070833334,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.070833334,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.070833334,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.070833334,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.070833334,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.070833334,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.079166667,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.079166667,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.079166667,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.079166667,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.079166667,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.079166667,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.079166667,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.0875,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.0875,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.0875,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.0875,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.0875,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.0875,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.095833334,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.095833334,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.095833334,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.095833334,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.095833334,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.095833334,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.104166667,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.104166667,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.104166667,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.104166667,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.104166667,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.104166667,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.1125,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.1125,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.1125,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.1125,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.1125,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.1125,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.1125,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.120833334,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.120833334,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.120833334,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.120833334,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.120833334,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.120833334,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.129166667,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.129166667,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.129166667,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.129166667,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.129166667,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.129166667,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.1375,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.1375,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.1375,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.1375,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.1375,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.1375,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.145833334,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.145833334,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.145833334,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.145833334,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.145833334,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.145833334,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.154166667,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.154166667,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.154166667,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.154166667,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.154166667,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.154166667,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.154166667,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.1625,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.1625,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.1625,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.1625,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.1625,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.1625,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.170833334,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.170833334,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.170833334,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.170833334,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.170833334,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.170833334,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.179166667,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.179166667,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.179166667,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.179166667,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.179166667,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.179166667,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.1875,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.1875,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.1875,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.1875,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.1875,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.1875,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.1875,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.195833334,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.195833334,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.195833334,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.195833334,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.195833334,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.195833334,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.204166667,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.204166667,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.204166667,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.204166667,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.204166667,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.204166667,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.2125,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.2125,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.2125,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.2125,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.2125,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.2125,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.220833334,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.220833334,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.220833334,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.220833334,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.220833334,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.220833334,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.220833334,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.229166667,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.229166667,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.229166667,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.229166667,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.229166667,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.229166667,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.2375,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.2375,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.2375,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.2375,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.2375,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.2375,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.245833334,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.245833334,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.245833334,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.245833334,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.245833334,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.245833334,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.254166667,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.254166667,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.254166667,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.254166667,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.254166667,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.254166667,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.2625,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.270833334,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.278085963,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.285592607,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.295833334,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.304166667,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.3125,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.3125,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.320833334,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.329166667,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.3375,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.343794883,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.354166667,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.3625,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.3625,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.370833334,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.379166667,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.3875,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.395833334,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.404166667,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.41063268,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.522339886,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.522339886,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.522339886,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.522339886,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.522339886,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.522339886,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.522339886,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.522339886,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.522339886,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.522339886,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.522339886,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.522339886,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.522339886,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.522339886,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.522339886,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.522339886,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.522339886,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.522339886,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.522339886,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.522339886,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.522339886,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.522339886,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.522339886,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.522339886,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.522339886,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.522339886,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.522339886,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.522339886,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.522339886,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
1.522339886,0,COU-AA-301,Abiraterone acetate,de Bono 2011,COU-AA-301 (de Bono 2011) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-de 
0.05,1,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.058333333,1,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.083333333,1,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.091666667,1,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.091666667,1,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.1,1,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.1,1,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.108333333,1,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.108333333,1,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.125,1,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.125,1,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.133333333,1,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.133333333,1,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.141666667,1,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.15,1,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.158333333,1,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.158333333,1,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.166666667,1,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.166666667,1,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.166666667,1,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.175,1,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.183333333,1,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.183333333,1,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.183333333,1,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.191666667,1,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.191666667,1,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.191666667,1,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.2,1,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.2,1,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.2,1,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.216666667,1,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.216666667,1,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.216666667,1,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.233333333,1,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.233333333,1,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.241666667,1,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.241666667,1,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.25,1,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.258333333,1,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.266666667,1,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.266666667,1,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.275,1,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.283333333,1,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.283333333,1,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.283333333,1,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.291666667,1,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.291666667,1,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.291666667,1,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.3,1,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.3,1,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.308333333,1,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.316666667,1,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.316666667,1,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.316666667,1,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.325,1,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.325,1,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.325,1,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.325,1,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.333333333,1,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.333333333,1,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.341666667,1,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.341666667,1,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.341666667,1,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.35,1,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.35,1,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.35,1,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.358333333,1,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.358333333,1,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.366666667,1,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.375,1,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.375,1,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.408333333,1,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.416666667,1,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.425,1,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.425,1,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.425,1,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.433333333,1,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.441666667,1,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.45,1,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.458333333,1,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.466666667,1,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.466666667,1,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.475,1,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.483333333,1,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.491666667,1,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.5,1,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.5,1,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.508333333,1,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.508333333,1,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.516666667,1,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.516666667,1,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.525,1,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.525,1,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.533333333,1,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.541666667,1,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.55,1,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.55,1,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.558333333,1,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.558333333,1,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.558333333,1,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.566666667,1,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.566666667,1,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.566666667,1,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.583333333,1,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.583333333,1,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.583333333,1,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.583333333,1,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.591666667,1,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.591666667,1,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.608333333,1,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.608333333,1,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.608333333,1,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.608333333,1,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.608333333,1,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.616666667,1,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.625,1,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.625,1,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.625,1,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.633333333,1,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.633333333,1,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.633333333,1,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.641666667,1,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.641666667,1,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.65,1,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.65,1,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.65,1,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.658333333,1,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.658333333,1,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.658333333,1,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.658333333,1,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.658333333,1,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.666666667,1,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.675,1,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.675,1,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.675,1,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.675,1,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.675,1,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.691666667,1,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.691666667,1,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.7,1,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.7,1,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.708333333,1,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.708333333,1,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.716666667,1,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.716666667,1,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.716666667,1,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.716666667,1,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.725,1,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.733333333,1,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.733333333,1,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.733333333,1,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.733333333,1,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.741666667,1,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.741666667,1,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.741666667,1,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.741666667,1,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.741666667,1,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.758333333,1,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.766666667,1,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.775,1,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.775,1,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.783333333,1,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.791666667,1,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.8,1,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.8,1,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.808333333,1,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.808333333,1,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.808333333,1,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.816666667,1,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.85,1,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.85,1,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.866666667,1,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.866666667,1,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.866666667,1,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.866666667,1,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.875,1,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.875,1,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.883333333,1,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.883333333,1,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.891666667,1,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.891666667,1,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.891666667,1,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.891666667,1,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.9,1,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.9,1,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.908333333,1,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.925,1,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.925,1,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.933333333,1,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.933333333,1,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.941666667,1,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.966666667,1,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.975,1,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.975,1,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.983333333,1,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.991666667,1,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
1,1,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
1,1,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
1.008333333,1,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
1.008333333,1,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
1.025,1,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
1.05,1,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
1.05,1,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
1.058333333,1,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
1.058333333,1,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
1.091666667,1,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
1.1,1,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
1.125,1,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
1.133333333,1,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
1.158333333,1,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
1.166666667,1,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
1.216666667,1,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
1.281058128,1,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
1.333333333,1,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
1.333333333,1,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
1.334654801,1,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
1.368141058,1,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
1.368141058,1,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
1.399376386,1,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
1.399376386,1,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
1.399376386,1,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.0375,0,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.070833334,0,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.104166667,0,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.145833334,0,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.179166667,0,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.2125,0,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.520833334,0,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.529166667,0,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.5375,0,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.545833334,0,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.554166667,0,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.5625,0,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.579166667,0,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.5875,0,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.595833334,0,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.604166667,0,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.6125,0,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.620833334,0,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.629166667,0,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.645833334,0,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.654166667,0,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.6625,0,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.670833334,0,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.679166667,0,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.6875,0,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.704166667,0,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.7125,0,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.720833334,0,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.729166667,0,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.7375,0,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.745833334,0,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.7625,0,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.7625,0,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.770833334,0,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.770833334,0,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.779166667,0,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.779166667,0,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.7875,0,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.7875,0,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.795833334,0,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.795833334,0,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.804166667,0,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.804166667,0,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.804166667,0,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.8125,0,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.8125,0,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.820833334,0,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.820833334,0,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.829166667,0,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.829166667,0,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.8375,0,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.8375,0,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.845833334,0,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.845833334,0,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.854166667,0,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.854166667,0,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.854166667,0,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.8625,0,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.8625,0,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.870833334,0,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.870833334,0,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.879166667,0,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.879166667,0,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.8875,0,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.8875,0,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.895833334,0,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.895833334,0,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.904166667,0,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.904166667,0,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.904166667,0,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.9125,0,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.9125,0,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.920833334,0,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.920833334,0,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.929166667,0,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.929166667,0,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.9375,0,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.9375,0,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.945833334,0,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.945833334,0,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.954166667,0,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.954166667,0,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.954166667,0,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.9625,0,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.9625,0,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.970833334,0,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.970833334,0,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.979166667,0,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.979166667,0,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.9875,0,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.9875,0,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.995833334,0,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.995833334,0,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
1.004166667,0,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
1.004166667,0,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
1.0125,0,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
1.0125,0,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
1.020833334,0,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
1.020833334,0,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
1.029166667,0,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
1.029166667,0,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
1.0375,0,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
1.0375,0,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
1.045833334,0,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
1.045833334,0,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
1.054166667,0,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
1.054166667,0,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
1.0625,0,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
1.0625,0,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
1.070833334,0,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
1.070833334,0,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
1.079166667,0,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
1.079166667,0,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
1.0875,0,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
1.0875,0,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
1.095833334,0,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
1.095833334,0,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
1.104166667,0,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
1.104166667,0,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
1.1125,0,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
1.1125,0,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
1.120833334,0,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
1.120833334,0,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
1.129166667,0,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
1.129166667,0,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
1.129166667,0,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
1.1375,0,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
1.1375,0,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
1.145833334,0,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
1.145833334,0,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
1.154166667,0,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
1.154166667,0,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
1.1625,0,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
1.1625,0,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
1.170833334,0,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
1.170833334,0,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
1.179166667,0,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
1.179166667,0,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
1.1875,0,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
1.1875,0,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
1.195833334,0,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
1.195833334,0,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
1.204166667,0,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
1.204166667,0,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
1.2125,0,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
1.2125,0,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
1.220833334,0,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
1.220833334,0,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
1.229166667,0,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
1.229166667,0,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
1.2375,0,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
1.2375,0,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
1.245833334,0,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
1.245833334,0,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
1.254166667,0,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
1.254166667,0,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
1.278029064,0,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
1.295833334,0,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
1.320833334,0,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
1.338177804,0,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
1.3625,0,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
1.379166667,0,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
1.641666667,0,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
1.641666667,0,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
1.641666667,0,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
1.641666667,0,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
1.641666667,0,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
1.641666667,0,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
1.641666667,0,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
1.641666667,0,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
1.641666667,0,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
1.641666667,0,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
1.641666667,0,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
1.641666667,0,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
1.641666667,0,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
1.641666667,0,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
1.641666667,0,COU-AA-301,Placebo,de Bono 2011,COU-AA-301 (de Bono 2011) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-de 
0.058333333,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.058333333,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.066666667,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.066666667,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.066666667,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.066666667,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.066666667,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.075,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.075,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.083333333,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.083333333,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.1,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.1,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.108333333,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.108333333,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.108333333,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.108333333,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.15,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.15,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.158333333,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.158333333,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.158333333,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.158333333,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.158333333,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.158333333,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.166666667,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.166666667,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.166666667,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.166666667,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.175,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.175,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.175,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.175,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.175,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.183333333,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.2,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.2,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.208333333,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.208333333,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.208333333,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.216666667,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.216666667,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.225,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.225,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.225,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.225,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.225,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.241666667,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.241666667,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.241666667,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.25,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.25,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.25,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.258333333,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.266666667,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.266666667,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.266666667,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.266666667,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.266666667,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.275,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.275,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.283333333,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.283333333,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.283333333,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.283333333,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.308333333,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.308333333,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.308333333,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.316666667,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.316666667,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.316666667,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.316666667,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.35,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.35,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.358333333,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.358333333,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.358333333,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.358333333,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.366666667,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.375,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.375,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.375,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.383333333,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.383333333,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.391666667,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.391666667,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.391666667,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.4,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.4,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.4,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.4,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.408333333,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.408333333,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.408333333,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.416666667,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.416666667,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.416666667,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.416666667,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.425,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.425,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.425,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.433333333,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.433333333,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.433333333,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.433333333,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.441666667,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.441666667,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.45,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.45,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.45,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.458333333,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.458333333,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.458333333,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.458333333,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.466666667,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.466666667,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.475,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.475,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.483333333,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.483333333,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.483333333,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.491666667,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.491666667,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.491666667,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.5,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.5,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.5,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.5,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.5,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.5,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.5,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.508333333,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.508333333,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.516666667,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.516666667,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.516666667,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.516666667,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.516666667,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.516666667,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.516666667,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.533333333,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.533333333,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.533333333,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.541666667,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.541666667,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.541666667,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.55,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.55,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.55,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.55,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.55,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.55,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.55,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.55,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.55,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.55,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.566666667,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.566666667,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.566666667,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.575,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.575,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.583333333,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.591666667,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.591666667,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.6,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.608333333,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.608333333,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.608333333,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.608333333,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.616666667,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.616666667,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.616666667,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.625,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.625,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.625,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.625,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.625,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.633333333,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.633333333,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.633333333,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.633333333,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.633333333,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.633333333,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.641666667,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.641666667,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.641666667,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.65,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.658333333,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.658333333,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.658333333,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.666666667,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.675,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.675,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.683333333,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.691666667,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.7,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.7,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.7,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.7,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.7,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.708333333,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.708333333,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.708333333,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.708333333,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.716666667,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.716666667,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.716666667,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.716666667,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.725,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.725,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.725,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.725,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.733333333,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.733333333,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.733333333,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.741666667,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.741666667,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.75,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.75,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.75,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.758333333,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.766666667,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.766666667,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.766666667,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.775,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.775,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.783333333,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.783333333,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.783333333,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.791666667,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.8,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.8,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.808333333,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.808333333,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.816666667,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.825,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.825,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.825,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.833333333,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.833333333,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.833333333,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.841666667,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.841666667,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.841666667,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.841666667,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.841666667,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.841666667,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.85,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.85,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.85,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.858333333,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.858333333,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.858333333,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.858333333,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.866666667,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.875,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.875,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.875,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.883333333,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.883333333,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.891666667,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.891666667,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.9,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.9,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.908333333,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.908333333,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.908333333,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.916666667,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.916666667,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.925,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.925,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.925,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.925,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.933333333,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.933333333,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.933333333,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.933333333,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.941666667,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.941666667,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.941666667,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.941666667,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.95,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.95,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.95,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.958333333,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.958333333,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.958333333,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.966666667,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.966666667,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.966666667,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.975,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.975,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.975,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.983333333,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.983333333,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.983333333,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.991666667,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.991666667,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.991666667,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.008333333,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.008333333,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.016666667,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.025,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.033333333,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.033333333,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.041666667,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.041666667,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.041666667,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.05,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.058333333,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.066666667,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.066666667,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.075,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.075,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.083333333,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.083333333,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.108333333,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.116666667,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.116666667,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.125,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.133333333,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.141666667,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.141666667,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.15,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.158333333,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.158333333,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.158333333,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.166666667,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.166666667,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.175,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.175,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.183333333,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.183333333,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.183333333,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.183333333,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.191666667,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.191666667,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.191666667,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.191666667,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.191666667,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.2,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.2,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.2,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.2,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.208333333,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.208333333,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.208333333,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.216666667,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.216666667,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.216666667,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.216666667,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.225,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.225,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.233333333,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.233333333,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.233333333,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.233333333,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.241666667,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.241666667,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.241666667,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.241666667,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.25,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.25,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.25,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.258333333,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.258333333,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.266666667,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.266666667,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.275,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.275,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.283333333,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.283333333,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.283333333,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.291666667,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.291666667,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.3,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.3,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.3,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.316666667,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.325,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.325,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.325,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.333333333,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.333333333,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.333333333,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.333333333,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.333333333,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.35,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.358333333,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.358333333,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.366666667,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.366666667,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.375,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.383333333,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.383333333,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.391666667,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.391666667,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.391666667,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.4,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.408333333,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.408333333,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.408333333,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.416666667,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.416666667,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.416666667,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.425,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.425,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.425,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.425,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.433333333,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.433333333,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.433333333,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.433333333,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.441666667,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.45,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.45,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.458333333,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.458333333,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.458333333,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.466666667,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.466666667,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.466666667,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.466666667,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.475,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.475,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.483333333,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.483333333,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.483333333,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.491666667,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.5,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.5,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.5,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.508333333,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.516666667,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.525,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.525,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.533333333,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.533333333,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.533333333,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.541666667,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.558333333,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.566666667,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.575,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.575,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.583333333,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.583333333,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.583333333,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.591666667,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.591666667,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.6,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.616666667,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.616666667,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.625,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.625,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.633333333,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.633333333,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.633333333,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.633333333,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.641666667,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.641666667,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.65,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.65,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.666666667,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.666666667,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.675,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.683333333,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.691666667,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.7,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.7,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.7,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.708333333,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.708333333,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.716666667,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.716666667,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.733333333,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.741666667,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.741666667,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.75,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.75,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.766666667,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.775,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.783333333,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.791666667,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.8,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.841666667,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.85,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.85,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.858333333,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.866666667,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.891666667,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.908333333,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.933333333,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.941666667,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.95,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
2.016666667,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
2.025,1,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.054166667,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.104166667,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.154166667,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.204166667,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.254166667,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.304166667,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.354166667,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.404166667,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.454166667,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.545833334,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.579166667,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.6125,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.654166667,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.6875,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.720833334,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.754166667,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.795833334,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.829166667,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.8625,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.904166667,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.9375,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.970833334,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.0125,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.020833334,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.029166667,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.0375,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.045833334,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.054166667,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.0625,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.070833334,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.070833334,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.079166667,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.0875,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.095833334,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.104166667,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.1125,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.120833334,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.129166667,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.129166667,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.1375,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.145833334,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.154166667,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.1625,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.170833334,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.179166667,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.1875,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.195833334,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.195833334,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.204166667,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.2125,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.220833334,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.229166667,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.2375,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.245833334,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.254166667,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.254166667,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.2625,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.270833334,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.279166667,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.2875,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.295833334,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.304166667,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.3125,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.320833334,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.320833334,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.329166667,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.3375,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.345833334,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.354166667,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.3625,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.370833334,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.379166667,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.379166667,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.3875,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.395833334,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.404166667,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.4125,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.420833334,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.429166667,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.4375,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.445833334,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.445833334,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.454166667,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.4625,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.470833334,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.479166667,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.4875,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.495833334,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.504166667,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.5125,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.5125,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.5125,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.520833334,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.520833334,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.520833334,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.529166667,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.529166667,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.529166667,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.529166667,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.5375,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.5375,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.5375,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.545833334,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.545833334,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.545833334,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.554166667,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.554166667,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.554166667,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.554166667,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.5625,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.5625,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.5625,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.570833334,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.570833334,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.570833334,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.579166667,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.579166667,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.579166667,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.579166667,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.5875,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.5875,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.5875,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.595833334,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.595833334,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.595833334,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.604166667,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.604166667,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.604166667,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.604166667,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.6125,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.6125,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.6125,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.620833334,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.620833334,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.620833334,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.629166667,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.629166667,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.629166667,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.629166667,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.6375,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.6375,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.6375,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.645833334,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.645833334,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.645833334,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.654166667,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.654166667,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.654166667,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.654166667,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.6625,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.6625,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.6625,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.670833334,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.670833334,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.670833334,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.679166667,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.679166667,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.679166667,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.679166667,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.6875,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.6875,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.6875,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.695833334,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.695833334,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.695833334,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.704166667,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.704166667,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.704166667,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.704166667,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.7125,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.7125,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.7125,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.720833334,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.720833334,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.720833334,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.729166667,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.729166667,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.729166667,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.729166667,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.7375,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.7375,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.7375,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.745833334,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.745833334,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.745833334,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.754166667,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.754166667,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.754166667,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.754166667,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.7625,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.7625,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.7625,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.770833334,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.770833334,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.770833334,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.779166667,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.779166667,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.779166667,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.779166667,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.7875,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.7875,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.7875,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.795833334,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.795833334,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.795833334,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.804166667,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.804166667,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.804166667,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.804166667,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.8125,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.8125,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.8125,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.820833334,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.820833334,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.820833334,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.829166667,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.829166667,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.829166667,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.829166667,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.8375,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.8375,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.8375,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.845833334,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.845833334,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.845833334,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.854166667,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.854166667,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.854166667,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.854166667,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.8625,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.8625,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.8625,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.870833334,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.870833334,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.870833334,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.879166667,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.879166667,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.879166667,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.879166667,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.8875,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.8875,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.8875,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.895833334,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.895833334,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.895833334,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.904166667,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.904166667,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.904166667,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.904166667,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.9125,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.9125,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.9125,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.920833334,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.920833334,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.920833334,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.929166667,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.929166667,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.929166667,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.929166667,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.9375,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.9375,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.9375,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.945833334,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.945833334,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.945833334,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.954166667,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.954166667,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.954166667,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.954166667,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.9625,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.9625,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.9625,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.970833334,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.970833334,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.970833334,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.979166667,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.979166667,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.979166667,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.979166667,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.9875,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.9875,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.9875,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.995833334,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.995833334,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
1.995833334,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
2.0125,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
2.045833334,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
2.045833334,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
2.045833334,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
2.0875,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
2.0875,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
2.129166667,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
2.129166667,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
2.129166667,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
2.170833334,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
2.170833334,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
2.2125,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
2.2125,0,COU-AA-301,Abiraterone acetate,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Abiraterone acetate,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Abi-Fiz
0.066666667,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
0.075,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
0.083333333,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
0.091666667,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
0.091666667,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
0.1,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
0.108333333,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
0.108333333,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
0.116666667,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
0.116666667,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
0.141666667,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
0.15,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
0.15,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
0.15,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
0.158333333,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
0.158333333,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
0.158333333,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
0.166666667,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
0.175,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
0.175,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
0.175,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
0.175,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
0.183333333,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
0.183333333,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
0.191666667,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
0.191666667,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
0.2,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
0.208333333,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
0.208333333,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
0.216666667,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
0.225,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
0.225,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
0.233333333,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
0.241666667,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
0.241666667,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
0.25,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
0.25,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
0.266666667,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
0.266666667,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
0.275,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
0.275,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
0.283333333,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
0.283333333,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
0.283333333,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
0.291666667,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
0.3,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
0.3,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
0.3,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
0.308333333,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
0.308333333,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
0.308333333,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
0.316666667,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
0.316666667,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
0.316666667,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
0.325,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
0.325,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
0.325,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
0.325,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
0.333333333,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
0.341666667,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
0.341666667,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
0.35,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
0.35,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
0.35,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
0.358333333,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
0.358333333,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
0.366666667,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
0.366666667,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
0.375,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
0.375,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
0.408333333,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
0.416666667,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
0.416666667,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
0.425,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
0.433333333,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
0.433333333,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
0.441666667,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
0.45,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
0.45,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
0.466666667,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
0.475,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
0.491666667,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
0.5,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
0.508333333,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
0.508333333,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
0.508333333,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
0.508333333,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
0.508333333,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
0.516666667,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
0.525,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
0.525,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
0.533333333,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
0.541666667,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
0.55,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
0.55,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
0.55,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
0.55,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
0.558333333,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
0.558333333,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
0.558333333,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
0.558333333,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
0.566666667,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
0.566666667,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
0.575,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
0.575,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
0.591666667,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
0.591666667,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
0.591666667,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
0.591666667,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
0.6,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
0.608333333,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
0.608333333,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
0.616666667,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
0.616666667,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
0.625,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
0.625,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
0.625,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
0.625,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
0.633333333,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
0.641666667,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
0.641666667,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
0.65,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
0.65,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
0.65,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
0.658333333,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
0.658333333,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
0.658333333,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
0.658333333,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
0.666666667,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
0.666666667,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
0.666666667,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
0.666666667,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
0.675,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
0.675,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
0.683333333,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
0.683333333,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
0.691666667,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
0.7,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
0.7,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
0.7,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
0.708333333,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
0.708333333,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
0.708333333,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
0.708333333,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
0.716666667,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
0.725,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
0.725,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
0.725,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
0.733333333,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
0.733333333,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
0.733333333,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
0.733333333,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
0.741666667,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
0.741666667,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
0.741666667,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
0.75,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
0.75,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
0.766666667,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
0.766666667,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
0.775,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
0.775,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
0.783333333,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
0.791666667,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
0.791666667,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
0.8,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
0.808333333,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
0.816666667,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
0.816666667,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
0.816666667,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
0.825,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
0.833333333,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
0.833333333,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
0.841666667,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
0.858333333,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
0.858333333,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
0.858333333,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
0.858333333,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
0.883333333,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
0.883333333,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
0.891666667,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
0.891666667,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
0.891666667,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
0.9,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
0.9,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
0.9,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
0.908333333,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
0.908333333,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
0.908333333,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
0.908333333,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
0.908333333,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
0.925,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
0.933333333,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
0.941666667,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
0.941666667,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
0.941666667,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
0.941666667,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
0.941666667,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
0.95,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
0.95,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
0.983333333,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
0.991666667,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
1,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
1.008333333,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
1.008333333,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
1.016666667,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
1.016666667,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
1.025,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
1.05,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
1.058333333,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
1.066666667,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
1.066666667,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
1.1,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
1.1,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
1.108333333,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
1.116666667,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
1.125,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
1.125,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
1.141666667,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
1.15,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
1.158333333,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
1.158333333,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
1.166666667,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
1.175,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
1.191666667,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
1.216666667,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
1.225,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
1.25,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
1.25,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
1.258333333,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
1.258333333,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
1.266666667,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
1.275,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
1.275,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
1.291666667,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
1.3,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
1.308333333,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
1.316666667,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
1.325,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
1.325,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
1.333333333,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
1.333333333,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
1.341666667,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
1.35,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
1.358333333,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
1.366666667,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
1.375,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
1.4,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
1.408333333,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
1.433333333,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
1.441666667,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
1.466666667,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
1.483333333,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
1.516666667,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
1.533333333,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
1.541666667,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
1.575,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
1.591666667,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
1.6,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
1.616666667,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
1.625,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
1.633333333,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
1.641666667,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
1.65,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
1.65,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
1.666666667,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
1.733333333,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
1.741666667,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
1.8,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
1.808333333,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
1.808333333,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
1.808333333,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
1.808333333,1,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
0.054166667,0,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
0.104166667,0,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
0.154166667,0,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
0.204166667,0,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
0.254166667,0,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
0.304166667,0,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
0.354166667,0,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
0.404166667,0,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
0.454166667,0,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
0.604166667,0,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
0.704166667,0,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
0.804166667,0,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
0.904166667,0,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
1.020833334,0,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
1.0375,0,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
1.054166667,0,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
1.070833334,0,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
1.079166667,0,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
1.095833334,0,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
1.1125,0,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
1.129166667,0,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
1.1375,0,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
1.154166667,0,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
1.170833334,0,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
1.1875,0,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
1.195833334,0,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
1.2125,0,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
1.229166667,0,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
1.245833334,0,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
1.254166667,0,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
1.270833334,0,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
1.2875,0,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
1.304166667,0,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
1.320833334,0,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
1.329166667,0,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
1.345833334,0,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
1.3625,0,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
1.379166667,0,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
1.3875,0,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
1.404166667,0,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
1.420833334,0,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
1.4375,0,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
1.445833334,0,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
1.4625,0,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
1.479166667,0,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
1.495833334,0,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
1.5125,0,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
1.520833334,0,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
1.529166667,0,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
1.5375,0,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
1.545833334,0,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
1.554166667,0,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
1.5625,0,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
1.570833334,0,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
1.579166667,0,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
1.5875,0,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
1.595833334,0,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
1.604166667,0,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
1.6125,0,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
1.620833334,0,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
1.620833334,0,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
1.629166667,0,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
1.6375,0,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
1.645833334,0,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
1.654166667,0,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
1.6625,0,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
1.670833334,0,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
1.679166667,0,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
1.6875,0,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
1.695833334,0,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
1.704166667,0,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
1.7125,0,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
1.720833334,0,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
1.729166667,0,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
1.7375,0,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
1.7375,0,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
1.745833334,0,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
1.754166667,0,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
1.7625,0,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
1.770833334,0,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
1.779166667,0,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
1.7875,0,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
1.795833334,0,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
1.804166667,0,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
2.091666667,0,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
2.091666667,0,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
2.091666667,0,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
2.091666667,0,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
2.091666667,0,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
2.091666667,0,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
2.091666667,0,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
2.091666667,0,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
2.091666667,0,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
2.091666667,0,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
2.091666667,0,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
2.091666667,0,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
2.091666667,0,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
2.091666667,0,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
2.091666667,0,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
2.091666667,0,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
2.091666667,0,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
2.091666667,0,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
2.091666667,0,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
2.091666667,0,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
2.091666667,0,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
2.091666667,0,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
2.091666667,0,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
2.091666667,0,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
2.091666667,0,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
2.091666667,0,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
2.091666667,0,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
2.091666667,0,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
2.091666667,0,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
2.091666667,0,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
2.091666667,0,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
2.091666667,0,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
2.091666667,0,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
2.091666667,0,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
2.091666667,0,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
2.091666667,0,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
2.091666667,0,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
2.091666667,0,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
2.091666667,0,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
2.091666667,0,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
2.091666667,0,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
2.091666667,0,COU-AA-301,Placebo,Fizazi 2012,COU-AA-301 (Fizazi 2012) - Placebo,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,COU-Pla-Fiz
0.016666667,1,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
0.016666667,1,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
0.241666667,1,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
0.241666667,1,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
0.258333333,1,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
0.266666667,1,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
0.341666667,1,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
0.383333333,1,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
0.433333333,1,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
0.466666667,1,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
0.483333333,1,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
0.541666667,1,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
0.558333333,1,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
0.566666667,1,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
0.575,1,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
0.575,1,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
0.575,1,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
0.591666667,1,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
0.6,1,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
0.6,1,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
0.625,1,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
0.65,1,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
0.666666667,1,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
0.675,1,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
0.683333333,1,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
0.691666667,1,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
0.7,1,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
0.716666667,1,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
0.741666667,1,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
0.741666667,1,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
0.741666667,1,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
0.758333333,1,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
0.775,1,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
0.783333333,1,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
0.816666667,1,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
0.816666667,1,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
0.833333333,1,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
0.833333333,1,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
0.841666667,1,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
0.866666667,1,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
0.891666667,1,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
0.925,1,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
0.941666667,1,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
0.958333333,1,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
0.966666667,1,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
0.975,1,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
0.975,1,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
1,1,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
1.016666667,1,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
1.016666667,1,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
1.033333333,1,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
1.033333333,1,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
1.05,1,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
1.066666667,1,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
1.075,1,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
1.083333333,1,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
1.1,1,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
1.116666667,1,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
1.141666667,1,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
1.166666667,1,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
1.183333333,1,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
1.183333333,1,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
1.191666667,1,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
1.191666667,1,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
1.2,1,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
1.2,1,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
1.2,1,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
1.216666667,1,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
1.216666667,1,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
1.216666667,1,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
1.216666667,1,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
1.233333333,1,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
1.233333333,1,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
1.233333333,1,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
1.241666667,1,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
1.241666667,1,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
1.25,1,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
1.258333333,1,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
1.291666667,1,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
1.325,1,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
1.333333333,1,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
1.341666667,1,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
1.35,1,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
1.35,1,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
1.35,1,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
1.35,1,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
1.366666667,1,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
1.366666667,1,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
1.375,1,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
1.383333333,1,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
1.391666667,1,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
1.4,1,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
1.4,1,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
1.408333333,1,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
1.416666667,1,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
1.433333333,1,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
1.45,1,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
1.45,1,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
1.466666667,1,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
1.466666667,1,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
1.483333333,1,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
1.483333333,1,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
1.491666667,1,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
1.5,1,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
1.508333333,1,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
1.508333333,1,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
1.516666667,1,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
1.533333333,1,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
1.533333333,1,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
1.541666667,1,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
1.541666667,1,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
1.558333333,1,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
1.583333333,1,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
1.591666667,1,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
1.6,1,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
1.608333333,1,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
1.616666667,1,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
1.625,1,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
1.625,1,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
1.65,1,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
1.65,1,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
1.708333333,1,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
1.708333333,1,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
1.716666667,1,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
1.725,1,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
1.725,1,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
1.733333333,1,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
1.741666667,1,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
1.75,1,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
1.758333333,1,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
1.775,1,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
1.775,1,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
1.775,1,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
1.8,1,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
1.825,1,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
1.833333333,1,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
1.841666667,1,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
1.85,1,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
1.858333333,1,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
1.858333333,1,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
1.866666667,1,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
1.866666667,1,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
1.883333333,1,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
1.883333333,1,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
1.916666667,1,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
1.916666667,1,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
1.925,1,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
1.925,1,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
1.933333333,1,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
1.933333333,1,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
1.95,1,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
1.95,1,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
1.95,1,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
1.95,1,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
1.966666667,1,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
1.975,1,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
1.975,1,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
1.983333333,1,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2,1,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2,1,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2,1,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.025,1,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.041666667,1,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.058333333,1,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.075,1,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.083333333,1,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.1,1,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.1,1,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.116666667,1,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.116666667,1,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.125,1,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.133333333,1,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.133333333,1,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.15,1,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.15,1,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.158333333,1,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.175,1,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.208333333,1,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.216666667,1,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.233333333,1,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.233333333,1,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.25,1,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.266666667,1,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.3,1,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.3,1,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.316666667,1,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.316666667,1,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.333333333,1,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.358333333,1,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.375,1,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.375,1,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.375,1,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.391666667,1,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.391666667,1,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.475,1,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.5,1,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.583333333,1,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.625,1,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.65,1,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.93601064,1,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.93601064,1,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.93601064,1,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.93601064,1,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.93601064,1,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.93601064,1,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.93601064,1,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.93601064,1,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.93601064,1,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.93601064,1,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.93601064,1,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.93601064,1,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.93601064,1,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.93601064,1,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.93601064,1,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
0.045833334,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
0.095833334,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
0.145833334,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
0.195833334,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
0.279166667,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
0.3125,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
0.345833334,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
0.370833334,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
0.404166667,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
0.4375,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
0.470833334,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
0.620833334,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
0.7875,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
0.829166667,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
0.870833334,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
0.9125,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
0.954166667,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
1.120833334,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
1.295833334,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
1.345833334,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
1.395833334,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
1.445833334,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
1.5625,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
1.620833334,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
1.6875,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
1.754166667,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
1.7625,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
1.770833334,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
1.779166667,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
1.7875,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
1.795833334,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
1.804166667,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
1.8125,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
1.820833334,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
1.829166667,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
1.8375,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
1.845833334,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
1.854166667,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
1.8625,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
1.870833334,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
1.879166667,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
1.8875,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
1.895833334,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
1.904166667,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
1.9125,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
1.920833334,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
1.929166667,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
1.9375,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
1.945833334,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
1.954166667,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
1.9625,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
1.970833334,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
1.979166667,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
1.9875,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
1.995833334,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.004166667,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.004166667,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.004166667,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.004166667,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.0125,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.0125,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.0125,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.0125,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.0125,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.020833334,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.020833334,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.020833334,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.020833334,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.029166667,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.029166667,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.029166667,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.029166667,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.029166667,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.0375,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.0375,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.0375,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.0375,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.045833334,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.045833334,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.045833334,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.045833334,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.045833334,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.054166667,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.054166667,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.054166667,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.054166667,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.0625,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.0625,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.0625,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.0625,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.0625,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.070833334,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.070833334,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.070833334,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.070833334,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.079166667,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.079166667,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.079166667,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.079166667,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.079166667,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.0875,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.0875,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.0875,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.0875,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.095833334,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.095833334,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.095833334,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.095833334,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.095833334,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.104166667,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.104166667,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.104166667,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.104166667,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.1125,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.1125,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.1125,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.1125,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.1125,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.120833334,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.120833334,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.120833334,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.120833334,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.120833334,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.129166667,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.129166667,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.129166667,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.129166667,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.1375,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.1375,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.1375,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.1375,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.1375,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.145833334,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.145833334,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.145833334,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.145833334,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.154166667,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.154166667,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.154166667,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.154166667,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.154166667,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.1625,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.1625,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.1625,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.1625,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.170833334,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.170833334,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.170833334,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.170833334,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.170833334,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.179166667,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.179166667,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.179166667,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.179166667,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.1875,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.1875,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.1875,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.1875,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.1875,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.195833334,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.195833334,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.195833334,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.195833334,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.204166667,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.204166667,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.204166667,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.204166667,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.204166667,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.2125,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.2125,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.2125,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.2125,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.220833334,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.220833334,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.220833334,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.220833334,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.220833334,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.229166667,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.229166667,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.229166667,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.229166667,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.2375,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.2375,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.2375,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.2375,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.2375,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.245833334,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.245833334,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.245833334,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.245833334,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.254166667,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.254166667,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.254166667,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.2625,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.2625,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.2625,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.270833334,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.270833334,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.270833334,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.279166667,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.279166667,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.279166667,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.2875,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.2875,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.2875,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.295833334,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.295833334,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.295833334,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.304166667,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.304166667,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.304166667,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.3125,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.3125,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.3125,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.3125,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.320833334,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.320833334,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.320833334,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.329166667,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.329166667,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.329166667,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.3375,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.3375,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.3375,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.345833334,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.345833334,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.345833334,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.354166667,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.354166667,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.354166667,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.3625,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.3625,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.3625,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.370833334,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.370833334,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.370833334,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.370833334,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.379166667,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.379166667,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.379166667,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.3875,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.3875,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.3875,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.395833334,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.395833334,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.395833334,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.404166667,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.404166667,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.404166667,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.4125,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.4125,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.4125,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.420833334,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.420833334,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.420833334,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.429166667,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.429166667,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.429166667,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.4375,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.4375,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.4375,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.4375,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.445833334,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.445833334,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.445833334,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.454166667,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.454166667,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.454166667,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.4625,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.4625,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.4625,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.470833334,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.470833334,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.470833334,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.479166667,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.479166667,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.479166667,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.4875,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.4875,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.4875,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.495833334,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.495833334,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.495833334,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.5125,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.520833334,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.529166667,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.5375,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.545833334,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.554166667,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.5625,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.570833334,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.579166667,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.5875,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.595833334,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.604166667,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.6125,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.620833334,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.629166667,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.6375,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.645833334,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.79300532,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.79300532,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.79300532,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.79300532,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.79300532,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.79300532,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.79300532,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.79300532,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.79300532,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.79300532,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.79300532,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.79300532,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.79300532,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.79300532,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.79300532,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.79300532,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.79300532,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.79300532,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.79300532,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.79300532,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.79300532,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.79300532,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.79300532,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.79300532,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.79300532,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.79300532,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.79300532,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.79300532,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.79300532,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.79300532,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.79300532,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
2.79300532,0,COU-AA-302,Abirateroneprednisone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rat
0.129076376,1,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
0.258333333,1,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
0.316666667,1,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
0.316666667,1,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
0.325,1,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
0.325,1,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
0.325,1,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
0.325,1,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
0.333333333,1,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
0.333333333,1,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
0.333333333,1,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
0.391666667,1,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
0.391666667,1,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
0.408333333,1,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
0.425,1,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
0.425,1,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
0.466666667,1,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
0.508333333,1,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
0.525,1,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
0.558333333,1,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
0.583333333,1,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
0.591666667,1,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
0.6,1,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
0.6,1,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
0.608333333,1,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
0.616666667,1,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
0.658333333,1,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
0.666666667,1,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
0.723271192,1,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
0.734889526,1,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
0.746507861,1,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
0.758126195,1,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
0.771404291,1,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
0.771404291,1,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
0.783022626,1,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
0.811238581,1,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
0.824516677,1,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
0.836135012,1,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
0.861031443,1,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
0.874309539,1,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
0.9,1,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
0.908333333,1,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
0.916666667,1,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
0.925,1,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
0.925,1,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
0.933333333,1,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
0.941666667,1,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
0.95,1,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
0.95,1,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
0.958333333,1,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
0.966666667,1,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
0.975,1,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
0.983333333,1,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
1,1,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
1.008333333,1,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
1.008333333,1,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
1.008333333,1,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
1.025,1,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
1.05,1,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
1.075,1,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
1.075,1,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
1.083333333,1,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
1.108333333,1,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
1.116666667,1,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
1.125,1,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
1.141666667,1,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
1.141666667,1,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
1.166666667,1,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
1.166666667,1,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
1.166666667,1,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
1.175,1,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
1.183333333,1,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
1.183333333,1,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
1.183333333,1,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
1.2,1,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
1.2,1,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
1.216666667,1,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
1.216666667,1,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
1.216666667,1,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
1.233333333,1,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
1.233333333,1,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
1.241666667,1,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
1.25,1,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
1.3,1,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
1.3,1,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
1.308333333,1,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
1.325,1,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
1.325,1,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
1.341666667,1,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
1.341666667,1,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
1.35,1,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
1.358333333,1,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
1.358333333,1,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
1.366666667,1,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
1.375,1,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
1.383333333,1,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
1.383333333,1,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
1.391666667,1,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
1.391666667,1,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
1.4,1,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
1.408333333,1,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
1.408333333,1,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
1.425,1,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
1.425,1,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
1.441666667,1,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
1.45,1,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
1.45,1,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
1.458333333,1,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
1.466666667,1,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
1.466666667,1,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
1.466666667,1,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
1.466666667,1,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
1.466666667,1,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
1.475,1,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
1.483333333,1,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
1.483333333,1,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
1.491666667,1,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
1.5,1,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
1.508333333,1,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
1.516666667,1,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
1.533333333,1,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
1.533333333,1,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
1.541666667,1,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
1.541666667,1,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
1.55,1,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
1.55,1,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
1.55,1,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
1.558333333,1,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
1.566666667,1,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
1.566666667,1,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
1.566666667,1,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
1.575,1,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
1.575,1,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
1.575,1,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
1.591666667,1,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
1.591666667,1,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
1.591666667,1,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
1.608333333,1,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
1.608333333,1,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
1.625,1,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
1.658333333,1,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
1.658333333,1,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
1.658333333,1,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
1.683333333,1,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
1.683333333,1,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
1.7,1,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
1.7,1,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
1.708333333,1,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
1.708333333,1,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
1.716666667,1,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
1.716666667,1,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
1.741666667,1,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
1.741666667,1,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
1.741666667,1,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
1.758333333,1,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
1.758333333,1,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
1.766666667,1,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
1.766666667,1,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
1.766666667,1,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
1.775,1,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
1.775,1,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
1.783333333,1,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
1.783333333,1,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
1.783333333,1,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
1.8,1,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
1.808333333,1,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
1.808333333,1,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
1.825,1,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
1.833333333,1,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
1.833333333,1,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
1.841666667,1,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
1.858333333,1,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
1.858333333,1,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
1.858333333,1,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
1.883333333,1,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
1.883333333,1,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
1.883333333,1,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
1.883333333,1,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
1.9,1,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
1.9,1,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
1.916666667,1,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
1.933333333,1,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
1.933333333,1,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
1.95,1,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
1.958333333,1,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
1.958333333,1,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
1.975,1,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
1.975,1,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
1.975,1,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
1.991666667,1,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
1.991666667,1,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.016666667,1,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.033333333,1,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.041666667,1,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.05,1,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.075,1,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.075,1,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.091666667,1,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.108333333,1,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.108333333,1,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.133333333,1,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.133333333,1,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.141666667,1,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.141666667,1,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.15,1,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.158333333,1,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.158333333,1,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.166666667,1,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.175,1,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.183333333,1,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.2,1,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.208333333,1,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.225,1,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.241666667,1,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.258333333,1,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.266666667,1,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.275,1,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.283333333,1,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.291666667,1,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.366666667,1,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.366666667,1,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.383333333,1,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.5,1,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.5,1,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.508333333,1,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.516666667,1,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.516666667,1,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.533333333,1,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.575,1,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.583333333,1,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.591666667,1,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.758139473,1,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.837808052,1,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.837808052,1,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.884281389,1,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
0.034469939,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
0.062685894,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
0.096711016,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
0.135715424,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
0.161441736,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
0.189657691,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
0.228662099,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
0.279166667,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
0.299168792,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
0.320833334,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
0.345833334,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
0.370833334,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
0.3875,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
0.4125,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
0.4375,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
0.454166667,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
0.479166667,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
0.5875,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
0.673392023,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
0.803769652,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
0.841944179,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
0.880948587,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
0.920833334,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
0.9625,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
1.370833334,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
1.579166667,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
1.6625,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
1.754166667,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
1.7625,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
1.770833334,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
1.770833334,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
1.779166667,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
1.7875,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
1.7875,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
1.795833334,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
1.804166667,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
1.8125,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
1.8125,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
1.820833334,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
1.829166667,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
1.829166667,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
1.8375,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
1.845833334,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
1.854166667,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
1.854166667,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
1.8625,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
1.870833334,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
1.870833334,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
1.879166667,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
1.8875,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
1.895833334,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
1.895833334,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
1.904166667,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
1.9125,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
1.9125,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
1.920833334,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
1.929166667,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
1.9375,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
1.9375,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
1.945833334,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
1.954166667,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
1.954166667,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
1.9625,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
1.970833334,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
1.979166667,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
1.979166667,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
1.9875,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
1.995833334,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.004166667,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.004166667,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.004166667,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.0125,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.0125,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.0125,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.0125,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.020833334,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.020833334,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.020833334,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.029166667,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.029166667,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.029166667,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.029166667,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.0375,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.0375,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.0375,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.0375,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.045833334,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.045833334,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.045833334,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.054166667,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.054166667,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.054166667,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.054166667,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.0625,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.0625,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.0625,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.070833334,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.070833334,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.070833334,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.070833334,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.079166667,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.079166667,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.079166667,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.079166667,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.0875,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.0875,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.0875,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.095833334,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.095833334,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.095833334,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.095833334,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.104166667,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.104166667,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.104166667,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.1125,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.1125,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.1125,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.1125,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.120833334,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.120833334,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.120833334,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.120833334,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.129166667,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.129166667,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.129166667,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.1375,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.1375,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.1375,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.1375,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.145833334,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.145833334,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.145833334,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.154166667,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.154166667,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.154166667,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.154166667,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.1625,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.1625,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.1625,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.1625,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.170833334,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.170833334,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.170833334,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.179166667,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.179166667,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.179166667,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.179166667,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.1875,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.1875,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.1875,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.195833334,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.195833334,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.195833334,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.195833334,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.204166667,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.204166667,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.204166667,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.204166667,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.2125,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.2125,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.2125,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.220833334,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.220833334,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.220833334,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.220833334,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.229166667,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.229166667,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.229166667,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.2375,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.2375,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.2375,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.2375,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.245833334,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.245833334,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.245833334,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.254166667,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.254166667,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.2625,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.2625,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.2625,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.270833334,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.270833334,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.279166667,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.279166667,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.279166667,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.2875,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.2875,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.2875,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.295833334,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.295833334,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.304166667,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.304166667,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.304166667,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.3125,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.3125,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.3125,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.320833334,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.320833334,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.329166667,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.329166667,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.329166667,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.3375,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.3375,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.345833334,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.345833334,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.345833334,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.354166667,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.354166667,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.354166667,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.3625,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.3625,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.370833334,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.370833334,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.370833334,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.379166667,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.379166667,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.379166667,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.3875,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.3875,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.433333334,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.433333334,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.433333334,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.433333334,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.433333334,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.433333334,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.433333334,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.433333334,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.433333334,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.433333334,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.433333334,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.433333334,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.433333334,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.433333334,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.433333334,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.433333334,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.433333334,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.433333334,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.433333334,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.433333334,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.433333334,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.433333334,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.433333334,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.433333334,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.433333334,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.433333334,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.433333334,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.479166667,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.479166667,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.4875,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.4875,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.4875,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.495833334,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.495833334,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.504166667,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.5125,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.5125,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.520833334,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.529166667,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.529166667,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.5375,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.5375,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.545833334,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.554166667,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.554166667,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.5625,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.570833334,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.570833334,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.579166667,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.579166667,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.5875,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.595833334,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.595833334,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.679069737,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.679069737,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.679069737,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.679069737,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.679069737,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.679069737,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.679069737,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.679069737,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.679069737,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.679069737,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.679069737,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.679069737,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.679069737,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.679069737,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.679069737,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.679069737,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.679069737,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.679069737,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.679069737,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.679069737,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.679069737,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.679069737,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.679069737,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.679069737,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.679069737,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.679069737,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.679069737,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.679069737,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.679069737,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.679069737,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.800463406,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.800463406,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.861044721,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.861044721,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
2.939281389,0,COU-AA-302,Prednisone alone,Rathkopf 2014,COU-AA-302 (Rathkopf 2014) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rat
0.258333333,1,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
0.266666667,1,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
0.308333333,1,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
0.325,1,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
0.45,1,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
0.475,1,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
0.516666667,1,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
0.541666667,1,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
0.55,1,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
0.558333333,1,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
0.566666667,1,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
0.575,1,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
0.583333333,1,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
0.591666667,1,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
0.6,1,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
0.608333333,1,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
0.608333333,1,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
0.625,1,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
0.633333333,1,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
0.633333333,1,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
0.65,1,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
0.65,1,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
0.7,1,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
0.708333333,1,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
0.716666667,1,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
0.733333333,1,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
0.733333333,1,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
0.75,1,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
0.75,1,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
0.775,1,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
0.783333333,1,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
0.791666667,1,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
0.8,1,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
0.816666667,1,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
0.833333333,1,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
0.833333333,1,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
0.866666667,1,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
0.866666667,1,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
0.883333333,1,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
0.941666667,1,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
0.958333333,1,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
0.975,1,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
0.991666667,1,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1,1,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1,1,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.016666667,1,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.033333333,1,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.033333333,1,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.041666667,1,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.083333333,1,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.083333333,1,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.083333333,1,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.1,1,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.125,1,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.15,1,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.15,1,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.166666667,1,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.166666667,1,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.183333333,1,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.191666667,1,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.191666667,1,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.208333333,1,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.208333333,1,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.208333333,1,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.208333333,1,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.216666667,1,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.216666667,1,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.225,1,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.233333333,1,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.233333333,1,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.241666667,1,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.25,1,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.25,1,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.258333333,1,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.266666667,1,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.266666667,1,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.308333333,1,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.333333333,1,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.333333333,1,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.341666667,1,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.35,1,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.358333333,1,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.358333333,1,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.366666667,1,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.366666667,1,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.375,1,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.375,1,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.383333333,1,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.4,1,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.4,1,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.416666667,1,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.416666667,1,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.425,1,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.441666667,1,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.45,1,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.458333333,1,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.458333333,1,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.475,1,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.483333333,1,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.491666667,1,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.5,1,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.508333333,1,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.516666667,1,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.525,1,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.533333333,1,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.533333333,1,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.55,1,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.55,1,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.55,1,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.566666667,1,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.591666667,1,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.608333333,1,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.608333333,1,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.616666667,1,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.625,1,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.633333333,1,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.65,1,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.708333333,1,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.725,1,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.725,1,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.725,1,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.733333333,1,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.741666667,1,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.741666667,1,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.758333333,1,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.775,1,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.833333333,1,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.85,1,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.85,1,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.858333333,1,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.866666667,1,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.916666667,1,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.933333333,1,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.958333333,1,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
2.008333333,1,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
2.041666667,1,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
2.041666667,1,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
2.066666667,1,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
2.091666667,1,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
2.108333333,1,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
2.116666667,1,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
2.125,1,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
2.141666667,1,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
2.241666667,1,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
0.029166667,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
0.054166667,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
0.079166667,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
0.1125,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
0.1375,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
0.1625,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
0.195833334,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
0.220833334,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
0.279166667,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
0.304166667,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
0.3375,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
0.3625,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
0.395833334,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
0.420833334,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
0.454166667,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
0.479166667,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
0.820833334,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
0.879166667,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
0.945833334,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.0875,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.170833334,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.279166667,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.295833334,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.3125,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.3375,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.354166667,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.370833334,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.395833334,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.4125,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.429166667,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.454166667,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.470833334,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.4875,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.5125,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.5125,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.5125,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.5125,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.520833334,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.520833334,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.520833334,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.520833334,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.520833334,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.529166667,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.529166667,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.529166667,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.529166667,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.5375,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.5375,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.5375,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.5375,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.5375,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.545833334,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.545833334,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.545833334,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.545833334,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.554166667,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.554166667,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.554166667,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.554166667,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.554166667,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.5625,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.5625,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.5625,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.5625,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.570833334,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.570833334,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.570833334,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.570833334,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.570833334,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.579166667,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.579166667,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.579166667,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.579166667,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.5875,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.5875,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.5875,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.5875,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.5875,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.595833334,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.595833334,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.595833334,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.595833334,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.595833334,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.604166667,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.604166667,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.604166667,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.604166667,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.6125,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.6125,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.6125,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.6125,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.6125,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.620833334,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.620833334,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.620833334,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.620833334,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.629166667,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.629166667,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.629166667,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.629166667,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.629166667,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.6375,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.6375,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.6375,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.6375,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.645833334,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.645833334,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.645833334,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.645833334,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.645833334,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.654166667,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.654166667,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.654166667,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.654166667,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.6625,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.6625,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.6625,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.6625,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.6625,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.670833334,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.670833334,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.670833334,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.670833334,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.670833334,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.679166667,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.679166667,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.679166667,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.679166667,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.6875,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.6875,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.6875,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.6875,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.6875,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.695833334,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.695833334,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.695833334,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.695833334,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.704166667,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.704166667,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.704166667,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.704166667,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.704166667,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.7125,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.7125,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.7125,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.7125,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.720833334,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.720833334,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.720833334,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.720833334,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.720833334,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.729166667,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.729166667,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.729166667,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.729166667,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.7375,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.7375,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.7375,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.7375,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.7375,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.745833334,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.745833334,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.745833334,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.745833334,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.754166667,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.754166667,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.754166667,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.754166667,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.7625,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.7625,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.7625,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.7625,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.770833334,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.770833334,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.770833334,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.770833334,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.779166667,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.779166667,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.779166667,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.779166667,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.779166667,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.7875,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.7875,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.7875,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.7875,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.795833334,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.795833334,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.795833334,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.795833334,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.804166667,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.804166667,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.804166667,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.804166667,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.804166667,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.8125,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.8125,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.8125,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.8125,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.820833334,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.820833334,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.820833334,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.820833334,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.829166667,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.829166667,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.829166667,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.829166667,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.829166667,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.8375,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.8375,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.8375,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.8375,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.845833334,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.845833334,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.845833334,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.845833334,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.854166667,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.854166667,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.854166667,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.854166667,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.8625,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.8625,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.8625,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.8625,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.8625,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.870833334,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.870833334,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.870833334,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.870833334,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.879166667,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.879166667,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.879166667,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.879166667,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.8875,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.8875,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.8875,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.8875,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.8875,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.895833334,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.895833334,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.895833334,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.895833334,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.904166667,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.904166667,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.904166667,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.904166667,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.9125,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.9125,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.9125,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.9125,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.9125,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.920833334,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.920833334,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.920833334,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.920833334,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.929166667,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.929166667,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.929166667,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.929166667,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.9375,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.9375,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.9375,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.9375,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.945833334,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.945833334,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.945833334,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.945833334,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.945833334,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.954166667,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.954166667,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.954166667,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.954166667,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.9625,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.9625,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.9625,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.9625,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.970833334,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.970833334,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.970833334,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.970833334,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.970833334,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.979166667,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.979166667,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.979166667,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.979166667,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.9875,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.9875,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.9875,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.9875,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.995833334,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.995833334,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.995833334,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.995833334,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
2.004166667,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
2.004166667,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
2.0125,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
2.0125,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
2.0125,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
2.020833334,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
2.020833334,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
2.020833334,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
2.029166667,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
2.029166667,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
2.029166667,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
2.0375,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
2.0375,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
2.0375,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
2.045833334,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
2.045833334,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
2.054166667,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
2.054166667,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
2.054166667,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
2.0625,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
2.0625,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
2.0625,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
2.070833334,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
2.070833334,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
2.070833334,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
2.079166667,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
2.079166667,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
2.079166667,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
2.0875,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
2.0875,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
2.095833334,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
2.095833334,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
2.095833334,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
2.104166667,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
2.104166667,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
2.104166667,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
2.1125,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
2.1125,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
2.1125,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
2.120833334,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
2.120833334,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
2.120833334,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
2.129166667,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
2.129166667,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
2.1375,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
2.1375,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
2.1375,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
2.145833334,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
2.145833334,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
2.145833334,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
2.154166667,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
2.154166667,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
2.154166667,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
2.1625,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
2.1625,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
2.1625,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
2.170833334,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
2.170833334,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
2.179166667,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
2.179166667,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
2.179166667,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
2.1875,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
2.1875,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
2.1875,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
2.195833334,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
2.195833334,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
2.195833334,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
2.204166667,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
2.204166667,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
2.204166667,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
2.2125,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
2.2125,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
2.220833334,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
2.220833334,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
2.220833334,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
2.229166667,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
2.229166667,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
2.229166667,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
2.2375,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
2.2375,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
2.2375,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
2.245833334,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
2.245833334,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
2.2625,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
2.270833334,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
2.279166667,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
2.2875,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
2.295833334,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
2.304166667,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
2.3125,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
2.320833334,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
2.329166667,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
2.3375,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
2.345833334,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
2.354166667,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
2.3625,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
2.370833334,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
2.3875,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
2.395833334,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
2.404166667,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
2.4125,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
2.420833334,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
2.429166667,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
2.4375,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
2.445833334,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
2.454166667,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
2.4625,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
2.470833334,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
2.479166667,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
2.4875,0,COU-AA-302,Abirateroneprednisone,Ryan 2013,COU-AA-302 (Ryan 2013) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
0.251389642,1,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
0.257547484,1,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
0.266666667,1,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
0.275,1,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
0.3,1,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
0.316666667,1,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
0.333333333,1,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
0.35,1,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
0.383333333,1,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
0.4,1,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
0.4,1,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
0.433333333,1,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
0.433333333,1,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
0.466666667,1,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
0.516666667,1,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
0.541666667,1,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
0.566666667,1,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
0.583333333,1,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
0.583333333,1,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
0.583333333,1,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
0.591666667,1,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
0.616666667,1,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
0.666663944,1,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
0.675,1,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
0.675,1,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
0.691666667,1,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
0.691666667,1,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
0.708333333,1,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
0.716666667,1,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
0.725,1,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
0.73333878,1,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
0.741666667,1,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
0.758333333,1,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
0.846414661,1,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
0.846414661,1,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
0.863134507,1,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
0.863134507,1,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
0.871046026,1,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
0.871046026,1,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
0.94500003,1,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
0.949395117,1,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
0.949395117,1,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
0.958188921,1,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
0.958188921,1,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
0.966666667,1,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
0.966666667,1,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
0.966666667,1,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
0.983333333,1,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
0.983333333,1,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
0.991666667,1,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1,1,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.016666667,1,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.016666667,1,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.033333333,1,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.033333333,1,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.058333333,1,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.058333333,1,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.075,1,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.075,1,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.075,1,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.091666667,1,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.125,1,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.141666667,1,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.158333333,1,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.166666667,1,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.175,1,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.175,1,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.183333333,1,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.183333333,1,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.191666667,1,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.191666667,1,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.2,1,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.2,1,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.208333333,1,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.216666667,1,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.216666667,1,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.233333333,1,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.241666667,1,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.25,1,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.25,1,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.258333333,1,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.266666667,1,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.308333333,1,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.325,1,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.333333333,1,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.341666667,1,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.35,1,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.358333333,1,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.358333333,1,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.358333333,1,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.366666667,1,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.375,1,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.391666667,1,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.4,1,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.4,1,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.408333333,1,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.408333333,1,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.416666667,1,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.433333333,1,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.441666667,1,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.45,1,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.45,1,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.458333333,1,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.458333333,1,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.475,1,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.475,1,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.475,1,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.483333333,1,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.491666667,1,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.491666667,1,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.491666667,1,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.5,1,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.5,1,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.508333333,1,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.516666667,1,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.516666667,1,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.533333333,1,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.533333333,1,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.541666667,1,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.55,1,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.55,1,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.558333333,1,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.558333333,1,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.558333333,1,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.566666667,1,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.566666667,1,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.566666667,1,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.575,1,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.583333333,1,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.591666667,1,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.591666667,1,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.591666667,1,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.608333333,1,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.608333333,1,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.616666667,1,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.625,1,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.633333333,1,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.65,1,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.666666667,1,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.675,1,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.691666667,1,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.7,1,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.7,1,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.716666667,1,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.716666667,1,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.716666667,1,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.733333333,1,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.758333333,1,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.766666667,1,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.775,1,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.775,1,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.775,1,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.791666667,1,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.791666667,1,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.8,1,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.808333333,1,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.808333333,1,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.808333333,1,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.825,1,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.841666667,1,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.85,1,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.85,1,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.866666667,1,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.891666667,1,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.9,1,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.9,1,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.916666667,1,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.916666667,1,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.941666667,1,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.958333333,1,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.975,1,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.991666667,1,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
2.016666667,1,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
2.033333333,1,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
2.133333333,1,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
2.15,1,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
2.158333333,1,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
2.166666667,1,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
2.183333333,1,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
2.2,1,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
2.208333333,1,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
2.225,1,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
2.274980031,1,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
2.299990015,1,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
0.025561886,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
0.0546192,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
0.085875872,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
0.115371605,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
0.14046499,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
0.16687908,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
0.19065176,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
0.224109607,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
0.270833334,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
0.295833334,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
0.3125,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
0.3375,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
0.3625,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
0.379166667,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
0.404166667,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
0.420833334,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
0.445833334,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
0.4625,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
0.4875,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
0.794916264,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
0.820890118,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
0.851256337,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
0.882932367,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
0.913308569,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
0.947197574,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
0.979166667,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.270833334,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.2875,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.304166667,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.320833334,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.329166667,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.345833334,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.3625,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.379166667,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.3875,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.404166667,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.420833334,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.4375,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.445833334,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.4625,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.479166667,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.495833334,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.5125,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.5125,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.5125,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.5125,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.520833334,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.520833334,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.520833334,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.520833334,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.529166667,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.529166667,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.529166667,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.529166667,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.5375,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.5375,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.5375,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.5375,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.545833334,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.545833334,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.545833334,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.545833334,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.554166667,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.554166667,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.554166667,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.554166667,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.5625,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.5625,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.5625,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.5625,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.570833334,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.570833334,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.570833334,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.570833334,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.579166667,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.579166667,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.579166667,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.579166667,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.5875,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.5875,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.5875,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.5875,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.595833334,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.595833334,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.595833334,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.595833334,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.604166667,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.604166667,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.604166667,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.604166667,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.6125,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.6125,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.6125,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.6125,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.620833334,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.620833334,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.620833334,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.620833334,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.629166667,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.629166667,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.629166667,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.629166667,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.6375,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.6375,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.6375,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.6375,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.645833334,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.645833334,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.645833334,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.645833334,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.654166667,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.654166667,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.654166667,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.654166667,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.6625,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.6625,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.6625,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.6625,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.670833334,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.670833334,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.670833334,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.670833334,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.679166667,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.679166667,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.679166667,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.679166667,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.6875,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.6875,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.6875,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.6875,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.695833334,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.695833334,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.695833334,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.695833334,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.704166667,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.704166667,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.704166667,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.704166667,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.7125,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.7125,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.7125,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.7125,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.720833334,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.720833334,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.720833334,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.720833334,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.729166667,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.729166667,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.729166667,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.729166667,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.7375,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.7375,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.7375,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.7375,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.745833334,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.745833334,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.745833334,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.745833334,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.754166667,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.754166667,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.754166667,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.7625,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.7625,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.7625,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.7625,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.770833334,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.770833334,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.770833334,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.779166667,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.779166667,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.779166667,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.779166667,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.7875,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.7875,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.7875,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.795833334,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.795833334,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.795833334,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.795833334,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.804166667,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.804166667,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.804166667,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.8125,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.8125,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.8125,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.8125,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.820833334,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.820833334,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.820833334,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.820833334,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.829166667,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.829166667,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.829166667,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.8375,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.8375,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.8375,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.8375,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.845833334,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.845833334,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.845833334,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.854166667,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.854166667,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.854166667,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.854166667,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.8625,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.8625,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.8625,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.870833334,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.870833334,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.870833334,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.870833334,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.879166667,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.879166667,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.879166667,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.879166667,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.8875,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.8875,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.8875,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.895833334,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.895833334,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.895833334,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.895833334,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.904166667,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.904166667,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.904166667,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.9125,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.9125,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.9125,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.9125,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.920833334,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.920833334,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.920833334,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.929166667,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.929166667,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.929166667,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.929166667,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.9375,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.9375,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.9375,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.9375,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.945833334,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.945833334,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.945833334,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.954166667,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.954166667,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.954166667,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.954166667,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.9625,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.9625,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.9625,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.970833334,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.970833334,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.970833334,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.970833334,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.979166667,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.979166667,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.979166667,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.9875,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.9875,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.9875,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.9875,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.995833334,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.995833334,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.995833334,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
2.004166667,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
2.004166667,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
2.0125,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
2.0125,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
2.020833334,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
2.020833334,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
2.020833334,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
2.029166667,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
2.029166667,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
2.0375,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
2.0375,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
2.045833334,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
2.045833334,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
2.045833334,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
2.054166667,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
2.054166667,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
2.0625,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
2.0625,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
2.0625,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
2.070833334,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
2.070833334,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
2.079166667,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
2.079166667,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
2.0875,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
2.0875,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
2.0875,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
2.095833334,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
2.095833334,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
2.104166667,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
2.104166667,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
2.104166667,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
2.1125,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
2.1125,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
2.120833334,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
2.120833334,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
2.129166667,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
2.129166667,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
2.129166667,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
2.1375,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
2.1375,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
2.145833334,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
2.145833334,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
2.154166667,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
2.154166667,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
2.154166667,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
2.1625,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
2.1625,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
2.170833334,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
2.170833334,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
2.170833334,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
2.179166667,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
2.179166667,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
2.1875,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
2.1875,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
2.195833334,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
2.195833334,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
2.195833334,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
2.204166667,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
2.204166667,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
2.2125,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
2.2125,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
2.2125,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
2.220833334,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
2.220833334,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
2.229166667,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
2.229166667,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
2.237501815,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
2.237501815,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
2.237501815,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
2.246495047,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
2.246495047,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
2.264255947,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
2.270823349,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
2.2875,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
2.295828341,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
2.304161674,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
2.320833334,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
2.329166667,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
2.345833334,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
2.354166667,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
2.3625,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
2.379166667,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
2.3875,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
2.395833334,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
2.4125,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
2.420833334,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
2.429166667,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
2.445833334,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
2.454166667,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
2.4625,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
2.479166667,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
2.4875,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
2.520833334,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
2.545833334,0,COU-AA-302,Prednisone alone,Ryan 2013,COU-AA-302 (Ryan 2013) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
0.25,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
0.25,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
0.258333333,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
0.266666667,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
0.275,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
0.325,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
0.35,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
0.358333333,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
0.45,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
0.458333333,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
0.458333333,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
0.575,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
0.575,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
0.575,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
0.583333333,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
0.583333333,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
0.583333333,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
0.591666667,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
0.608333333,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
0.616666667,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
0.633333333,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
0.641666667,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
0.666666667,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
0.666666667,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
0.675,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
0.691666667,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
0.7,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
0.708333333,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
0.725,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
0.741666667,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
0.75,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
0.75,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
0.75,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
0.783333333,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
0.791666667,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
0.825,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
0.825,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
0.833333333,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
0.85,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
0.858333333,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
0.9,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
0.908333333,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
0.958333333,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
0.958333333,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
0.966666667,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
0.975,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
0.983333333,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.016666667,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.025,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.025,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.025,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.033333333,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.05,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.058333333,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.075,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.083333333,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.1,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.15,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.15,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.158333333,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.166666667,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.183333333,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.183333333,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.191666667,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.191666667,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.208333333,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.208333333,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.208333333,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.216666667,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.216666667,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.225,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.225,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.233333333,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.233333333,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.233333333,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.25,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.258333333,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.258333333,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.266666667,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.3,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.333333333,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.341666667,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.341666667,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.341666667,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.35,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.358333333,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.366666667,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.375,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.383333333,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.383333333,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.391666667,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.4,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.408333333,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.408333333,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.425,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.433333333,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.441666667,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.441666667,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.45,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.458333333,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.466666667,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.483333333,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.491666667,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.5,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.5,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.508333333,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.525,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.525,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.533333333,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.541666667,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.55,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.55,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.566666667,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.583333333,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.591666667,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.6,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.616666667,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.625,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.625,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.625,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.633333333,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.666666667,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.675,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.708333333,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.716666667,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.716666667,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.725,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.725,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.741666667,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.741666667,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.75,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.766666667,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.775,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.8,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.808333333,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.825,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.833333333,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.85,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.85,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.858333333,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.858333333,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.858333333,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.866666667,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.866666667,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.883333333,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.908333333,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.916666667,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.933333333,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.941666667,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.941666667,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.95,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.95,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.95,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.958333333,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.958333333,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.966666667,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.966666667,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.966666667,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.975,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.991666667,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.991666667,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.991666667,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
2,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
2,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
2.041666667,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
2.041666667,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
2.041666667,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
2.05,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
2.05,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
2.075,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
2.083333333,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
2.108333333,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
2.108333333,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
2.116666667,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
2.116666667,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
2.125,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
2.125,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
2.133333333,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
2.15,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
2.158333333,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
2.158333333,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
2.175,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
2.175,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
2.183333333,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
2.183333333,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
2.191666667,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
2.216666667,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
2.225,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
2.241666667,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
2.25,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
2.25,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
2.258333333,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
2.258333333,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
2.266666667,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
2.266666667,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
2.3,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
2.3,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
2.308333333,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
2.308333333,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
2.316666667,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
2.325,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
2.325,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
2.333333333,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
2.358333333,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
2.366666667,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
2.366666667,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
2.366666667,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
2.366666667,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
2.375,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
2.375,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
2.375,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
2.375,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
2.375,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
2.383333333,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
2.4,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
2.4,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
2.408333333,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
2.408333333,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
2.416666667,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
2.475,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
2.483333333,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
2.491666667,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
2.5,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
2.508333333,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
2.533333333,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
2.541666667,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
2.558333333,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
2.583333333,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
2.583333333,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
2.591666667,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
2.591666667,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
2.6,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
2.608333333,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
2.633333333,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
2.633333333,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
2.658333333,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
2.691666667,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
2.7,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
2.716666667,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
2.725,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
2.733333333,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
2.741666667,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
2.741666667,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
2.75,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
2.758333333,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
2.766666667,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
2.775,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
2.775,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
2.791666667,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
2.8,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
2.808333333,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
2.816666667,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
2.816666667,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
2.816666667,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
2.825,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
2.841666667,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
2.858333333,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
2.866666667,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
2.866666667,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
2.875,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
2.875,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
2.883333333,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
2.883333333,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
2.883333333,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
2.9,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
2.908333333,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
2.916666667,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
2.925,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
2.925,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
2.933333333,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
2.941666667,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
2.941666667,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
2.941666667,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
2.95,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
2.95,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
2.966666667,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
2.966666667,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
2.975,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
2.975,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
3,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
3.041666667,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
3.05,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
3.066666667,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
3.066666667,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
3.075,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
3.091666667,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
3.1,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
3.108333333,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
3.116666667,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
3.116666667,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
3.116666667,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
3.133333333,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
3.158333333,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
3.166666667,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
3.2,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
3.208333333,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
3.216666667,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
3.241666667,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
3.266666667,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
3.291666667,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
3.291666667,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
3.3,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
3.3,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
3.35,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
3.366666667,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
3.375,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
3.375,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
3.391666667,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
3.441666667,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
3.45,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
3.466666667,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
3.475,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
3.475,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
3.483333333,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
3.483333333,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
3.508333333,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
3.541666667,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
3.55,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
3.55,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
3.55,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
3.666666667,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
3.666666667,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
3.675,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
3.716666667,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
3.725,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
3.725,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
3.733333333,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
3.758333333,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
3.766666667,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
3.766666667,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
3.8,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
3.816666667,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
3.816666667,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
3.858333333,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
3.875,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
3.883333333,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
3.891666667,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
3.9,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
3.916666667,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
3.925,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
3.941666667,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
3.975,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
4.066666667,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
4.108333333,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
4.166666667,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
4.2,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
4.208333333,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
4.225,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
4.233333333,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
4.25,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
4.258333333,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
4.283333333,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
4.3,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
4.308333333,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
4.458333333,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
4.466666667,1,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
0.029166667,0,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
0.054166667,0,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
0.079166667,0,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
0.1125,0,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
0.1375,0,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
0.1625,0,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
0.195833334,0,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
0.220833334,0,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
0.3375,0,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
0.420833334,0,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
0.795833334,0,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
0.829166667,0,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
0.8625,0,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
0.904166667,0,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
0.9375,0,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
0.970833334,0,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.129166667,0,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.3375,0,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.420833334,0,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.570833334,0,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.629166667,0,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.6875,0,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.8125,0,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.870833334,0,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
1.9375,0,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
2.079166667,0,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
2.1625,0,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
2.370833334,0,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
2.579166667,0,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
2.6625,0,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
2.829166667,0,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
2.9125,0,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
3.754166667,0,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
3.7625,0,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
3.7625,0,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
3.770833334,0,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
3.770833334,0,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
3.779166667,0,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
3.779166667,0,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
3.7875,0,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
3.7875,0,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
3.795833334,0,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
3.795833334,0,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
3.804166667,0,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
3.8125,0,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
3.8125,0,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
3.820833334,0,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
3.820833334,0,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
3.829166667,0,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
3.829166667,0,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
3.8375,0,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
3.8375,0,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
3.845833334,0,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
3.845833334,0,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
3.854166667,0,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
3.8625,0,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
3.8625,0,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
3.870833334,0,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
3.870833334,0,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
3.879166667,0,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
3.879166667,0,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
3.8875,0,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
3.8875,0,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
3.895833334,0,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
3.895833334,0,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
3.904166667,0,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
3.9125,0,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
3.9125,0,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
3.920833334,0,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
3.920833334,0,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
3.929166667,0,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
3.929166667,0,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
3.9375,0,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
3.9375,0,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
3.945833334,0,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
3.945833334,0,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
3.954166667,0,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
3.9625,0,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
3.9625,0,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
3.970833334,0,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
3.970833334,0,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
3.979166667,0,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
3.979166667,0,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
3.9875,0,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
3.9875,0,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
3.995833334,0,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
4.004166667,0,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
4.0125,0,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
4.0125,0,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
4.020833334,0,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
4.020833334,0,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
4.029166667,0,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
4.029166667,0,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
4.0375,0,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
4.045833334,0,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
4.045833334,0,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
4.054166667,0,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
4.054166667,0,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
4.0625,0,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
4.0625,0,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
4.070833334,0,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
4.079166667,0,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
4.079166667,0,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
4.0875,0,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
4.0875,0,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
4.095833334,0,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
4.095833334,0,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
4.104166667,0,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
4.1125,0,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
4.1125,0,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
4.120833334,0,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
4.120833334,0,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
4.129166667,0,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
4.129166667,0,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
4.1375,0,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
4.1375,0,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
4.145833334,0,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
4.154166667,0,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
4.154166667,0,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
4.1625,0,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
4.1625,0,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
4.170833334,0,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
4.170833334,0,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
4.179166667,0,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
4.1875,0,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
4.1875,0,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
4.195833334,0,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
4.195833334,0,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
4.204166667,0,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
4.204166667,0,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
4.2125,0,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
4.220833334,0,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
4.220833334,0,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
4.229166667,0,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
4.229166667,0,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
4.2375,0,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
4.2375,0,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
4.245833334,0,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
4.254166667,0,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
4.2625,0,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
4.270833334,0,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
4.279166667,0,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
4.279166667,0,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
4.2875,0,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
4.295833334,0,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
4.304166667,0,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
4.3125,0,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
4.3125,0,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
4.320833334,0,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
4.329166667,0,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
4.3375,0,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
4.345833334,0,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
4.345833334,0,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
4.354166667,0,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
4.3625,0,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
4.370833334,0,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
4.370833334,0,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
4.379166667,0,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
4.3875,0,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
4.395833334,0,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
4.404166667,0,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
4.404166667,0,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
4.4125,0,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
4.420833334,0,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
4.429166667,0,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
4.4375,0,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
4.4375,0,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
4.445833334,0,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
4.454166667,0,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
4.4625,0,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
4.470833334,0,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
4.470833334,0,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
4.479166667,0,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
4.4875,0,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
4.495833334,0,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
4.520833334,0,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
4.545833334,0,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
4.570833334,0,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
4.595833334,0,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
4.620833334,0,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
4.645833334,0,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
4.670833334,0,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
4.695833334,0,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
4.720833334,0,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
4.741666667,0,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
4.741666667,0,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
4.741666667,0,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
4.741666667,0,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
4.741666667,0,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
4.741666667,0,COU-AA-302,Abirateroneprednisone,Ryan 2015,COU-AA-302 (Ryan 2015) - Abirateroneprednisone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Abi-Rya
0.25,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
0.25,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
0.25,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
0.25,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
0.25,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
0.308333333,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
0.339677961,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
0.339677961,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
0.35,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
0.35,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
0.408333333,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
0.408333333,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
0.416666667,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
0.416666667,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
0.416666667,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
0.425,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
0.433333333,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
0.525,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
0.583333333,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
0.583333333,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
0.616666667,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
0.616666667,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
0.625,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
0.633333333,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
0.633333333,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
0.708333333,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
0.708333333,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
0.716666667,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
0.716666667,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
0.716666667,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
0.741666667,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
0.741666667,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
0.741666667,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
0.741666667,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
0.8,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
0.808333333,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
0.816666667,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
0.816666667,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
0.883333333,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
0.908333333,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
0.908333333,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
0.916666667,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
0.925,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
0.933333333,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
0.958333333,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
0.958333333,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
0.966666667,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
0.966666667,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
0.975,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
0.983333333,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
0.983333333,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
0.991666667,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.016666667,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.016666667,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.025,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.025,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.041666667,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.05,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.066666667,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.066666667,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.075,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.075,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.1,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.116666667,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.125,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.15,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.158333333,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.158333333,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.175,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.183333333,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.183333333,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.191666667,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.191666667,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.208333333,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.208333333,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.216666667,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.216666667,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.225,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.233333333,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.233333333,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.25,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.25,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.258333333,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.316666667,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.333333333,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.333333333,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.333333333,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.341666667,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.341666667,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.358333333,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.366666667,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.391666667,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.391666667,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.4,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.4,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.408333333,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.408333333,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.408333333,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.408333333,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.416666667,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.416666667,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.433333333,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.441666667,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.441666667,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.458333333,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.458333333,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.466666667,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.466666667,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.466666667,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.491666667,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.491666667,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.491666667,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.5,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.5,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.5,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.5,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.516666667,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.516666667,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.525,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.533333333,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.533333333,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.541666667,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.55,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.55,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.558333333,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.558333333,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.558333333,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.566666667,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.566666667,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.566666667,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.575,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.583333333,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.583333333,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.591666667,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.6,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.6,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.6,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.608333333,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.608333333,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.625,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.633333333,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.658333333,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.666666667,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.666666667,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.691666667,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.7,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.708333333,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.716666667,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.716666667,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.716666667,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.725,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.733333333,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.75,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.758333333,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.758333333,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.766666667,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.766666667,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.766666667,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.775,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.775,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.783333333,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.783333333,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.783333333,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.791666667,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.791666667,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.8,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.8,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.808333333,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.833333333,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.841666667,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.841666667,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.85,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.866666667,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.866666667,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.875,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.883333333,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.891666667,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.891666667,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.891666667,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.891666667,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.9,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.908333333,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.933333333,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.933333333,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.941666667,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.966666667,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.975,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.983333333,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.983333333,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.991666667,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.991666667,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
2.008333333,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
2.016666667,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
2.025,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
2.058333333,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
2.066666667,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
2.075,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
2.083333333,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
2.083333333,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
2.108333333,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
2.116666667,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
2.116666667,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
2.141666667,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
2.141666667,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
2.15,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
2.15,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
2.15,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
2.166666667,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
2.175,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
2.183333333,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
2.191666667,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
2.191666667,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
2.2,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
2.208333333,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
2.216666667,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
2.216666667,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
2.225,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
2.225,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
2.266666667,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
2.266666667,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
2.275,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
2.275,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
2.291666667,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
2.3,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
2.3,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
2.308333333,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
2.308333333,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
2.325,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
2.325,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
2.333333333,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
2.333333333,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
2.333333333,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
2.383333333,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
2.383333333,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
2.391666667,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
2.391666667,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
2.4,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
2.408333333,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
2.416666667,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
2.425,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
2.433333333,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
2.466666667,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
2.475,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
2.491666667,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
2.5,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
2.5,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
2.508333333,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
2.508333333,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
2.508333333,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
2.516666667,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
2.516666667,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
2.516666667,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
2.525,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
2.525,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
2.525,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
2.525,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
2.533333333,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
2.541666667,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
2.575,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
2.575,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
2.575,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
2.583333333,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
2.583333333,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
2.583333333,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
2.583333333,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
2.591666667,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
2.625,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
2.633333333,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
2.65,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
2.658333333,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
2.658333333,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
2.691666667,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
2.7,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
2.733333333,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
2.741666667,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
2.758333333,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
2.766666667,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
2.766666667,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
2.775,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
2.775,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
2.791666667,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
2.8,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
2.808333333,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
2.808333333,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
2.808333333,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
2.808333333,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
2.816666667,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
2.816666667,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
2.858333333,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
2.9,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
2.9,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
2.908333333,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
2.908333333,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
2.908333333,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
2.908333333,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
2.916666667,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
2.916666667,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
2.983333333,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
3.008333333,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
3.016666667,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
3.033333333,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
3.041666667,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
3.041666667,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
3.075,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
3.075,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
3.083333333,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
3.091666667,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
3.1,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
3.108333333,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
3.116666667,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
3.125,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
3.133333333,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
3.141666667,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
3.141666667,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
3.183333333,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
3.183333333,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
3.191666667,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
3.191666667,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
3.208333333,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
3.216666667,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
3.216666667,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
3.266666667,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
3.266666667,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
3.266666667,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
3.266666667,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
3.291666667,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
3.291666667,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
3.3,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
3.3,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
3.308333333,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
3.316666667,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
3.333333333,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
3.375,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
3.4,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
3.408333333,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
3.425,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
3.425,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
3.433333333,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
3.441666667,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
3.45,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
3.458333333,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
3.466666667,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
3.466666667,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
3.466666667,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
3.475,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
3.483333333,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
3.483333333,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
3.491666667,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
3.491666667,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
3.508333333,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
3.516666667,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
3.516666667,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
3.583333333,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
3.591666667,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
3.591666667,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
3.658333333,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
3.658333333,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
3.658333333,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
3.658333333,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
3.666666667,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
3.666666667,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
3.666666667,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
3.7,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
3.708333333,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
3.791666667,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
3.808333333,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
3.808333333,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
3.816666667,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
3.816666667,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
3.9,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
3.908333333,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
3.916666667,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
3.966666667,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
4,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
4.008333333,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
4.091666667,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
4.1,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
4.158333333,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
4.216666667,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
4.225,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
4.382678375,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
4.423778285,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
4.423778285,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
4.458249178,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
4.458249178,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
4.540448998,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
4.708333333,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
4.708333333,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
4.708333333,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
4.708333333,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
4.849361225,1,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
0.029166667,0,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
0.054166667,0,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
0.079166667,0,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
0.1125,0,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
0.1375,0,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
0.1625,0,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
0.195833334,0,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
0.220833334,0,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
0.279166667,0,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
0.304166667,0,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
0.336505647,0,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
0.3625,0,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
0.395833334,0,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
0.420833334,0,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
0.454166667,0,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
0.479166667,0,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
0.7875,0,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
0.820833334,0,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
0.854166667,0,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
0.879166667,0,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
0.9125,0,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
0.945833334,0,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
0.979166667,0,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.379166667,0,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.5875,0,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.670833334,0,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.829166667,0,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
1.9125,0,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
2.0625,0,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
2.120833334,0,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
2.1875,0,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
2.2875,0,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
2.329166667,0,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
2.370833334,0,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
2.4125,0,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
2.454166667,0,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
2.5625,0,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
2.620833334,0,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
2.6875,0,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
2.8125,0,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
2.870833334,0,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
2.9375,0,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
3.079166667,0,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
3.1625,0,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
3.620833334,0,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
3.754166667,0,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
3.7625,0,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
3.770833334,0,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
3.770833334,0,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
3.779166667,0,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
3.7875,0,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
3.795833334,0,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
3.795833334,0,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
3.804166667,0,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
3.8125,0,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
3.820833334,0,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
3.820833334,0,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
3.829166667,0,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
3.8375,0,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
3.845833334,0,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
3.845833334,0,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
3.854166667,0,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
3.8625,0,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
3.870833334,0,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
3.870833334,0,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
3.879166667,0,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
3.8875,0,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
3.895833334,0,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
3.895833334,0,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
3.904166667,0,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
3.9125,0,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
3.920833334,0,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
3.920833334,0,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
3.929166667,0,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
3.9375,0,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
3.945833334,0,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
3.945833334,0,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
3.954166667,0,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
3.9625,0,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
3.970833334,0,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
3.970833334,0,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
3.979166667,0,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
3.9875,0,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
3.995833334,0,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
4.004166667,0,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
4.0125,0,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
4.020833334,0,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
4.029166667,0,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
4.0375,0,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
4.0375,0,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
4.045833334,0,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
4.054166667,0,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
4.0625,0,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
4.070833334,0,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
4.079166667,0,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
4.079166667,0,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
4.0875,0,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
4.095833334,0,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
4.104166667,0,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
4.1125,0,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
4.120833334,0,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
4.120833334,0,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
4.129166667,0,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
4.1375,0,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
4.145833334,0,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
4.154166667,0,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
4.1625,0,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
4.1625,0,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
4.170833334,0,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
4.179166667,0,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
4.1875,0,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
4.195833334,0,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
4.204166667,0,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
4.204166667,0,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
4.2125,0,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
4.220833334,0,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
4.229166667,0,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
4.2375,0,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
4.245833334,0,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
4.2625,0,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
4.270833334,0,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
4.279166667,0,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
4.2875,0,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
4.295833334,0,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
4.304166667,0,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
4.3125,0,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
4.320833334,0,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
4.329166667,0,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
4.3375,0,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
4.345833334,0,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
4.354166667,0,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
4.3625,0,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
4.370833334,0,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
4.3875,0,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
4.395833334,0,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
4.404166667,0,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
4.4125,0,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
4.420222476,0,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
4.429218711,0,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
4.4375,0,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
4.445833334,0,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
4.453461687,0,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
4.4625,0,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
4.470833334,0,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
4.479166667,0,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
4.4875,0,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
4.624391166,0,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
4.624391166,0,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
4.716666667,0,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
4.787180613,0,COU-AA-302,Prednisone alone,Ryan 2015,COU-AA-302 (Ryan 2015) - Prednisone alone,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,COU-Pre-Rya
0.13963039,1,CS21,Degarelix 240-80,Tombal 2010,CS21 (Tombal 2010) - Degarelix 240-80,advanced hormone-dependent prostate cancer,CS2-Deg-Tom
0.235455168,1,CS21,Degarelix 240-80,Tombal 2010,CS21 (Tombal 2010) - Degarelix 240-80,advanced hormone-dependent prostate cancer,CS2-Deg-Tom
0.366872005,1,CS21,Degarelix 240-80,Tombal 2010,CS21 (Tombal 2010) - Degarelix 240-80,advanced hormone-dependent prostate cancer,CS2-Deg-Tom
0.377823409,1,CS21,Degarelix 240-80,Tombal 2010,CS21 (Tombal 2010) - Degarelix 240-80,advanced hormone-dependent prostate cancer,CS2-Deg-Tom
0.783025325,1,CS21,Degarelix 240-80,Tombal 2010,CS21 (Tombal 2010) - Degarelix 240-80,advanced hormone-dependent prostate cancer,CS2-Deg-Tom
0.993839836,0,CS21,Degarelix 240-80,Tombal 2010,CS21 (Tombal 2010) - Degarelix 240-80,advanced hormone-dependent prostate cancer,CS2-Deg-Tom
0.993839836,0,CS21,Degarelix 240-80,Tombal 2010,CS21 (Tombal 2010) - Degarelix 240-80,advanced hormone-dependent prostate cancer,CS2-Deg-Tom
0.993839836,0,CS21,Degarelix 240-80,Tombal 2010,CS21 (Tombal 2010) - Degarelix 240-80,advanced hormone-dependent prostate cancer,CS2-Deg-Tom
0.993839836,0,CS21,Degarelix 240-80,Tombal 2010,CS21 (Tombal 2010) - Degarelix 240-80,advanced hormone-dependent prostate cancer,CS2-Deg-Tom
0.993839836,0,CS21,Degarelix 240-80,Tombal 2010,CS21 (Tombal 2010) - Degarelix 240-80,advanced hormone-dependent prostate cancer,CS2-Deg-Tom
0.993839836,0,CS21,Degarelix 240-80,Tombal 2010,CS21 (Tombal 2010) - Degarelix 240-80,advanced hormone-dependent prostate cancer,CS2-Deg-Tom
0.993839836,0,CS21,Degarelix 240-80,Tombal 2010,CS21 (Tombal 2010) - Degarelix 240-80,advanced hormone-dependent prostate cancer,CS2-Deg-Tom
0.993839836,0,CS21,Degarelix 240-80,Tombal 2010,CS21 (Tombal 2010) - Degarelix 240-80,advanced hormone-dependent prostate cancer,CS2-Deg-Tom
0.993839836,0,CS21,Degarelix 240-80,Tombal 2010,CS21 (Tombal 2010) - Degarelix 240-80,advanced hormone-dependent prostate cancer,CS2-Deg-Tom
0.993839836,0,CS21,Degarelix 240-80,Tombal 2010,CS21 (Tombal 2010) - Degarelix 240-80,advanced hormone-dependent prostate cancer,CS2-Deg-Tom
0.993839836,0,CS21,Degarelix 240-80,Tombal 2010,CS21 (Tombal 2010) - Degarelix 240-80,advanced hormone-dependent prostate cancer,CS2-Deg-Tom
0.993839836,0,CS21,Degarelix 240-80,Tombal 2010,CS21 (Tombal 2010) - Degarelix 240-80,advanced hormone-dependent prostate cancer,CS2-Deg-Tom
0.993839836,0,CS21,Degarelix 240-80,Tombal 2010,CS21 (Tombal 2010) - Degarelix 240-80,advanced hormone-dependent prostate cancer,CS2-Deg-Tom
0.993839836,0,CS21,Degarelix 240-80,Tombal 2010,CS21 (Tombal 2010) - Degarelix 240-80,advanced hormone-dependent prostate cancer,CS2-Deg-Tom
0.993839836,0,CS21,Degarelix 240-80,Tombal 2010,CS21 (Tombal 2010) - Degarelix 240-80,advanced hormone-dependent prostate cancer,CS2-Deg-Tom
0.993839836,0,CS21,Degarelix 240-80,Tombal 2010,CS21 (Tombal 2010) - Degarelix 240-80,advanced hormone-dependent prostate cancer,CS2-Deg-Tom
0.993839836,0,CS21,Degarelix 240-80,Tombal 2010,CS21 (Tombal 2010) - Degarelix 240-80,advanced hormone-dependent prostate cancer,CS2-Deg-Tom
0.993839836,0,CS21,Degarelix 240-80,Tombal 2010,CS21 (Tombal 2010) - Degarelix 240-80,advanced hormone-dependent prostate cancer,CS2-Deg-Tom
0.993839836,0,CS21,Degarelix 240-80,Tombal 2010,CS21 (Tombal 2010) - Degarelix 240-80,advanced hormone-dependent prostate cancer,CS2-Deg-Tom
0.993839836,0,CS21,Degarelix 240-80,Tombal 2010,CS21 (Tombal 2010) - Degarelix 240-80,advanced hormone-dependent prostate cancer,CS2-Deg-Tom
0.993839836,0,CS21,Degarelix 240-80,Tombal 2010,CS21 (Tombal 2010) - Degarelix 240-80,advanced hormone-dependent prostate cancer,CS2-Deg-Tom
0.993839836,0,CS21,Degarelix 240-80,Tombal 2010,CS21 (Tombal 2010) - Degarelix 240-80,advanced hormone-dependent prostate cancer,CS2-Deg-Tom
0.993839836,0,CS21,Degarelix 240-80,Tombal 2010,CS21 (Tombal 2010) - Degarelix 240-80,advanced hormone-dependent prostate cancer,CS2-Deg-Tom
0.993839836,0,CS21,Degarelix 240-80,Tombal 2010,CS21 (Tombal 2010) - Degarelix 240-80,advanced hormone-dependent prostate cancer,CS2-Deg-Tom
0.993839836,0,CS21,Degarelix 240-80,Tombal 2010,CS21 (Tombal 2010) - Degarelix 240-80,advanced hormone-dependent prostate cancer,CS2-Deg-Tom
0.993839836,0,CS21,Degarelix 240-80,Tombal 2010,CS21 (Tombal 2010) - Degarelix 240-80,advanced hormone-dependent prostate cancer,CS2-Deg-Tom
0.993839836,0,CS21,Degarelix 240-80,Tombal 2010,CS21 (Tombal 2010) - Degarelix 240-80,advanced hormone-dependent prostate cancer,CS2-Deg-Tom
0.993839836,0,CS21,Degarelix 240-80,Tombal 2010,CS21 (Tombal 2010) - Degarelix 240-80,advanced hormone-dependent prostate cancer,CS2-Deg-Tom
0.993839836,0,CS21,Degarelix 240-80,Tombal 2010,CS21 (Tombal 2010) - Degarelix 240-80,advanced hormone-dependent prostate cancer,CS2-Deg-Tom
0.993839836,0,CS21,Degarelix 240-80,Tombal 2010,CS21 (Tombal 2010) - Degarelix 240-80,advanced hormone-dependent prostate cancer,CS2-Deg-Tom
0.993839836,0,CS21,Degarelix 240-80,Tombal 2010,CS21 (Tombal 2010) - Degarelix 240-80,advanced hormone-dependent prostate cancer,CS2-Deg-Tom
0.993839836,0,CS21,Degarelix 240-80,Tombal 2010,CS21 (Tombal 2010) - Degarelix 240-80,advanced hormone-dependent prostate cancer,CS2-Deg-Tom
0.993839836,0,CS21,Degarelix 240-80,Tombal 2010,CS21 (Tombal 2010) - Degarelix 240-80,advanced hormone-dependent prostate cancer,CS2-Deg-Tom
0.993839836,0,CS21,Degarelix 240-80,Tombal 2010,CS21 (Tombal 2010) - Degarelix 240-80,advanced hormone-dependent prostate cancer,CS2-Deg-Tom
0.993839836,0,CS21,Degarelix 240-80,Tombal 2010,CS21 (Tombal 2010) - Degarelix 240-80,advanced hormone-dependent prostate cancer,CS2-Deg-Tom
0.993839836,0,CS21,Degarelix 240-80,Tombal 2010,CS21 (Tombal 2010) - Degarelix 240-80,advanced hormone-dependent prostate cancer,CS2-Deg-Tom
0.993839836,0,CS21,Degarelix 240-80,Tombal 2010,CS21 (Tombal 2010) - Degarelix 240-80,advanced hormone-dependent prostate cancer,CS2-Deg-Tom
0.993839836,0,CS21,Degarelix 240-80,Tombal 2010,CS21 (Tombal 2010) - Degarelix 240-80,advanced hormone-dependent prostate cancer,CS2-Deg-Tom
0.993839836,0,CS21,Degarelix 240-80,Tombal 2010,CS21 (Tombal 2010) - Degarelix 240-80,advanced hormone-dependent prostate cancer,CS2-Deg-Tom
0.993839836,0,CS21,Degarelix 240-80,Tombal 2010,CS21 (Tombal 2010) - Degarelix 240-80,advanced hormone-dependent prostate cancer,CS2-Deg-Tom
0.993839836,0,CS21,Degarelix 240-80,Tombal 2010,CS21 (Tombal 2010) - Degarelix 240-80,advanced hormone-dependent prostate cancer,CS2-Deg-Tom
0.993839836,0,CS21,Degarelix 240-80,Tombal 2010,CS21 (Tombal 2010) - Degarelix 240-80,advanced hormone-dependent prostate cancer,CS2-Deg-Tom
0.993839836,0,CS21,Degarelix 240-80,Tombal 2010,CS21 (Tombal 2010) - Degarelix 240-80,advanced hormone-dependent prostate cancer,CS2-Deg-Tom
0.993839836,0,CS21,Degarelix 240-80,Tombal 2010,CS21 (Tombal 2010) - Degarelix 240-80,advanced hormone-dependent prostate cancer,CS2-Deg-Tom
0.993839836,0,CS21,Degarelix 240-80,Tombal 2010,CS21 (Tombal 2010) - Degarelix 240-80,advanced hormone-dependent prostate cancer,CS2-Deg-Tom
0.993839836,0,CS21,Degarelix 240-80,Tombal 2010,CS21 (Tombal 2010) - Degarelix 240-80,advanced hormone-dependent prostate cancer,CS2-Deg-Tom
0.993839836,0,CS21,Degarelix 240-80,Tombal 2010,CS21 (Tombal 2010) - Degarelix 240-80,advanced hormone-dependent prostate cancer,CS2-Deg-Tom
0.993839836,0,CS21,Degarelix 240-80,Tombal 2010,CS21 (Tombal 2010) - Degarelix 240-80,advanced hormone-dependent prostate cancer,CS2-Deg-Tom
0.993839836,0,CS21,Degarelix 240-80,Tombal 2010,CS21 (Tombal 2010) - Degarelix 240-80,advanced hormone-dependent prostate cancer,CS2-Deg-Tom
0.993839836,0,CS21,Degarelix 240-80,Tombal 2010,CS21 (Tombal 2010) - Degarelix 240-80,advanced hormone-dependent prostate cancer,CS2-Deg-Tom
0.993839836,0,CS21,Degarelix 240-80,Tombal 2010,CS21 (Tombal 2010) - Degarelix 240-80,advanced hormone-dependent prostate cancer,CS2-Deg-Tom
0.993839836,0,CS21,Degarelix 240-80,Tombal 2010,CS21 (Tombal 2010) - Degarelix 240-80,advanced hormone-dependent prostate cancer,CS2-Deg-Tom
0.993839836,0,CS21,Degarelix 240-80,Tombal 2010,CS21 (Tombal 2010) - Degarelix 240-80,advanced hormone-dependent prostate cancer,CS2-Deg-Tom
0.993839836,0,CS21,Degarelix 240-80,Tombal 2010,CS21 (Tombal 2010) - Degarelix 240-80,advanced hormone-dependent prostate cancer,CS2-Deg-Tom
0.993839836,0,CS21,Degarelix 240-80,Tombal 2010,CS21 (Tombal 2010) - Degarelix 240-80,advanced hormone-dependent prostate cancer,CS2-Deg-Tom
0.993839836,0,CS21,Degarelix 240-80,Tombal 2010,CS21 (Tombal 2010) - Degarelix 240-80,advanced hormone-dependent prostate cancer,CS2-Deg-Tom
0.993839836,0,CS21,Degarelix 240-80,Tombal 2010,CS21 (Tombal 2010) - Degarelix 240-80,advanced hormone-dependent prostate cancer,CS2-Deg-Tom
0.993839836,0,CS21,Degarelix 240-80,Tombal 2010,CS21 (Tombal 2010) - Degarelix 240-80,advanced hormone-dependent prostate cancer,CS2-Deg-Tom
0.993839836,0,CS21,Degarelix 240-80,Tombal 2010,CS21 (Tombal 2010) - Degarelix 240-80,advanced hormone-dependent prostate cancer,CS2-Deg-Tom
0.993839836,0,CS21,Degarelix 240-80,Tombal 2010,CS21 (Tombal 2010) - Degarelix 240-80,advanced hormone-dependent prostate cancer,CS2-Deg-Tom
0.993839836,0,CS21,Degarelix 240-80,Tombal 2010,CS21 (Tombal 2010) - Degarelix 240-80,advanced hormone-dependent prostate cancer,CS2-Deg-Tom
0.993839836,0,CS21,Degarelix 240-80,Tombal 2010,CS21 (Tombal 2010) - Degarelix 240-80,advanced hormone-dependent prostate cancer,CS2-Deg-Tom
0.993839836,0,CS21,Degarelix 240-80,Tombal 2010,CS21 (Tombal 2010) - Degarelix 240-80,advanced hormone-dependent prostate cancer,CS2-Deg-Tom
0.993839836,0,CS21,Degarelix 240-80,Tombal 2010,CS21 (Tombal 2010) - Degarelix 240-80,advanced hormone-dependent prostate cancer,CS2-Deg-Tom
0.993839836,0,CS21,Degarelix 240-80,Tombal 2010,CS21 (Tombal 2010) - Degarelix 240-80,advanced hormone-dependent prostate cancer,CS2-Deg-Tom
0.993839836,0,CS21,Degarelix 240-80,Tombal 2010,CS21 (Tombal 2010) - Degarelix 240-80,advanced hormone-dependent prostate cancer,CS2-Deg-Tom
0.993839836,0,CS21,Degarelix 240-80,Tombal 2010,CS21 (Tombal 2010) - Degarelix 240-80,advanced hormone-dependent prostate cancer,CS2-Deg-Tom
0.993839836,0,CS21,Degarelix 240-80,Tombal 2010,CS21 (Tombal 2010) - Degarelix 240-80,advanced hormone-dependent prostate cancer,CS2-Deg-Tom
0.993839836,0,CS21,Degarelix 240-80,Tombal 2010,CS21 (Tombal 2010) - Degarelix 240-80,advanced hormone-dependent prostate cancer,CS2-Deg-Tom
0.993839836,0,CS21,Degarelix 240-80,Tombal 2010,CS21 (Tombal 2010) - Degarelix 240-80,advanced hormone-dependent prostate cancer,CS2-Deg-Tom
0.993839836,0,CS21,Degarelix 240-80,Tombal 2010,CS21 (Tombal 2010) - Degarelix 240-80,advanced hormone-dependent prostate cancer,CS2-Deg-Tom
0.993839836,0,CS21,Degarelix 240-80,Tombal 2010,CS21 (Tombal 2010) - Degarelix 240-80,advanced hormone-dependent prostate cancer,CS2-Deg-Tom
0.993839836,0,CS21,Degarelix 240-80,Tombal 2010,CS21 (Tombal 2010) - Degarelix 240-80,advanced hormone-dependent prostate cancer,CS2-Deg-Tom
0.993839836,0,CS21,Degarelix 240-80,Tombal 2010,CS21 (Tombal 2010) - Degarelix 240-80,advanced hormone-dependent prostate cancer,CS2-Deg-Tom
0.993839836,0,CS21,Degarelix 240-80,Tombal 2010,CS21 (Tombal 2010) - Degarelix 240-80,advanced hormone-dependent prostate cancer,CS2-Deg-Tom
0.993839836,0,CS21,Degarelix 240-80,Tombal 2010,CS21 (Tombal 2010) - Degarelix 240-80,advanced hormone-dependent prostate cancer,CS2-Deg-Tom
0.993839836,0,CS21,Degarelix 240-80,Tombal 2010,CS21 (Tombal 2010) - Degarelix 240-80,advanced hormone-dependent prostate cancer,CS2-Deg-Tom
0.993839836,0,CS21,Degarelix 240-80,Tombal 2010,CS21 (Tombal 2010) - Degarelix 240-80,advanced hormone-dependent prostate cancer,CS2-Deg-Tom
0.993839836,0,CS21,Degarelix 240-80,Tombal 2010,CS21 (Tombal 2010) - Degarelix 240-80,advanced hormone-dependent prostate cancer,CS2-Deg-Tom
0.993839836,0,CS21,Degarelix 240-80,Tombal 2010,CS21 (Tombal 2010) - Degarelix 240-80,advanced hormone-dependent prostate cancer,CS2-Deg-Tom
0.993839836,0,CS21,Degarelix 240-80,Tombal 2010,CS21 (Tombal 2010) - Degarelix 240-80,advanced hormone-dependent prostate cancer,CS2-Deg-Tom
0.993839836,0,CS21,Degarelix 240-80,Tombal 2010,CS21 (Tombal 2010) - Degarelix 240-80,advanced hormone-dependent prostate cancer,CS2-Deg-Tom
0.993839836,0,CS21,Degarelix 240-80,Tombal 2010,CS21 (Tombal 2010) - Degarelix 240-80,advanced hormone-dependent prostate cancer,CS2-Deg-Tom
0.993839836,0,CS21,Degarelix 240-80,Tombal 2010,CS21 (Tombal 2010) - Degarelix 240-80,advanced hormone-dependent prostate cancer,CS2-Deg-Tom
0.993839836,0,CS21,Degarelix 240-80,Tombal 2010,CS21 (Tombal 2010) - Degarelix 240-80,advanced hormone-dependent prostate cancer,CS2-Deg-Tom
0.993839836,0,CS21,Degarelix 240-80,Tombal 2010,CS21 (Tombal 2010) - Degarelix 240-80,advanced hormone-dependent prostate cancer,CS2-Deg-Tom
0.993839836,0,CS21,Degarelix 240-80,Tombal 2010,CS21 (Tombal 2010) - Degarelix 240-80,advanced hormone-dependent prostate cancer,CS2-Deg-Tom
0.993839836,0,CS21,Degarelix 240-80,Tombal 2010,CS21 (Tombal 2010) - Degarelix 240-80,advanced hormone-dependent prostate cancer,CS2-Deg-Tom
0.993839836,0,CS21,Degarelix 240-80,Tombal 2010,CS21 (Tombal 2010) - Degarelix 240-80,advanced hormone-dependent prostate cancer,CS2-Deg-Tom
0.993839836,0,CS21,Degarelix 240-80,Tombal 2010,CS21 (Tombal 2010) - Degarelix 240-80,advanced hormone-dependent prostate cancer,CS2-Deg-Tom
0.993839836,0,CS21,Degarelix 240-80,Tombal 2010,CS21 (Tombal 2010) - Degarelix 240-80,advanced hormone-dependent prostate cancer,CS2-Deg-Tom
0.993839836,0,CS21,Degarelix 240-80,Tombal 2010,CS21 (Tombal 2010) - Degarelix 240-80,advanced hormone-dependent prostate cancer,CS2-Deg-Tom
0.993839836,0,CS21,Degarelix 240-80,Tombal 2010,CS21 (Tombal 2010) - Degarelix 240-80,advanced hormone-dependent prostate cancer,CS2-Deg-Tom
0.993839836,0,CS21,Degarelix 240-80,Tombal 2010,CS21 (Tombal 2010) - Degarelix 240-80,advanced hormone-dependent prostate cancer,CS2-Deg-Tom
0.993839836,0,CS21,Degarelix 240-80,Tombal 2010,CS21 (Tombal 2010) - Degarelix 240-80,advanced hormone-dependent prostate cancer,CS2-Deg-Tom
0.993839836,0,CS21,Degarelix 240-80,Tombal 2010,CS21 (Tombal 2010) - Degarelix 240-80,advanced hormone-dependent prostate cancer,CS2-Deg-Tom
0.993839836,0,CS21,Degarelix 240-80,Tombal 2010,CS21 (Tombal 2010) - Degarelix 240-80,advanced hormone-dependent prostate cancer,CS2-Deg-Tom
0.993839836,0,CS21,Degarelix 240-80,Tombal 2010,CS21 (Tombal 2010) - Degarelix 240-80,advanced hormone-dependent prostate cancer,CS2-Deg-Tom
0.993839836,0,CS21,Degarelix 240-80,Tombal 2010,CS21 (Tombal 2010) - Degarelix 240-80,advanced hormone-dependent prostate cancer,CS2-Deg-Tom
0.993839836,0,CS21,Degarelix 240-80,Tombal 2010,CS21 (Tombal 2010) - Degarelix 240-80,advanced hormone-dependent prostate cancer,CS2-Deg-Tom
0.993839836,0,CS21,Degarelix 240-80,Tombal 2010,CS21 (Tombal 2010) - Degarelix 240-80,advanced hormone-dependent prostate cancer,CS2-Deg-Tom
0.993839836,0,CS21,Degarelix 240-80,Tombal 2010,CS21 (Tombal 2010) - Degarelix 240-80,advanced hormone-dependent prostate cancer,CS2-Deg-Tom
0.993839836,0,CS21,Degarelix 240-80,Tombal 2010,CS21 (Tombal 2010) - Degarelix 240-80,advanced hormone-dependent prostate cancer,CS2-Deg-Tom
0.993839836,0,CS21,Degarelix 240-80,Tombal 2010,CS21 (Tombal 2010) - Degarelix 240-80,advanced hormone-dependent prostate cancer,CS2-Deg-Tom
0.993839836,0,CS21,Degarelix 240-80,Tombal 2010,CS21 (Tombal 2010) - Degarelix 240-80,advanced hormone-dependent prostate cancer,CS2-Deg-Tom
0.993839836,0,CS21,Degarelix 240-80,Tombal 2010,CS21 (Tombal 2010) - Degarelix 240-80,advanced hormone-dependent prostate cancer,CS2-Deg-Tom
0.993839836,0,CS21,Degarelix 240-80,Tombal 2010,CS21 (Tombal 2010) - Degarelix 240-80,advanced hormone-dependent prostate cancer,CS2-Deg-Tom
0.993839836,0,CS21,Degarelix 240-80,Tombal 2010,CS21 (Tombal 2010) - Degarelix 240-80,advanced hormone-dependent prostate cancer,CS2-Deg-Tom
0.993839836,0,CS21,Degarelix 240-80,Tombal 2010,CS21 (Tombal 2010) - Degarelix 240-80,advanced hormone-dependent prostate cancer,CS2-Deg-Tom
0.993839836,0,CS21,Degarelix 240-80,Tombal 2010,CS21 (Tombal 2010) - Degarelix 240-80,advanced hormone-dependent prostate cancer,CS2-Deg-Tom
0.993839836,0,CS21,Degarelix 240-80,Tombal 2010,CS21 (Tombal 2010) - Degarelix 240-80,advanced hormone-dependent prostate cancer,CS2-Deg-Tom
0.993839836,0,CS21,Degarelix 240-80,Tombal 2010,CS21 (Tombal 2010) - Degarelix 240-80,advanced hormone-dependent prostate cancer,CS2-Deg-Tom
0.993839836,0,CS21,Degarelix 240-80,Tombal 2010,CS21 (Tombal 2010) - Degarelix 240-80,advanced hormone-dependent prostate cancer,CS2-Deg-Tom
0.993839836,0,CS21,Degarelix 240-80,Tombal 2010,CS21 (Tombal 2010) - Degarelix 240-80,advanced hormone-dependent prostate cancer,CS2-Deg-Tom
0.993839836,0,CS21,Degarelix 240-80,Tombal 2010,CS21 (Tombal 2010) - Degarelix 240-80,advanced hormone-dependent prostate cancer,CS2-Deg-Tom
0.993839836,0,CS21,Degarelix 240-80,Tombal 2010,CS21 (Tombal 2010) - Degarelix 240-80,advanced hormone-dependent prostate cancer,CS2-Deg-Tom
0.993839836,0,CS21,Degarelix 240-80,Tombal 2010,CS21 (Tombal 2010) - Degarelix 240-80,advanced hormone-dependent prostate cancer,CS2-Deg-Tom
0.993839836,0,CS21,Degarelix 240-80,Tombal 2010,CS21 (Tombal 2010) - Degarelix 240-80,advanced hormone-dependent prostate cancer,CS2-Deg-Tom
0.993839836,0,CS21,Degarelix 240-80,Tombal 2010,CS21 (Tombal 2010) - Degarelix 240-80,advanced hormone-dependent prostate cancer,CS2-Deg-Tom
0.993839836,0,CS21,Degarelix 240-80,Tombal 2010,CS21 (Tombal 2010) - Degarelix 240-80,advanced hormone-dependent prostate cancer,CS2-Deg-Tom
0.993839836,0,CS21,Degarelix 240-80,Tombal 2010,CS21 (Tombal 2010) - Degarelix 240-80,advanced hormone-dependent prostate cancer,CS2-Deg-Tom
0.993839836,0,CS21,Degarelix 240-80,Tombal 2010,CS21 (Tombal 2010) - Degarelix 240-80,advanced hormone-dependent prostate cancer,CS2-Deg-Tom
0.993839836,0,CS21,Degarelix 240-80,Tombal 2010,CS21 (Tombal 2010) - Degarelix 240-80,advanced hormone-dependent prostate cancer,CS2-Deg-Tom
0.993839836,0,CS21,Degarelix 240-80,Tombal 2010,CS21 (Tombal 2010) - Degarelix 240-80,advanced hormone-dependent prostate cancer,CS2-Deg-Tom
0.993839836,0,CS21,Degarelix 240-80,Tombal 2010,CS21 (Tombal 2010) - Degarelix 240-80,advanced hormone-dependent prostate cancer,CS2-Deg-Tom
0.993839836,0,CS21,Degarelix 240-80,Tombal 2010,CS21 (Tombal 2010) - Degarelix 240-80,advanced hormone-dependent prostate cancer,CS2-Deg-Tom
0.993839836,0,CS21,Degarelix 240-80,Tombal 2010,CS21 (Tombal 2010) - Degarelix 240-80,advanced hormone-dependent prostate cancer,CS2-Deg-Tom
0.993839836,0,CS21,Degarelix 240-80,Tombal 2010,CS21 (Tombal 2010) - Degarelix 240-80,advanced hormone-dependent prostate cancer,CS2-Deg-Tom
0.993839836,0,CS21,Degarelix 240-80,Tombal 2010,CS21 (Tombal 2010) - Degarelix 240-80,advanced hormone-dependent prostate cancer,CS2-Deg-Tom
0.993839836,0,CS21,Degarelix 240-80,Tombal 2010,CS21 (Tombal 2010) - Degarelix 240-80,advanced hormone-dependent prostate cancer,CS2-Deg-Tom
0.993839836,0,CS21,Degarelix 240-80,Tombal 2010,CS21 (Tombal 2010) - Degarelix 240-80,advanced hormone-dependent prostate cancer,CS2-Deg-Tom
0.993839836,0,CS21,Degarelix 240-80,Tombal 2010,CS21 (Tombal 2010) - Degarelix 240-80,advanced hormone-dependent prostate cancer,CS2-Deg-Tom
0.993839836,0,CS21,Degarelix 240-80,Tombal 2010,CS21 (Tombal 2010) - Degarelix 240-80,advanced hormone-dependent prostate cancer,CS2-Deg-Tom
0.993839836,0,CS21,Degarelix 240-80,Tombal 2010,CS21 (Tombal 2010) - Degarelix 240-80,advanced hormone-dependent prostate cancer,CS2-Deg-Tom
0.993839836,0,CS21,Degarelix 240-80,Tombal 2010,CS21 (Tombal 2010) - Degarelix 240-80,advanced hormone-dependent prostate cancer,CS2-Deg-Tom
0.993839836,0,CS21,Degarelix 240-80,Tombal 2010,CS21 (Tombal 2010) - Degarelix 240-80,advanced hormone-dependent prostate cancer,CS2-Deg-Tom
0.993839836,0,CS21,Degarelix 240-80,Tombal 2010,CS21 (Tombal 2010) - Degarelix 240-80,advanced hormone-dependent prostate cancer,CS2-Deg-Tom
0.993839836,0,CS21,Degarelix 240-80,Tombal 2010,CS21 (Tombal 2010) - Degarelix 240-80,advanced hormone-dependent prostate cancer,CS2-Deg-Tom
0.993839836,0,CS21,Degarelix 240-80,Tombal 2010,CS21 (Tombal 2010) - Degarelix 240-80,advanced hormone-dependent prostate cancer,CS2-Deg-Tom
0.993839836,0,CS21,Degarelix 240-80,Tombal 2010,CS21 (Tombal 2010) - Degarelix 240-80,advanced hormone-dependent prostate cancer,CS2-Deg-Tom
0.993839836,0,CS21,Degarelix 240-80,Tombal 2010,CS21 (Tombal 2010) - Degarelix 240-80,advanced hormone-dependent prostate cancer,CS2-Deg-Tom
0.993839836,0,CS21,Degarelix 240-80,Tombal 2010,CS21 (Tombal 2010) - Degarelix 240-80,advanced hormone-dependent prostate cancer,CS2-Deg-Tom
0.993839836,0,CS21,Degarelix 240-80,Tombal 2010,CS21 (Tombal 2010) - Degarelix 240-80,advanced hormone-dependent prostate cancer,CS2-Deg-Tom
0.993839836,0,CS21,Degarelix 240-80,Tombal 2010,CS21 (Tombal 2010) - Degarelix 240-80,advanced hormone-dependent prostate cancer,CS2-Deg-Tom
0.993839836,0,CS21,Degarelix 240-80,Tombal 2010,CS21 (Tombal 2010) - Degarelix 240-80,advanced hormone-dependent prostate cancer,CS2-Deg-Tom
0.993839836,0,CS21,Degarelix 240-80,Tombal 2010,CS21 (Tombal 2010) - Degarelix 240-80,advanced hormone-dependent prostate cancer,CS2-Deg-Tom
0.993839836,0,CS21,Degarelix 240-80,Tombal 2010,CS21 (Tombal 2010) - Degarelix 240-80,advanced hormone-dependent prostate cancer,CS2-Deg-Tom
0.993839836,0,CS21,Degarelix 240-80,Tombal 2010,CS21 (Tombal 2010) - Degarelix 240-80,advanced hormone-dependent prostate cancer,CS2-Deg-Tom
0.993839836,0,CS21,Degarelix 240-80,Tombal 2010,CS21 (Tombal 2010) - Degarelix 240-80,advanced hormone-dependent prostate cancer,CS2-Deg-Tom
0.993839836,0,CS21,Degarelix 240-80,Tombal 2010,CS21 (Tombal 2010) - Degarelix 240-80,advanced hormone-dependent prostate cancer,CS2-Deg-Tom
0.993839836,0,CS21,Degarelix 240-80,Tombal 2010,CS21 (Tombal 2010) - Degarelix 240-80,advanced hormone-dependent prostate cancer,CS2-Deg-Tom
0.993839836,0,CS21,Degarelix 240-80,Tombal 2010,CS21 (Tombal 2010) - Degarelix 240-80,advanced hormone-dependent prostate cancer,CS2-Deg-Tom
0.993839836,0,CS21,Degarelix 240-80,Tombal 2010,CS21 (Tombal 2010) - Degarelix 240-80,advanced hormone-dependent prostate cancer,CS2-Deg-Tom
0.993839836,0,CS21,Degarelix 240-80,Tombal 2010,CS21 (Tombal 2010) - Degarelix 240-80,advanced hormone-dependent prostate cancer,CS2-Deg-Tom
0.993839836,0,CS21,Degarelix 240-80,Tombal 2010,CS21 (Tombal 2010) - Degarelix 240-80,advanced hormone-dependent prostate cancer,CS2-Deg-Tom
0.993839836,0,CS21,Degarelix 240-80,Tombal 2010,CS21 (Tombal 2010) - Degarelix 240-80,advanced hormone-dependent prostate cancer,CS2-Deg-Tom
0.993839836,0,CS21,Degarelix 240-80,Tombal 2010,CS21 (Tombal 2010) - Degarelix 240-80,advanced hormone-dependent prostate cancer,CS2-Deg-Tom
0.993839836,0,CS21,Degarelix 240-80,Tombal 2010,CS21 (Tombal 2010) - Degarelix 240-80,advanced hormone-dependent prostate cancer,CS2-Deg-Tom
0.993839836,0,CS21,Degarelix 240-80,Tombal 2010,CS21 (Tombal 2010) - Degarelix 240-80,advanced hormone-dependent prostate cancer,CS2-Deg-Tom
0.993839836,0,CS21,Degarelix 240-80,Tombal 2010,CS21 (Tombal 2010) - Degarelix 240-80,advanced hormone-dependent prostate cancer,CS2-Deg-Tom
0.993839836,0,CS21,Degarelix 240-80,Tombal 2010,CS21 (Tombal 2010) - Degarelix 240-80,advanced hormone-dependent prostate cancer,CS2-Deg-Tom
0.993839836,0,CS21,Degarelix 240-80,Tombal 2010,CS21 (Tombal 2010) - Degarelix 240-80,advanced hormone-dependent prostate cancer,CS2-Deg-Tom
0.993839836,0,CS21,Degarelix 240-80,Tombal 2010,CS21 (Tombal 2010) - Degarelix 240-80,advanced hormone-dependent prostate cancer,CS2-Deg-Tom
0.993839836,0,CS21,Degarelix 240-80,Tombal 2010,CS21 (Tombal 2010) - Degarelix 240-80,advanced hormone-dependent prostate cancer,CS2-Deg-Tom
0.993839836,0,CS21,Degarelix 240-80,Tombal 2010,CS21 (Tombal 2010) - Degarelix 240-80,advanced hormone-dependent prostate cancer,CS2-Deg-Tom
0.993839836,0,CS21,Degarelix 240-80,Tombal 2010,CS21 (Tombal 2010) - Degarelix 240-80,advanced hormone-dependent prostate cancer,CS2-Deg-Tom
0.993839836,0,CS21,Degarelix 240-80,Tombal 2010,CS21 (Tombal 2010) - Degarelix 240-80,advanced hormone-dependent prostate cancer,CS2-Deg-Tom
0.993839836,0,CS21,Degarelix 240-80,Tombal 2010,CS21 (Tombal 2010) - Degarelix 240-80,advanced hormone-dependent prostate cancer,CS2-Deg-Tom
0.993839836,0,CS21,Degarelix 240-80,Tombal 2010,CS21 (Tombal 2010) - Degarelix 240-80,advanced hormone-dependent prostate cancer,CS2-Deg-Tom
0.993839836,0,CS21,Degarelix 240-80,Tombal 2010,CS21 (Tombal 2010) - Degarelix 240-80,advanced hormone-dependent prostate cancer,CS2-Deg-Tom
0.993839836,0,CS21,Degarelix 240-80,Tombal 2010,CS21 (Tombal 2010) - Degarelix 240-80,advanced hormone-dependent prostate cancer,CS2-Deg-Tom
0.993839836,0,CS21,Degarelix 240-80,Tombal 2010,CS21 (Tombal 2010) - Degarelix 240-80,advanced hormone-dependent prostate cancer,CS2-Deg-Tom
0.993839836,0,CS21,Degarelix 240-80,Tombal 2010,CS21 (Tombal 2010) - Degarelix 240-80,advanced hormone-dependent prostate cancer,CS2-Deg-Tom
0.993839836,0,CS21,Degarelix 240-80,Tombal 2010,CS21 (Tombal 2010) - Degarelix 240-80,advanced hormone-dependent prostate cancer,CS2-Deg-Tom
0.993839836,0,CS21,Degarelix 240-80,Tombal 2010,CS21 (Tombal 2010) - Degarelix 240-80,advanced hormone-dependent prostate cancer,CS2-Deg-Tom
0.993839836,0,CS21,Degarelix 240-80,Tombal 2010,CS21 (Tombal 2010) - Degarelix 240-80,advanced hormone-dependent prostate cancer,CS2-Deg-Tom
0.993839836,0,CS21,Degarelix 240-80,Tombal 2010,CS21 (Tombal 2010) - Degarelix 240-80,advanced hormone-dependent prostate cancer,CS2-Deg-Tom
0.993839836,0,CS21,Degarelix 240-80,Tombal 2010,CS21 (Tombal 2010) - Degarelix 240-80,advanced hormone-dependent prostate cancer,CS2-Deg-Tom
0.993839836,0,CS21,Degarelix 240-80,Tombal 2010,CS21 (Tombal 2010) - Degarelix 240-80,advanced hormone-dependent prostate cancer,CS2-Deg-Tom
0.993839836,0,CS21,Degarelix 240-80,Tombal 2010,CS21 (Tombal 2010) - Degarelix 240-80,advanced hormone-dependent prostate cancer,CS2-Deg-Tom
0.993839836,0,CS21,Degarelix 240-80,Tombal 2010,CS21 (Tombal 2010) - Degarelix 240-80,advanced hormone-dependent prostate cancer,CS2-Deg-Tom
0.993839836,0,CS21,Degarelix 240-80,Tombal 2010,CS21 (Tombal 2010) - Degarelix 240-80,advanced hormone-dependent prostate cancer,CS2-Deg-Tom
0.993839836,0,CS21,Degarelix 240-80,Tombal 2010,CS21 (Tombal 2010) - Degarelix 240-80,advanced hormone-dependent prostate cancer,CS2-Deg-Tom
0.993839836,0,CS21,Degarelix 240-80,Tombal 2010,CS21 (Tombal 2010) - Degarelix 240-80,advanced hormone-dependent prostate cancer,CS2-Deg-Tom
0.993839836,0,CS21,Degarelix 240-80,Tombal 2010,CS21 (Tombal 2010) - Degarelix 240-80,advanced hormone-dependent prostate cancer,CS2-Deg-Tom
0.993839836,0,CS21,Degarelix 240-80,Tombal 2010,CS21 (Tombal 2010) - Degarelix 240-80,advanced hormone-dependent prostate cancer,CS2-Deg-Tom
0.993839836,0,CS21,Degarelix 240-80,Tombal 2010,CS21 (Tombal 2010) - Degarelix 240-80,advanced hormone-dependent prostate cancer,CS2-Deg-Tom
0.993839836,0,CS21,Degarelix 240-80,Tombal 2010,CS21 (Tombal 2010) - Degarelix 240-80,advanced hormone-dependent prostate cancer,CS2-Deg-Tom
0.993839836,0,CS21,Degarelix 240-80,Tombal 2010,CS21 (Tombal 2010) - Degarelix 240-80,advanced hormone-dependent prostate cancer,CS2-Deg-Tom
0.993839836,0,CS21,Degarelix 240-80,Tombal 2010,CS21 (Tombal 2010) - Degarelix 240-80,advanced hormone-dependent prostate cancer,CS2-Deg-Tom
0.993839836,0,CS21,Degarelix 240-80,Tombal 2010,CS21 (Tombal 2010) - Degarelix 240-80,advanced hormone-dependent prostate cancer,CS2-Deg-Tom
0.993839836,0,CS21,Degarelix 240-80,Tombal 2010,CS21 (Tombal 2010) - Degarelix 240-80,advanced hormone-dependent prostate cancer,CS2-Deg-Tom
0.993839836,0,CS21,Degarelix 240-80,Tombal 2010,CS21 (Tombal 2010) - Degarelix 240-80,advanced hormone-dependent prostate cancer,CS2-Deg-Tom
0.993839836,0,CS21,Degarelix 240-80,Tombal 2010,CS21 (Tombal 2010) - Degarelix 240-80,advanced hormone-dependent prostate cancer,CS2-Deg-Tom
0.993839836,0,CS21,Degarelix 240-80,Tombal 2010,CS21 (Tombal 2010) - Degarelix 240-80,advanced hormone-dependent prostate cancer,CS2-Deg-Tom
0.993839836,0,CS21,Degarelix 240-80,Tombal 2010,CS21 (Tombal 2010) - Degarelix 240-80,advanced hormone-dependent prostate cancer,CS2-Deg-Tom
0.993839836,0,CS21,Degarelix 240-80,Tombal 2010,CS21 (Tombal 2010) - Degarelix 240-80,advanced hormone-dependent prostate cancer,CS2-Deg-Tom
0.993839836,0,CS21,Degarelix 240-80,Tombal 2010,CS21 (Tombal 2010) - Degarelix 240-80,advanced hormone-dependent prostate cancer,CS2-Deg-Tom
0.993839836,0,CS21,Degarelix 240-80,Tombal 2010,CS21 (Tombal 2010) - Degarelix 240-80,advanced hormone-dependent prostate cancer,CS2-Deg-Tom
0.993839836,0,CS21,Degarelix 240-80,Tombal 2010,CS21 (Tombal 2010) - Degarelix 240-80,advanced hormone-dependent prostate cancer,CS2-Deg-Tom
0.993839836,0,CS21,Degarelix 240-80,Tombal 2010,CS21 (Tombal 2010) - Degarelix 240-80,advanced hormone-dependent prostate cancer,CS2-Deg-Tom
0.993839836,0,CS21,Degarelix 240-80,Tombal 2010,CS21 (Tombal 2010) - Degarelix 240-80,advanced hormone-dependent prostate cancer,CS2-Deg-Tom
0.054801527,1,CS21,Leuprolide 7.5,Tombal 2010,CS21 (Tombal 2010) - Leuprolide 7.5,advanced hormone-dependent prostate cancer,CS2-Leu-Tom
0.158715747,1,CS21,Leuprolide 7.5,Tombal 2010,CS21 (Tombal 2010) - Leuprolide 7.5,advanced hormone-dependent prostate cancer,CS2-Leu-Tom
0.439599315,1,CS21,Leuprolide 7.5,Tombal 2010,CS21 (Tombal 2010) - Leuprolide 7.5,advanced hormone-dependent prostate cancer,CS2-Leu-Tom
0.50002617,1,CS21,Leuprolide 7.5,Tombal 2010,CS21 (Tombal 2010) - Leuprolide 7.5,advanced hormone-dependent prostate cancer,CS2-Leu-Tom
0.577840163,1,CS21,Leuprolide 7.5,Tombal 2010,CS21 (Tombal 2010) - Leuprolide 7.5,advanced hormone-dependent prostate cancer,CS2-Leu-Tom
0.583162218,1,CS21,Leuprolide 7.5,Tombal 2010,CS21 (Tombal 2010) - Leuprolide 7.5,advanced hormone-dependent prostate cancer,CS2-Leu-Tom
0.596535544,1,CS21,Leuprolide 7.5,Tombal 2010,CS21 (Tombal 2010) - Leuprolide 7.5,advanced hormone-dependent prostate cancer,CS2-Leu-Tom
0.747167396,1,CS21,Leuprolide 7.5,Tombal 2010,CS21 (Tombal 2010) - Leuprolide 7.5,advanced hormone-dependent prostate cancer,CS2-Leu-Tom
0.810069328,1,CS21,Leuprolide 7.5,Tombal 2010,CS21 (Tombal 2010) - Leuprolide 7.5,advanced hormone-dependent prostate cancer,CS2-Leu-Tom
0.991101985,0,CS21,Leuprolide 7.5,Tombal 2010,CS21 (Tombal 2010) - Leuprolide 7.5,advanced hormone-dependent prostate cancer,CS2-Leu-Tom
0.991101985,0,CS21,Leuprolide 7.5,Tombal 2010,CS21 (Tombal 2010) - Leuprolide 7.5,advanced hormone-dependent prostate cancer,CS2-Leu-Tom
0.991101985,0,CS21,Leuprolide 7.5,Tombal 2010,CS21 (Tombal 2010) - Leuprolide 7.5,advanced hormone-dependent prostate cancer,CS2-Leu-Tom
0.991101985,0,CS21,Leuprolide 7.5,Tombal 2010,CS21 (Tombal 2010) - Leuprolide 7.5,advanced hormone-dependent prostate cancer,CS2-Leu-Tom
0.991101985,0,CS21,Leuprolide 7.5,Tombal 2010,CS21 (Tombal 2010) - Leuprolide 7.5,advanced hormone-dependent prostate cancer,CS2-Leu-Tom
0.991101985,0,CS21,Leuprolide 7.5,Tombal 2010,CS21 (Tombal 2010) - Leuprolide 7.5,advanced hormone-dependent prostate cancer,CS2-Leu-Tom
0.991101985,0,CS21,Leuprolide 7.5,Tombal 2010,CS21 (Tombal 2010) - Leuprolide 7.5,advanced hormone-dependent prostate cancer,CS2-Leu-Tom
0.991101985,0,CS21,Leuprolide 7.5,Tombal 2010,CS21 (Tombal 2010) - Leuprolide 7.5,advanced hormone-dependent prostate cancer,CS2-Leu-Tom
0.991101985,0,CS21,Leuprolide 7.5,Tombal 2010,CS21 (Tombal 2010) - Leuprolide 7.5,advanced hormone-dependent prostate cancer,CS2-Leu-Tom
0.991101985,0,CS21,Leuprolide 7.5,Tombal 2010,CS21 (Tombal 2010) - Leuprolide 7.5,advanced hormone-dependent prostate cancer,CS2-Leu-Tom
0.991101985,0,CS21,Leuprolide 7.5,Tombal 2010,CS21 (Tombal 2010) - Leuprolide 7.5,advanced hormone-dependent prostate cancer,CS2-Leu-Tom
0.991101985,0,CS21,Leuprolide 7.5,Tombal 2010,CS21 (Tombal 2010) - Leuprolide 7.5,advanced hormone-dependent prostate cancer,CS2-Leu-Tom
0.991101985,0,CS21,Leuprolide 7.5,Tombal 2010,CS21 (Tombal 2010) - Leuprolide 7.5,advanced hormone-dependent prostate cancer,CS2-Leu-Tom
0.991101985,0,CS21,Leuprolide 7.5,Tombal 2010,CS21 (Tombal 2010) - Leuprolide 7.5,advanced hormone-dependent prostate cancer,CS2-Leu-Tom
0.991101985,0,CS21,Leuprolide 7.5,Tombal 2010,CS21 (Tombal 2010) - Leuprolide 7.5,advanced hormone-dependent prostate cancer,CS2-Leu-Tom
0.991101985,0,CS21,Leuprolide 7.5,Tombal 2010,CS21 (Tombal 2010) - Leuprolide 7.5,advanced hormone-dependent prostate cancer,CS2-Leu-Tom
0.991101985,0,CS21,Leuprolide 7.5,Tombal 2010,CS21 (Tombal 2010) - Leuprolide 7.5,advanced hormone-dependent prostate cancer,CS2-Leu-Tom
0.991101985,0,CS21,Leuprolide 7.5,Tombal 2010,CS21 (Tombal 2010) - Leuprolide 7.5,advanced hormone-dependent prostate cancer,CS2-Leu-Tom
0.991101985,0,CS21,Leuprolide 7.5,Tombal 2010,CS21 (Tombal 2010) - Leuprolide 7.5,advanced hormone-dependent prostate cancer,CS2-Leu-Tom
0.991101985,0,CS21,Leuprolide 7.5,Tombal 2010,CS21 (Tombal 2010) - Leuprolide 7.5,advanced hormone-dependent prostate cancer,CS2-Leu-Tom
0.991101985,0,CS21,Leuprolide 7.5,Tombal 2010,CS21 (Tombal 2010) - Leuprolide 7.5,advanced hormone-dependent prostate cancer,CS2-Leu-Tom
0.991101985,0,CS21,Leuprolide 7.5,Tombal 2010,CS21 (Tombal 2010) - Leuprolide 7.5,advanced hormone-dependent prostate cancer,CS2-Leu-Tom
0.991101985,0,CS21,Leuprolide 7.5,Tombal 2010,CS21 (Tombal 2010) - Leuprolide 7.5,advanced hormone-dependent prostate cancer,CS2-Leu-Tom
0.991101985,0,CS21,Leuprolide 7.5,Tombal 2010,CS21 (Tombal 2010) - Leuprolide 7.5,advanced hormone-dependent prostate cancer,CS2-Leu-Tom
0.991101985,0,CS21,Leuprolide 7.5,Tombal 2010,CS21 (Tombal 2010) - Leuprolide 7.5,advanced hormone-dependent prostate cancer,CS2-Leu-Tom
0.991101985,0,CS21,Leuprolide 7.5,Tombal 2010,CS21 (Tombal 2010) - Leuprolide 7.5,advanced hormone-dependent prostate cancer,CS2-Leu-Tom
0.991101985,0,CS21,Leuprolide 7.5,Tombal 2010,CS21 (Tombal 2010) - Leuprolide 7.5,advanced hormone-dependent prostate cancer,CS2-Leu-Tom
0.991101985,0,CS21,Leuprolide 7.5,Tombal 2010,CS21 (Tombal 2010) - Leuprolide 7.5,advanced hormone-dependent prostate cancer,CS2-Leu-Tom
0.991101985,0,CS21,Leuprolide 7.5,Tombal 2010,CS21 (Tombal 2010) - Leuprolide 7.5,advanced hormone-dependent prostate cancer,CS2-Leu-Tom
0.991101985,0,CS21,Leuprolide 7.5,Tombal 2010,CS21 (Tombal 2010) - Leuprolide 7.5,advanced hormone-dependent prostate cancer,CS2-Leu-Tom
0.991101985,0,CS21,Leuprolide 7.5,Tombal 2010,CS21 (Tombal 2010) - Leuprolide 7.5,advanced hormone-dependent prostate cancer,CS2-Leu-Tom
0.991101985,0,CS21,Leuprolide 7.5,Tombal 2010,CS21 (Tombal 2010) - Leuprolide 7.5,advanced hormone-dependent prostate cancer,CS2-Leu-Tom
0.991101985,0,CS21,Leuprolide 7.5,Tombal 2010,CS21 (Tombal 2010) - Leuprolide 7.5,advanced hormone-dependent prostate cancer,CS2-Leu-Tom
0.991101985,0,CS21,Leuprolide 7.5,Tombal 2010,CS21 (Tombal 2010) - Leuprolide 7.5,advanced hormone-dependent prostate cancer,CS2-Leu-Tom
0.991101985,0,CS21,Leuprolide 7.5,Tombal 2010,CS21 (Tombal 2010) - Leuprolide 7.5,advanced hormone-dependent prostate cancer,CS2-Leu-Tom
0.991101985,0,CS21,Leuprolide 7.5,Tombal 2010,CS21 (Tombal 2010) - Leuprolide 7.5,advanced hormone-dependent prostate cancer,CS2-Leu-Tom
0.991101985,0,CS21,Leuprolide 7.5,Tombal 2010,CS21 (Tombal 2010) - Leuprolide 7.5,advanced hormone-dependent prostate cancer,CS2-Leu-Tom
0.991101985,0,CS21,Leuprolide 7.5,Tombal 2010,CS21 (Tombal 2010) - Leuprolide 7.5,advanced hormone-dependent prostate cancer,CS2-Leu-Tom
0.991101985,0,CS21,Leuprolide 7.5,Tombal 2010,CS21 (Tombal 2010) - Leuprolide 7.5,advanced hormone-dependent prostate cancer,CS2-Leu-Tom
0.991101985,0,CS21,Leuprolide 7.5,Tombal 2010,CS21 (Tombal 2010) - Leuprolide 7.5,advanced hormone-dependent prostate cancer,CS2-Leu-Tom
0.991101985,0,CS21,Leuprolide 7.5,Tombal 2010,CS21 (Tombal 2010) - Leuprolide 7.5,advanced hormone-dependent prostate cancer,CS2-Leu-Tom
0.991101985,0,CS21,Leuprolide 7.5,Tombal 2010,CS21 (Tombal 2010) - Leuprolide 7.5,advanced hormone-dependent prostate cancer,CS2-Leu-Tom
0.991101985,0,CS21,Leuprolide 7.5,Tombal 2010,CS21 (Tombal 2010) - Leuprolide 7.5,advanced hormone-dependent prostate cancer,CS2-Leu-Tom
0.991101985,0,CS21,Leuprolide 7.5,Tombal 2010,CS21 (Tombal 2010) - Leuprolide 7.5,advanced hormone-dependent prostate cancer,CS2-Leu-Tom
0.991101985,0,CS21,Leuprolide 7.5,Tombal 2010,CS21 (Tombal 2010) - Leuprolide 7.5,advanced hormone-dependent prostate cancer,CS2-Leu-Tom
0.991101985,0,CS21,Leuprolide 7.5,Tombal 2010,CS21 (Tombal 2010) - Leuprolide 7.5,advanced hormone-dependent prostate cancer,CS2-Leu-Tom
0.991101985,0,CS21,Leuprolide 7.5,Tombal 2010,CS21 (Tombal 2010) - Leuprolide 7.5,advanced hormone-dependent prostate cancer,CS2-Leu-Tom
0.991101985,0,CS21,Leuprolide 7.5,Tombal 2010,CS21 (Tombal 2010) - Leuprolide 7.5,advanced hormone-dependent prostate cancer,CS2-Leu-Tom
0.991101985,0,CS21,Leuprolide 7.5,Tombal 2010,CS21 (Tombal 2010) - Leuprolide 7.5,advanced hormone-dependent prostate cancer,CS2-Leu-Tom
0.991101985,0,CS21,Leuprolide 7.5,Tombal 2010,CS21 (Tombal 2010) - Leuprolide 7.5,advanced hormone-dependent prostate cancer,CS2-Leu-Tom
0.991101985,0,CS21,Leuprolide 7.5,Tombal 2010,CS21 (Tombal 2010) - Leuprolide 7.5,advanced hormone-dependent prostate cancer,CS2-Leu-Tom
0.991101985,0,CS21,Leuprolide 7.5,Tombal 2010,CS21 (Tombal 2010) - Leuprolide 7.5,advanced hormone-dependent prostate cancer,CS2-Leu-Tom
0.991101985,0,CS21,Leuprolide 7.5,Tombal 2010,CS21 (Tombal 2010) - Leuprolide 7.5,advanced hormone-dependent prostate cancer,CS2-Leu-Tom
0.991101985,0,CS21,Leuprolide 7.5,Tombal 2010,CS21 (Tombal 2010) - Leuprolide 7.5,advanced hormone-dependent prostate cancer,CS2-Leu-Tom
0.991101985,0,CS21,Leuprolide 7.5,Tombal 2010,CS21 (Tombal 2010) - Leuprolide 7.5,advanced hormone-dependent prostate cancer,CS2-Leu-Tom
0.991101985,0,CS21,Leuprolide 7.5,Tombal 2010,CS21 (Tombal 2010) - Leuprolide 7.5,advanced hormone-dependent prostate cancer,CS2-Leu-Tom
0.991101985,0,CS21,Leuprolide 7.5,Tombal 2010,CS21 (Tombal 2010) - Leuprolide 7.5,advanced hormone-dependent prostate cancer,CS2-Leu-Tom
0.991101985,0,CS21,Leuprolide 7.5,Tombal 2010,CS21 (Tombal 2010) - Leuprolide 7.5,advanced hormone-dependent prostate cancer,CS2-Leu-Tom
0.991101985,0,CS21,Leuprolide 7.5,Tombal 2010,CS21 (Tombal 2010) - Leuprolide 7.5,advanced hormone-dependent prostate cancer,CS2-Leu-Tom
0.991101985,0,CS21,Leuprolide 7.5,Tombal 2010,CS21 (Tombal 2010) - Leuprolide 7.5,advanced hormone-dependent prostate cancer,CS2-Leu-Tom
0.991101985,0,CS21,Leuprolide 7.5,Tombal 2010,CS21 (Tombal 2010) - Leuprolide 7.5,advanced hormone-dependent prostate cancer,CS2-Leu-Tom
0.991101985,0,CS21,Leuprolide 7.5,Tombal 2010,CS21 (Tombal 2010) - Leuprolide 7.5,advanced hormone-dependent prostate cancer,CS2-Leu-Tom
0.991101985,0,CS21,Leuprolide 7.5,Tombal 2010,CS21 (Tombal 2010) - Leuprolide 7.5,advanced hormone-dependent prostate cancer,CS2-Leu-Tom
0.991101985,0,CS21,Leuprolide 7.5,Tombal 2010,CS21 (Tombal 2010) - Leuprolide 7.5,advanced hormone-dependent prostate cancer,CS2-Leu-Tom
0.991101985,0,CS21,Leuprolide 7.5,Tombal 2010,CS21 (Tombal 2010) - Leuprolide 7.5,advanced hormone-dependent prostate cancer,CS2-Leu-Tom
0.991101985,0,CS21,Leuprolide 7.5,Tombal 2010,CS21 (Tombal 2010) - Leuprolide 7.5,advanced hormone-dependent prostate cancer,CS2-Leu-Tom
0.991101985,0,CS21,Leuprolide 7.5,Tombal 2010,CS21 (Tombal 2010) - Leuprolide 7.5,advanced hormone-dependent prostate cancer,CS2-Leu-Tom
0.991101985,0,CS21,Leuprolide 7.5,Tombal 2010,CS21 (Tombal 2010) - Leuprolide 7.5,advanced hormone-dependent prostate cancer,CS2-Leu-Tom
0.991101985,0,CS21,Leuprolide 7.5,Tombal 2010,CS21 (Tombal 2010) - Leuprolide 7.5,advanced hormone-dependent prostate cancer,CS2-Leu-Tom
0.991101985,0,CS21,Leuprolide 7.5,Tombal 2010,CS21 (Tombal 2010) - Leuprolide 7.5,advanced hormone-dependent prostate cancer,CS2-Leu-Tom
0.991101985,0,CS21,Leuprolide 7.5,Tombal 2010,CS21 (Tombal 2010) - Leuprolide 7.5,advanced hormone-dependent prostate cancer,CS2-Leu-Tom
0.991101985,0,CS21,Leuprolide 7.5,Tombal 2010,CS21 (Tombal 2010) - Leuprolide 7.5,advanced hormone-dependent prostate cancer,CS2-Leu-Tom
0.991101985,0,CS21,Leuprolide 7.5,Tombal 2010,CS21 (Tombal 2010) - Leuprolide 7.5,advanced hormone-dependent prostate cancer,CS2-Leu-Tom
0.991101985,0,CS21,Leuprolide 7.5,Tombal 2010,CS21 (Tombal 2010) - Leuprolide 7.5,advanced hormone-dependent prostate cancer,CS2-Leu-Tom
0.991101985,0,CS21,Leuprolide 7.5,Tombal 2010,CS21 (Tombal 2010) - Leuprolide 7.5,advanced hormone-dependent prostate cancer,CS2-Leu-Tom
0.991101985,0,CS21,Leuprolide 7.5,Tombal 2010,CS21 (Tombal 2010) - Leuprolide 7.5,advanced hormone-dependent prostate cancer,CS2-Leu-Tom
0.991101985,0,CS21,Leuprolide 7.5,Tombal 2010,CS21 (Tombal 2010) - Leuprolide 7.5,advanced hormone-dependent prostate cancer,CS2-Leu-Tom
0.991101985,0,CS21,Leuprolide 7.5,Tombal 2010,CS21 (Tombal 2010) - Leuprolide 7.5,advanced hormone-dependent prostate cancer,CS2-Leu-Tom
0.991101985,0,CS21,Leuprolide 7.5,Tombal 2010,CS21 (Tombal 2010) - Leuprolide 7.5,advanced hormone-dependent prostate cancer,CS2-Leu-Tom
0.991101985,0,CS21,Leuprolide 7.5,Tombal 2010,CS21 (Tombal 2010) - Leuprolide 7.5,advanced hormone-dependent prostate cancer,CS2-Leu-Tom
0.991101985,0,CS21,Leuprolide 7.5,Tombal 2010,CS21 (Tombal 2010) - Leuprolide 7.5,advanced hormone-dependent prostate cancer,CS2-Leu-Tom
0.991101985,0,CS21,Leuprolide 7.5,Tombal 2010,CS21 (Tombal 2010) - Leuprolide 7.5,advanced hormone-dependent prostate cancer,CS2-Leu-Tom
0.991101985,0,CS21,Leuprolide 7.5,Tombal 2010,CS21 (Tombal 2010) - Leuprolide 7.5,advanced hormone-dependent prostate cancer,CS2-Leu-Tom
0.991101985,0,CS21,Leuprolide 7.5,Tombal 2010,CS21 (Tombal 2010) - Leuprolide 7.5,advanced hormone-dependent prostate cancer,CS2-Leu-Tom
0.991101985,0,CS21,Leuprolide 7.5,Tombal 2010,CS21 (Tombal 2010) - Leuprolide 7.5,advanced hormone-dependent prostate cancer,CS2-Leu-Tom
0.991101985,0,CS21,Leuprolide 7.5,Tombal 2010,CS21 (Tombal 2010) - Leuprolide 7.5,advanced hormone-dependent prostate cancer,CS2-Leu-Tom
0.991101985,0,CS21,Leuprolide 7.5,Tombal 2010,CS21 (Tombal 2010) - Leuprolide 7.5,advanced hormone-dependent prostate cancer,CS2-Leu-Tom
0.991101985,0,CS21,Leuprolide 7.5,Tombal 2010,CS21 (Tombal 2010) - Leuprolide 7.5,advanced hormone-dependent prostate cancer,CS2-Leu-Tom
0.991101985,0,CS21,Leuprolide 7.5,Tombal 2010,CS21 (Tombal 2010) - Leuprolide 7.5,advanced hormone-dependent prostate cancer,CS2-Leu-Tom
0.991101985,0,CS21,Leuprolide 7.5,Tombal 2010,CS21 (Tombal 2010) - Leuprolide 7.5,advanced hormone-dependent prostate cancer,CS2-Leu-Tom
0.991101985,0,CS21,Leuprolide 7.5,Tombal 2010,CS21 (Tombal 2010) - Leuprolide 7.5,advanced hormone-dependent prostate cancer,CS2-Leu-Tom
0.991101985,0,CS21,Leuprolide 7.5,Tombal 2010,CS21 (Tombal 2010) - Leuprolide 7.5,advanced hormone-dependent prostate cancer,CS2-Leu-Tom
0.991101985,0,CS21,Leuprolide 7.5,Tombal 2010,CS21 (Tombal 2010) - Leuprolide 7.5,advanced hormone-dependent prostate cancer,CS2-Leu-Tom
0.991101985,0,CS21,Leuprolide 7.5,Tombal 2010,CS21 (Tombal 2010) - Leuprolide 7.5,advanced hormone-dependent prostate cancer,CS2-Leu-Tom
0.991101985,0,CS21,Leuprolide 7.5,Tombal 2010,CS21 (Tombal 2010) - Leuprolide 7.5,advanced hormone-dependent prostate cancer,CS2-Leu-Tom
0.991101985,0,CS21,Leuprolide 7.5,Tombal 2010,CS21 (Tombal 2010) - Leuprolide 7.5,advanced hormone-dependent prostate cancer,CS2-Leu-Tom
0.991101985,0,CS21,Leuprolide 7.5,Tombal 2010,CS21 (Tombal 2010) - Leuprolide 7.5,advanced hormone-dependent prostate cancer,CS2-Leu-Tom
0.991101985,0,CS21,Leuprolide 7.5,Tombal 2010,CS21 (Tombal 2010) - Leuprolide 7.5,advanced hormone-dependent prostate cancer,CS2-Leu-Tom
0.991101985,0,CS21,Leuprolide 7.5,Tombal 2010,CS21 (Tombal 2010) - Leuprolide 7.5,advanced hormone-dependent prostate cancer,CS2-Leu-Tom
0.991101985,0,CS21,Leuprolide 7.5,Tombal 2010,CS21 (Tombal 2010) - Leuprolide 7.5,advanced hormone-dependent prostate cancer,CS2-Leu-Tom
0.991101985,0,CS21,Leuprolide 7.5,Tombal 2010,CS21 (Tombal 2010) - Leuprolide 7.5,advanced hormone-dependent prostate cancer,CS2-Leu-Tom
0.991101985,0,CS21,Leuprolide 7.5,Tombal 2010,CS21 (Tombal 2010) - Leuprolide 7.5,advanced hormone-dependent prostate cancer,CS2-Leu-Tom
0.991101985,0,CS21,Leuprolide 7.5,Tombal 2010,CS21 (Tombal 2010) - Leuprolide 7.5,advanced hormone-dependent prostate cancer,CS2-Leu-Tom
0.991101985,0,CS21,Leuprolide 7.5,Tombal 2010,CS21 (Tombal 2010) - Leuprolide 7.5,advanced hormone-dependent prostate cancer,CS2-Leu-Tom
0.991101985,0,CS21,Leuprolide 7.5,Tombal 2010,CS21 (Tombal 2010) - Leuprolide 7.5,advanced hormone-dependent prostate cancer,CS2-Leu-Tom
0.991101985,0,CS21,Leuprolide 7.5,Tombal 2010,CS21 (Tombal 2010) - Leuprolide 7.5,advanced hormone-dependent prostate cancer,CS2-Leu-Tom
0.991101985,0,CS21,Leuprolide 7.5,Tombal 2010,CS21 (Tombal 2010) - Leuprolide 7.5,advanced hormone-dependent prostate cancer,CS2-Leu-Tom
0.991101985,0,CS21,Leuprolide 7.5,Tombal 2010,CS21 (Tombal 2010) - Leuprolide 7.5,advanced hormone-dependent prostate cancer,CS2-Leu-Tom
0.991101985,0,CS21,Leuprolide 7.5,Tombal 2010,CS21 (Tombal 2010) - Leuprolide 7.5,advanced hormone-dependent prostate cancer,CS2-Leu-Tom
0.991101985,0,CS21,Leuprolide 7.5,Tombal 2010,CS21 (Tombal 2010) - Leuprolide 7.5,advanced hormone-dependent prostate cancer,CS2-Leu-Tom
0.991101985,0,CS21,Leuprolide 7.5,Tombal 2010,CS21 (Tombal 2010) - Leuprolide 7.5,advanced hormone-dependent prostate cancer,CS2-Leu-Tom
0.991101985,0,CS21,Leuprolide 7.5,Tombal 2010,CS21 (Tombal 2010) - Leuprolide 7.5,advanced hormone-dependent prostate cancer,CS2-Leu-Tom
0.991101985,0,CS21,Leuprolide 7.5,Tombal 2010,CS21 (Tombal 2010) - Leuprolide 7.5,advanced hormone-dependent prostate cancer,CS2-Leu-Tom
0.991101985,0,CS21,Leuprolide 7.5,Tombal 2010,CS21 (Tombal 2010) - Leuprolide 7.5,advanced hormone-dependent prostate cancer,CS2-Leu-Tom
0.991101985,0,CS21,Leuprolide 7.5,Tombal 2010,CS21 (Tombal 2010) - Leuprolide 7.5,advanced hormone-dependent prostate cancer,CS2-Leu-Tom
0.991101985,0,CS21,Leuprolide 7.5,Tombal 2010,CS21 (Tombal 2010) - Leuprolide 7.5,advanced hormone-dependent prostate cancer,CS2-Leu-Tom
0.991101985,0,CS21,Leuprolide 7.5,Tombal 2010,CS21 (Tombal 2010) - Leuprolide 7.5,advanced hormone-dependent prostate cancer,CS2-Leu-Tom
0.991101985,0,CS21,Leuprolide 7.5,Tombal 2010,CS21 (Tombal 2010) - Leuprolide 7.5,advanced hormone-dependent prostate cancer,CS2-Leu-Tom
0.991101985,0,CS21,Leuprolide 7.5,Tombal 2010,CS21 (Tombal 2010) - Leuprolide 7.5,advanced hormone-dependent prostate cancer,CS2-Leu-Tom
0.991101985,0,CS21,Leuprolide 7.5,Tombal 2010,CS21 (Tombal 2010) - Leuprolide 7.5,advanced hormone-dependent prostate cancer,CS2-Leu-Tom
0.991101985,0,CS21,Leuprolide 7.5,Tombal 2010,CS21 (Tombal 2010) - Leuprolide 7.5,advanced hormone-dependent prostate cancer,CS2-Leu-Tom
0.991101985,0,CS21,Leuprolide 7.5,Tombal 2010,CS21 (Tombal 2010) - Leuprolide 7.5,advanced hormone-dependent prostate cancer,CS2-Leu-Tom
0.991101985,0,CS21,Leuprolide 7.5,Tombal 2010,CS21 (Tombal 2010) - Leuprolide 7.5,advanced hormone-dependent prostate cancer,CS2-Leu-Tom
0.991101985,0,CS21,Leuprolide 7.5,Tombal 2010,CS21 (Tombal 2010) - Leuprolide 7.5,advanced hormone-dependent prostate cancer,CS2-Leu-Tom
0.991101985,0,CS21,Leuprolide 7.5,Tombal 2010,CS21 (Tombal 2010) - Leuprolide 7.5,advanced hormone-dependent prostate cancer,CS2-Leu-Tom
0.991101985,0,CS21,Leuprolide 7.5,Tombal 2010,CS21 (Tombal 2010) - Leuprolide 7.5,advanced hormone-dependent prostate cancer,CS2-Leu-Tom
0.991101985,0,CS21,Leuprolide 7.5,Tombal 2010,CS21 (Tombal 2010) - Leuprolide 7.5,advanced hormone-dependent prostate cancer,CS2-Leu-Tom
0.991101985,0,CS21,Leuprolide 7.5,Tombal 2010,CS21 (Tombal 2010) - Leuprolide 7.5,advanced hormone-dependent prostate cancer,CS2-Leu-Tom
0.991101985,0,CS21,Leuprolide 7.5,Tombal 2010,CS21 (Tombal 2010) - Leuprolide 7.5,advanced hormone-dependent prostate cancer,CS2-Leu-Tom
0.991101985,0,CS21,Leuprolide 7.5,Tombal 2010,CS21 (Tombal 2010) - Leuprolide 7.5,advanced hormone-dependent prostate cancer,CS2-Leu-Tom
0.991101985,0,CS21,Leuprolide 7.5,Tombal 2010,CS21 (Tombal 2010) - Leuprolide 7.5,advanced hormone-dependent prostate cancer,CS2-Leu-Tom
0.991101985,0,CS21,Leuprolide 7.5,Tombal 2010,CS21 (Tombal 2010) - Leuprolide 7.5,advanced hormone-dependent prostate cancer,CS2-Leu-Tom
0.991101985,0,CS21,Leuprolide 7.5,Tombal 2010,CS21 (Tombal 2010) - Leuprolide 7.5,advanced hormone-dependent prostate cancer,CS2-Leu-Tom
0.991101985,0,CS21,Leuprolide 7.5,Tombal 2010,CS21 (Tombal 2010) - Leuprolide 7.5,advanced hormone-dependent prostate cancer,CS2-Leu-Tom
0.991101985,0,CS21,Leuprolide 7.5,Tombal 2010,CS21 (Tombal 2010) - Leuprolide 7.5,advanced hormone-dependent prostate cancer,CS2-Leu-Tom
0.991101985,0,CS21,Leuprolide 7.5,Tombal 2010,CS21 (Tombal 2010) - Leuprolide 7.5,advanced hormone-dependent prostate cancer,CS2-Leu-Tom
0.991101985,0,CS21,Leuprolide 7.5,Tombal 2010,CS21 (Tombal 2010) - Leuprolide 7.5,advanced hormone-dependent prostate cancer,CS2-Leu-Tom
0.991101985,0,CS21,Leuprolide 7.5,Tombal 2010,CS21 (Tombal 2010) - Leuprolide 7.5,advanced hormone-dependent prostate cancer,CS2-Leu-Tom
0.991101985,0,CS21,Leuprolide 7.5,Tombal 2010,CS21 (Tombal 2010) - Leuprolide 7.5,advanced hormone-dependent prostate cancer,CS2-Leu-Tom
0.991101985,0,CS21,Leuprolide 7.5,Tombal 2010,CS21 (Tombal 2010) - Leuprolide 7.5,advanced hormone-dependent prostate cancer,CS2-Leu-Tom
0.991101985,0,CS21,Leuprolide 7.5,Tombal 2010,CS21 (Tombal 2010) - Leuprolide 7.5,advanced hormone-dependent prostate cancer,CS2-Leu-Tom
0.991101985,0,CS21,Leuprolide 7.5,Tombal 2010,CS21 (Tombal 2010) - Leuprolide 7.5,advanced hormone-dependent prostate cancer,CS2-Leu-Tom
0.991101985,0,CS21,Leuprolide 7.5,Tombal 2010,CS21 (Tombal 2010) - Leuprolide 7.5,advanced hormone-dependent prostate cancer,CS2-Leu-Tom
0.991101985,0,CS21,Leuprolide 7.5,Tombal 2010,CS21 (Tombal 2010) - Leuprolide 7.5,advanced hormone-dependent prostate cancer,CS2-Leu-Tom
0.991101985,0,CS21,Leuprolide 7.5,Tombal 2010,CS21 (Tombal 2010) - Leuprolide 7.5,advanced hormone-dependent prostate cancer,CS2-Leu-Tom
0.991101985,0,CS21,Leuprolide 7.5,Tombal 2010,CS21 (Tombal 2010) - Leuprolide 7.5,advanced hormone-dependent prostate cancer,CS2-Leu-Tom
0.991101985,0,CS21,Leuprolide 7.5,Tombal 2010,CS21 (Tombal 2010) - Leuprolide 7.5,advanced hormone-dependent prostate cancer,CS2-Leu-Tom
0.991101985,0,CS21,Leuprolide 7.5,Tombal 2010,CS21 (Tombal 2010) - Leuprolide 7.5,advanced hormone-dependent prostate cancer,CS2-Leu-Tom
0.991101985,0,CS21,Leuprolide 7.5,Tombal 2010,CS21 (Tombal 2010) - Leuprolide 7.5,advanced hormone-dependent prostate cancer,CS2-Leu-Tom
0.991101985,0,CS21,Leuprolide 7.5,Tombal 2010,CS21 (Tombal 2010) - Leuprolide 7.5,advanced hormone-dependent prostate cancer,CS2-Leu-Tom
0.991101985,0,CS21,Leuprolide 7.5,Tombal 2010,CS21 (Tombal 2010) - Leuprolide 7.5,advanced hormone-dependent prostate cancer,CS2-Leu-Tom
0.991101985,0,CS21,Leuprolide 7.5,Tombal 2010,CS21 (Tombal 2010) - Leuprolide 7.5,advanced hormone-dependent prostate cancer,CS2-Leu-Tom
0.991101985,0,CS21,Leuprolide 7.5,Tombal 2010,CS21 (Tombal 2010) - Leuprolide 7.5,advanced hormone-dependent prostate cancer,CS2-Leu-Tom
0.991101985,0,CS21,Leuprolide 7.5,Tombal 2010,CS21 (Tombal 2010) - Leuprolide 7.5,advanced hormone-dependent prostate cancer,CS2-Leu-Tom
0.991101985,0,CS21,Leuprolide 7.5,Tombal 2010,CS21 (Tombal 2010) - Leuprolide 7.5,advanced hormone-dependent prostate cancer,CS2-Leu-Tom
0.991101985,0,CS21,Leuprolide 7.5,Tombal 2010,CS21 (Tombal 2010) - Leuprolide 7.5,advanced hormone-dependent prostate cancer,CS2-Leu-Tom
0.991101985,0,CS21,Leuprolide 7.5,Tombal 2010,CS21 (Tombal 2010) - Leuprolide 7.5,advanced hormone-dependent prostate cancer,CS2-Leu-Tom
0.991101985,0,CS21,Leuprolide 7.5,Tombal 2010,CS21 (Tombal 2010) - Leuprolide 7.5,advanced hormone-dependent prostate cancer,CS2-Leu-Tom
0.991101985,0,CS21,Leuprolide 7.5,Tombal 2010,CS21 (Tombal 2010) - Leuprolide 7.5,advanced hormone-dependent prostate cancer,CS2-Leu-Tom
0.991101985,0,CS21,Leuprolide 7.5,Tombal 2010,CS21 (Tombal 2010) - Leuprolide 7.5,advanced hormone-dependent prostate cancer,CS2-Leu-Tom
0.991101985,0,CS21,Leuprolide 7.5,Tombal 2010,CS21 (Tombal 2010) - Leuprolide 7.5,advanced hormone-dependent prostate cancer,CS2-Leu-Tom
0.991101985,0,CS21,Leuprolide 7.5,Tombal 2010,CS21 (Tombal 2010) - Leuprolide 7.5,advanced hormone-dependent prostate cancer,CS2-Leu-Tom
0.991101985,0,CS21,Leuprolide 7.5,Tombal 2010,CS21 (Tombal 2010) - Leuprolide 7.5,advanced hormone-dependent prostate cancer,CS2-Leu-Tom
0.991101985,0,CS21,Leuprolide 7.5,Tombal 2010,CS21 (Tombal 2010) - Leuprolide 7.5,advanced hormone-dependent prostate cancer,CS2-Leu-Tom
0.991101985,0,CS21,Leuprolide 7.5,Tombal 2010,CS21 (Tombal 2010) - Leuprolide 7.5,advanced hormone-dependent prostate cancer,CS2-Leu-Tom
0.991101985,0,CS21,Leuprolide 7.5,Tombal 2010,CS21 (Tombal 2010) - Leuprolide 7.5,advanced hormone-dependent prostate cancer,CS2-Leu-Tom
0.991101985,0,CS21,Leuprolide 7.5,Tombal 2010,CS21 (Tombal 2010) - Leuprolide 7.5,advanced hormone-dependent prostate cancer,CS2-Leu-Tom
0.991101985,0,CS21,Leuprolide 7.5,Tombal 2010,CS21 (Tombal 2010) - Leuprolide 7.5,advanced hormone-dependent prostate cancer,CS2-Leu-Tom
0.991101985,0,CS21,Leuprolide 7.5,Tombal 2010,CS21 (Tombal 2010) - Leuprolide 7.5,advanced hormone-dependent prostate cancer,CS2-Leu-Tom
0.991101985,0,CS21,Leuprolide 7.5,Tombal 2010,CS21 (Tombal 2010) - Leuprolide 7.5,advanced hormone-dependent prostate cancer,CS2-Leu-Tom
0.991101985,0,CS21,Leuprolide 7.5,Tombal 2010,CS21 (Tombal 2010) - Leuprolide 7.5,advanced hormone-dependent prostate cancer,CS2-Leu-Tom
0.991101985,0,CS21,Leuprolide 7.5,Tombal 2010,CS21 (Tombal 2010) - Leuprolide 7.5,advanced hormone-dependent prostate cancer,CS2-Leu-Tom
0.991101985,0,CS21,Leuprolide 7.5,Tombal 2010,CS21 (Tombal 2010) - Leuprolide 7.5,advanced hormone-dependent prostate cancer,CS2-Leu-Tom
0.991101985,0,CS21,Leuprolide 7.5,Tombal 2010,CS21 (Tombal 2010) - Leuprolide 7.5,advanced hormone-dependent prostate cancer,CS2-Leu-Tom
0.991101985,0,CS21,Leuprolide 7.5,Tombal 2010,CS21 (Tombal 2010) - Leuprolide 7.5,advanced hormone-dependent prostate cancer,CS2-Leu-Tom
0.991101985,0,CS21,Leuprolide 7.5,Tombal 2010,CS21 (Tombal 2010) - Leuprolide 7.5,advanced hormone-dependent prostate cancer,CS2-Leu-Tom
0.991101985,0,CS21,Leuprolide 7.5,Tombal 2010,CS21 (Tombal 2010) - Leuprolide 7.5,advanced hormone-dependent prostate cancer,CS2-Leu-Tom
0.991101985,0,CS21,Leuprolide 7.5,Tombal 2010,CS21 (Tombal 2010) - Leuprolide 7.5,advanced hormone-dependent prostate cancer,CS2-Leu-Tom
0.991101985,0,CS21,Leuprolide 7.5,Tombal 2010,CS21 (Tombal 2010) - Leuprolide 7.5,advanced hormone-dependent prostate cancer,CS2-Leu-Tom
0.991101985,0,CS21,Leuprolide 7.5,Tombal 2010,CS21 (Tombal 2010) - Leuprolide 7.5,advanced hormone-dependent prostate cancer,CS2-Leu-Tom
0.991101985,0,CS21,Leuprolide 7.5,Tombal 2010,CS21 (Tombal 2010) - Leuprolide 7.5,advanced hormone-dependent prostate cancer,CS2-Leu-Tom
0.991101985,0,CS21,Leuprolide 7.5,Tombal 2010,CS21 (Tombal 2010) - Leuprolide 7.5,advanced hormone-dependent prostate cancer,CS2-Leu-Tom
0.991101985,0,CS21,Leuprolide 7.5,Tombal 2010,CS21 (Tombal 2010) - Leuprolide 7.5,advanced hormone-dependent prostate cancer,CS2-Leu-Tom
0.991101985,0,CS21,Leuprolide 7.5,Tombal 2010,CS21 (Tombal 2010) - Leuprolide 7.5,advanced hormone-dependent prostate cancer,CS2-Leu-Tom
0.991101985,0,CS21,Leuprolide 7.5,Tombal 2010,CS21 (Tombal 2010) - Leuprolide 7.5,advanced hormone-dependent prostate cancer,CS2-Leu-Tom
0.991101985,0,CS21,Leuprolide 7.5,Tombal 2010,CS21 (Tombal 2010) - Leuprolide 7.5,advanced hormone-dependent prostate cancer,CS2-Leu-Tom
0.991101985,0,CS21,Leuprolide 7.5,Tombal 2010,CS21 (Tombal 2010) - Leuprolide 7.5,advanced hormone-dependent prostate cancer,CS2-Leu-Tom
0.991101985,0,CS21,Leuprolide 7.5,Tombal 2010,CS21 (Tombal 2010) - Leuprolide 7.5,advanced hormone-dependent prostate cancer,CS2-Leu-Tom
0.991101985,0,CS21,Leuprolide 7.5,Tombal 2010,CS21 (Tombal 2010) - Leuprolide 7.5,advanced hormone-dependent prostate cancer,CS2-Leu-Tom
0.991101985,0,CS21,Leuprolide 7.5,Tombal 2010,CS21 (Tombal 2010) - Leuprolide 7.5,advanced hormone-dependent prostate cancer,CS2-Leu-Tom
0.991101985,0,CS21,Leuprolide 7.5,Tombal 2010,CS21 (Tombal 2010) - Leuprolide 7.5,advanced hormone-dependent prostate cancer,CS2-Leu-Tom
0.991101985,0,CS21,Leuprolide 7.5,Tombal 2010,CS21 (Tombal 2010) - Leuprolide 7.5,advanced hormone-dependent prostate cancer,CS2-Leu-Tom
0.091666667,1,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
0.091666667,1,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
0.091666667,1,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
0.091666667,1,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
0.133333333,1,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
0.233333333,1,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
0.25,1,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
0.283333333,1,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
0.3,1,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
0.316666667,1,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
0.316666667,1,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
0.325,1,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
0.341666667,1,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
0.366666667,1,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
0.383333333,1,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
0.391666667,1,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
0.416666667,1,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
0.425,1,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
0.441666667,1,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
0.458333333,1,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
0.516666667,1,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
0.533333333,1,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
0.55,1,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
0.566666667,1,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
0.575,1,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
0.583333333,1,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
0.591666667,1,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
0.591666667,1,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
0.608333333,1,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
0.608333333,1,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
0.616666667,1,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
0.633333333,1,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
0.65,1,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
0.675,1,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
0.675,1,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
0.683333333,1,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
0.683333333,1,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
0.683333333,1,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
0.691666667,1,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
0.708333333,1,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
0.716666667,1,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
0.716666667,1,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
0.725,1,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
0.725,1,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
0.733333333,1,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
0.741666667,1,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
0.75,1,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
0.766666667,1,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
0.775,1,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
0.8,1,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
0.808333333,1,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
0.825,1,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
0.85,1,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
0.858333333,1,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
0.866666667,1,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
0.875,1,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
0.875,1,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
0.891666667,1,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
0.891666667,1,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
0.9,1,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
0.9,1,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
0.908333333,1,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
0.908333333,1,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
0.916666667,1,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
0.95,1,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
0.966666667,1,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
0.966666667,1,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
0.966666667,1,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
0.975,1,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
0.975,1,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
0.983333333,1,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1,1,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.008333333,1,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.008333333,1,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.016666667,1,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.025,1,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.033333333,1,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.05,1,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.05,1,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.05,1,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.058333333,1,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.066666667,1,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.075,1,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.083333333,1,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.091666667,1,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.108333333,1,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.116666667,1,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.125,1,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.125,1,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.133333333,1,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.133333333,1,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.141666667,1,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.141666667,1,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.15,1,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.15,1,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.158333333,1,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.158333333,1,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.175,1,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.175,1,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.175,1,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.183333333,1,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.183333333,1,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.191666667,1,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.191666667,1,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.2,1,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.208333333,1,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.216666667,1,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.233333333,1,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.233333333,1,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.25,1,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.258333333,1,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.258333333,1,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.258333333,1,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.266666667,1,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.291666667,1,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.3,1,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.308333333,1,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.316666667,1,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.316666667,1,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.325,1,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.333333333,1,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.333333333,1,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.341666667,1,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.35,1,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.358333333,1,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.358333333,1,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.366666667,1,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.375,1,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.375,1,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.383333333,1,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.391666667,1,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.391666667,1,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.391666667,1,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.408333333,1,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.408333333,1,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.408333333,1,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.416666667,1,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.416666667,1,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.425,1,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.425,1,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.433333333,1,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.433333333,1,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.441666667,1,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.441666667,1,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.45,1,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.45,1,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.458333333,1,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.466666667,1,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.475,1,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.475,1,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.483333333,1,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.483333333,1,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.491666667,1,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.5,1,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.508333333,1,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.508333333,1,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.516666667,1,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.525,1,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.558333333,1,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.566666667,1,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.575,1,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.591666667,1,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.6,1,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.6,1,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.608333333,1,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.608333333,1,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.616666667,1,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.616666667,1,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.625,1,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.633333333,1,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.633333333,1,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.641666667,1,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.658333333,1,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.658333333,1,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.683333333,1,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.708333333,1,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.725,1,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.733333333,1,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.741666667,1,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.75,1,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.758333333,1,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.758333333,1,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.775,1,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.775,1,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.783333333,1,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.783333333,1,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.791666667,1,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.8,1,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.825,1,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.833333333,1,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.833333333,1,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.841666667,1,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.841666667,1,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.85,1,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.85,1,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.858333333,1,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.858333333,1,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.866666667,1,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.866666667,1,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.875,1,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.875,1,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.883333333,1,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.883333333,1,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.891666667,1,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.9,1,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.9,1,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.908333333,1,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.916666667,1,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.933333333,1,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.95,1,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.958333333,1,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.975,1,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.983333333,1,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.991666667,1,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2,1,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.008333333,1,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.041666667,1,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.05,1,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.066666667,1,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.083333333,1,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.1,1,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.15,1,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.175,1,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.183333333,1,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.191666667,1,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.2,1,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.208333333,1,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.241666667,1,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.258333333,1,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.283333333,1,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.308333333,1,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.316666667,1,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.325,1,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.333333333,1,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.341666667,1,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.35,1,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.358333333,1,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.503967756,1,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.620412168,1,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.620412168,1,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.691866693,1,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.691866693,1,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.691866693,1,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
0.0625,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
0.120833334,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
0.1875,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.020833334,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.0375,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.054166667,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.070833334,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.0875,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.104166667,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.120833334,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.1375,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.154166667,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.170833334,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.1875,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.204166667,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.220833334,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.2375,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.2625,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.2625,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.2625,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.2625,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.270833334,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.270833334,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.270833334,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.270833334,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.270833334,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.279166667,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.279166667,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.279166667,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.279166667,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.2875,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.2875,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.2875,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.2875,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.2875,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.295833334,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.295833334,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.295833334,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.295833334,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.304166667,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.304166667,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.304166667,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.304166667,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.304166667,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.3125,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.3125,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.3125,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.3125,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.320833334,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.320833334,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.320833334,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.320833334,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.320833334,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.329166667,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.329166667,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.329166667,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.329166667,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.3375,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.3375,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.3375,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.3375,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.3375,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.345833334,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.345833334,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.345833334,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.345833334,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.354166667,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.354166667,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.354166667,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.354166667,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.354166667,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.3625,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.3625,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.3625,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.3625,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.370833334,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.370833334,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.370833334,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.370833334,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.370833334,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.379166667,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.379166667,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.379166667,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.379166667,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.379166667,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.3875,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.3875,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.3875,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.3875,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.395833334,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.395833334,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.395833334,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.395833334,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.395833334,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.404166667,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.404166667,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.404166667,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.404166667,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.4125,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.4125,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.4125,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.4125,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.4125,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.420833334,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.420833334,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.420833334,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.420833334,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.429166667,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.429166667,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.429166667,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.429166667,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.429166667,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.4375,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.4375,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.4375,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.4375,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.445833334,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.445833334,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.445833334,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.445833334,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.445833334,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.454166667,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.454166667,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.454166667,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.454166667,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.4625,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.4625,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.4625,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.4625,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.4625,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.470833334,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.470833334,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.470833334,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.470833334,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.479166667,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.479166667,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.479166667,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.479166667,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.479166667,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.4875,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.4875,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.4875,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.4875,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.495833334,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.495833334,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.495833334,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.495833334,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.495833334,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.504166667,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.504166667,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.504166667,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.504166667,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.5125,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.5125,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.5125,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.5125,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.5125,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.520833334,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.520833334,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.520833334,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.520833334,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.520833334,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.529166667,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.529166667,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.529166667,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.529166667,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.529166667,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.5375,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.5375,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.5375,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.5375,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.5375,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.545833334,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.545833334,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.545833334,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.545833334,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.545833334,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.554166667,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.554166667,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.554166667,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.554166667,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.554166667,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.5625,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.5625,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.5625,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.5625,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.5625,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.570833334,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.570833334,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.570833334,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.570833334,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.570833334,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.579166667,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.579166667,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.579166667,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.579166667,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.579166667,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.5875,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.5875,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.5875,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.5875,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.5875,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.595833334,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.595833334,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.595833334,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.595833334,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.595833334,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.604166667,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.604166667,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.604166667,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.604166667,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.604166667,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.6125,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.6125,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.6125,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.6125,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.6125,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.620833334,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.620833334,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.620833334,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.620833334,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.620833334,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.629166667,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.629166667,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.629166667,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.629166667,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.629166667,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.629166667,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.6375,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.6375,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.6375,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.6375,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.6375,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.645833334,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.645833334,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.645833334,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.645833334,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.645833334,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.654166667,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.654166667,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.654166667,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.654166667,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.654166667,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.6625,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.6625,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.6625,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.6625,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.6625,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.670833334,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.670833334,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.670833334,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.670833334,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.670833334,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.679166667,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.679166667,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.679166667,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.679166667,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.679166667,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.6875,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.6875,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.6875,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.6875,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.6875,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.695833334,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.695833334,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.695833334,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.695833334,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.695833334,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.704166667,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.704166667,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.704166667,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.704166667,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.704166667,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.7125,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.7125,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.7125,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.7125,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.7125,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.720833334,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.720833334,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.720833334,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.720833334,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.720833334,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.729166667,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.729166667,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.729166667,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.729166667,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.729166667,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.7375,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.7375,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.7375,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.7375,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.7375,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.745833334,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.745833334,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.745833334,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.745833334,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.745833334,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.754166667,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.754166667,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.754166667,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.7625,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.7625,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.7625,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.7625,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.770833334,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.770833334,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.770833334,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.770833334,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.779166667,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.779166667,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.779166667,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.779166667,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.7875,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.7875,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.7875,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.7875,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.795833334,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.795833334,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.795833334,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.795833334,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.804166667,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.804166667,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.804166667,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.804166667,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.8125,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.8125,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.8125,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.8125,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.820833334,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.820833334,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.820833334,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.820833334,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.829166667,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.829166667,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.829166667,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.829166667,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.8375,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.8375,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.8375,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.845833334,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.845833334,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.845833334,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.845833334,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.854166667,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.854166667,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.854166667,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.854166667,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.8625,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.8625,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.8625,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.8625,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.870833334,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.870833334,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.870833334,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.870833334,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.879166667,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.879166667,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.879166667,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.879166667,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.8875,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.8875,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.8875,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.8875,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.895833334,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.895833334,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.895833334,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.895833334,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.904166667,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.904166667,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.904166667,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.904166667,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.9125,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.9125,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.9125,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.9125,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.920833334,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.920833334,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.920833334,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.929166667,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.929166667,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.929166667,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.929166667,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.9375,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.9375,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.9375,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.9375,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.945833334,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.945833334,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.945833334,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.945833334,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.954166667,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.954166667,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.954166667,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.954166667,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.9625,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.9625,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.9625,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.9625,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.970833334,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.970833334,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.970833334,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.970833334,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.979166667,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.979166667,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.979166667,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.979166667,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.9875,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.9875,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.9875,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.9875,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.995833334,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.995833334,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.995833334,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.004166667,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.004166667,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.004166667,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.0125,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.0125,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.0125,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.020833334,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.020833334,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.020833334,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.020833334,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.029166667,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.029166667,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.029166667,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.0375,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.0375,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.0375,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.0375,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.045833334,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.045833334,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.045833334,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.054166667,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.054166667,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.054166667,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.054166667,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.0625,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.0625,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.0625,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.070833334,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.070833334,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.070833334,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.079166667,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.079166667,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.079166667,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.079166667,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.0875,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.0875,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.0875,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.095833334,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.095833334,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.095833334,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.095833334,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.104166667,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.104166667,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.104166667,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.1125,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.1125,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.1125,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.1125,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.120833334,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.120833334,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.120833334,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.129166667,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.129166667,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.129166667,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.1375,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.1375,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.1375,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.1375,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.145833334,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.145833334,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.145833334,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.154166667,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.154166667,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.154166667,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.154166667,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.1625,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.1625,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.1625,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.170833334,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.170833334,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.170833334,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.170833334,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.179166667,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.179166667,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.179166667,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.1875,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.1875,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.1875,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.195833334,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.195833334,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.195833334,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.195833334,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.204166667,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.204166667,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.204166667,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.2125,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.2125,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.2125,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.2125,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.220833334,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.220833334,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.220833334,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.229166667,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.229166667,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.229166667,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.229166667,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.2375,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.2375,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.2375,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.245833334,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.245833334,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.245833334,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.254166667,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.254166667,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.2625,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.2625,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.2625,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.270833334,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.270833334,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.270833334,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.279166667,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.279166667,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.279166667,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.2875,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.2875,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.2875,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.295833334,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.295833334,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.295833334,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.304166667,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.304166667,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.304166667,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.3125,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.3125,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.3125,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.320833334,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.320833334,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.320833334,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.329166667,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.329166667,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.329166667,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.3375,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.3375,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.345833334,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.345833334,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.345833334,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.354166667,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.354166667,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.354166667,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.3625,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.3625,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.3625,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.370833334,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.370833334,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.370833334,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.379166667,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.379166667,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.379166667,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.3875,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.3875,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.3875,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.395833334,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.395833334,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.395833334,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.404166667,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.404166667,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.404166667,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.4125,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.4125,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.4125,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.420833334,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.420833334,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.429166667,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.429166667,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.429166667,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.4375,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.4375,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.4375,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.445833334,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.445833334,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.445833334,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.454166667,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.454166667,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.454166667,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.4625,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.4625,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.4625,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.470833334,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.470833334,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.470833334,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.479166667,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.479166667,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.479166667,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.4875,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.4875,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.4875,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.495833334,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.495833334,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.5125,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.520833334,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.529166667,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.5375,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.545833334,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.554166667,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.570833334,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.579166667,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.5875,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.595833334,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.604166667,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.613931673,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.656139431,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.656139431,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.656139431,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.656139431,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.656139431,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.656139431,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.656139431,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.702452549,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.702452549,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.702452549,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.717449177,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.728917187,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.742987212,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.770378455,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.785375084,0,PREVAIL,Enzalutamide,Beer 2014,PREVAIL (Beer 2014) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
0.058333333,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.058333333,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.058333333,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.1,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.133333333,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.158333333,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.166666667,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.2,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.25,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.258333333,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.258333333,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.275,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.283333333,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.3,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.308333333,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.316666667,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.316666667,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.35,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.35,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.35,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.358333333,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.366666667,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.366666667,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.366666667,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.375,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.383333333,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.383333333,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.383333333,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.391666667,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.391666667,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.408333333,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.408333333,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.408333333,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.408333333,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.408333333,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.425,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.425,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.433333333,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.433333333,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.433333333,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.441666667,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.441666667,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.45,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.45,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.458333333,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.458333333,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.466666667,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.475,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.475,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.475,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.483333333,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.483333333,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.483333333,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.5,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.5,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.5,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.516666667,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.516666667,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.525,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.525,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.525,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.533333333,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.55,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.55,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.55,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.558333333,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.558333333,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.566666667,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.566666667,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.591666667,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.591666667,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.6,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.608333333,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.608333333,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.633333333,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.633333333,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.641666667,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.658333333,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.675,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.675,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.683333333,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.691666667,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.708333333,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.716666667,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.716666667,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.716666667,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.725,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.725,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.725,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.741666667,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.741666667,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.75,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.758333333,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.766666667,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.766666667,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.783333333,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.791666667,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.791666667,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.791666667,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.808333333,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.808333333,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.816666667,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.825,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.841666667,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.85,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.866666667,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.866666667,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.875,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.875,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.875,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.875,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.883333333,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.891666667,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.891666667,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.891666667,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.908333333,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.908333333,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.916666667,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.916666667,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.933333333,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.933333333,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.941666667,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.941666667,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.941666667,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.95,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.958333333,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.958333333,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.966666667,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.966666667,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.966666667,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.991666667,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.991666667,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.991666667,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.008333333,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.016666667,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.016666667,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.016666667,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.033333333,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.05,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.05,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.066666667,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.075,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.083333333,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.083333333,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.091666667,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.1,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.1,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.1,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.1,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.116666667,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.116666667,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.125,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.125,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.15,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.15,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.15,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.158333333,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.158333333,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.166666667,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.166666667,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.166666667,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.166666667,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.183333333,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.191666667,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.2,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.216666667,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.216666667,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.216666667,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.225,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.225,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.225,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.233333333,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.233333333,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.233333333,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.241666667,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.241666667,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.241666667,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.241666667,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.25,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.258333333,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.266666667,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.291666667,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.3,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.308333333,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.325,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.325,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.333333333,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.341666667,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.35,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.35,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.375,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.375,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.375,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.375,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.391666667,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.391666667,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.4,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.4,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.4,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.4,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.425,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.425,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.425,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.425,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.433333333,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.433333333,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.441666667,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.45,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.45,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.466666667,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.466666667,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.475,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.483333333,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.483333333,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.483333333,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.491666667,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.491666667,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.491666667,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.516666667,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.516666667,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.525,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.533333333,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.533333333,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.541666667,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.541666667,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.541666667,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.541666667,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.55,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.55,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.55,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.558333333,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.558333333,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.575,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.583333333,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.583333333,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.591666667,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.591666667,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.6,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.6,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.6,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.6,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.608333333,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.616666667,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.625,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.633333333,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.633333333,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.641666667,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.641666667,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.65,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.658333333,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.658333333,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.658333333,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.658333333,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.666666667,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.7,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.716666667,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.725,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.741666667,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.766666667,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.775,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.808333333,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.833333333,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.833333333,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.858333333,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.875,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.875,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.883333333,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.883333333,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.9,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.9,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.9,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.908333333,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.925,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.925,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.941666667,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.95,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.016666667,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.033333333,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.041666667,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.091666667,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.108333333,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.116666667,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.125,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.158333333,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.166666667,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.175,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.208333333,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.225,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.233333333,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.275,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.283333333,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.325,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.333333333,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.375,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.408333333,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.508333333,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.511331395,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.558333333,1,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.079166667,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.1625,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.2875,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.320833334,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.3625,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.395833334,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.4375,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.470833334,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.629166667,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.879166667,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.029166667,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.045833334,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.070833334,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.0875,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.1125,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.129166667,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.154166667,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.170833334,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.195833334,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.2125,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.2375,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.2625,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.2625,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.2625,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.2625,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.270833334,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.270833334,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.270833334,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.270833334,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.279166667,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.279166667,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.279166667,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.279166667,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.2875,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.2875,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.2875,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.2875,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.295833334,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.295833334,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.295833334,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.295833334,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.304166667,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.304166667,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.304166667,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.304166667,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.3125,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.3125,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.3125,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.3125,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.320833334,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.320833334,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.320833334,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.320833334,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.329166667,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.329166667,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.329166667,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.329166667,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.3375,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.3375,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.3375,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.3375,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.345833334,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.345833334,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.345833334,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.345833334,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.354166667,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.354166667,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.354166667,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.354166667,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.3625,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.3625,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.3625,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.3625,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.370833334,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.370833334,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.370833334,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.370833334,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.379166667,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.379166667,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.379166667,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.379166667,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.379166667,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.3875,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.3875,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.3875,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.3875,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.395833334,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.395833334,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.395833334,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.395833334,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.404166667,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.404166667,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.404166667,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.404166667,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.4125,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.4125,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.4125,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.4125,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.420833334,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.420833334,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.420833334,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.420833334,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.429166667,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.429166667,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.429166667,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.429166667,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.4375,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.4375,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.4375,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.4375,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.445833334,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.445833334,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.445833334,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.445833334,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.454166667,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.454166667,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.454166667,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.454166667,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.4625,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.4625,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.4625,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.4625,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.470833334,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.470833334,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.470833334,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.470833334,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.479166667,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.479166667,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.479166667,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.479166667,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.4875,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.4875,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.4875,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.4875,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.495833334,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.495833334,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.495833334,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.495833334,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.504166667,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.504166667,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.504166667,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.504166667,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.5125,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.5125,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.5125,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.5125,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.520833334,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.520833334,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.520833334,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.520833334,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.529166667,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.529166667,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.529166667,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.529166667,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.5375,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.5375,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.5375,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.5375,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.545833334,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.545833334,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.545833334,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.545833334,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.554166667,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.554166667,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.554166667,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.554166667,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.5625,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.5625,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.5625,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.5625,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.570833334,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.570833334,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.570833334,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.570833334,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.579166667,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.579166667,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.579166667,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.579166667,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.5875,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.5875,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.5875,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.5875,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.595833334,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.595833334,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.595833334,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.595833334,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.604166667,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.604166667,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.604166667,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.604166667,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.6125,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.6125,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.6125,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.6125,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.620833334,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.620833334,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.620833334,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.620833334,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.629166667,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.629166667,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.629166667,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.629166667,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.6375,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.6375,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.6375,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.6375,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.645833334,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.645833334,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.645833334,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.645833334,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.654166667,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.654166667,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.654166667,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.654166667,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.6625,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.6625,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.6625,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.6625,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.670833334,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.670833334,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.670833334,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.670833334,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.679166667,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.679166667,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.679166667,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.679166667,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.6875,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.6875,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.6875,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.6875,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.695833334,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.695833334,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.695833334,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.695833334,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.704166667,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.704166667,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.704166667,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.704166667,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.7125,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.7125,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.7125,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.7125,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.720833334,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.720833334,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.720833334,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.720833334,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.729166667,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.729166667,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.729166667,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.729166667,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.7375,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.7375,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.7375,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.7375,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.745833334,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.745833334,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.745833334,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.745833334,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.754166667,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.754166667,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.754166667,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.7625,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.7625,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.7625,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.770833334,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.770833334,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.770833334,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.779166667,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.779166667,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.779166667,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.779166667,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.7875,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.7875,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.7875,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.795833334,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.795833334,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.795833334,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.804166667,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.804166667,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.804166667,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.8125,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.8125,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.8125,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.8125,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.820833334,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.820833334,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.820833334,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.829166667,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.829166667,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.829166667,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.8375,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.8375,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.8375,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.845833334,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.845833334,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.845833334,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.845833334,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.854166667,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.854166667,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.854166667,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.8625,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.8625,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.8625,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.870833334,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.870833334,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.870833334,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.870833334,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.879166667,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.879166667,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.879166667,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.8875,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.8875,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.8875,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.895833334,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.895833334,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.895833334,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.904166667,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.904166667,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.904166667,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.904166667,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.9125,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.9125,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.9125,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.920833334,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.920833334,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.920833334,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.929166667,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.929166667,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.929166667,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.9375,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.9375,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.9375,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.9375,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.945833334,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.945833334,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.945833334,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.954166667,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.954166667,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.954166667,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.9625,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.9625,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.9625,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.970833334,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.970833334,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.970833334,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.970833334,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.979166667,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.979166667,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.979166667,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.9875,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.9875,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.9875,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.995833334,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.995833334,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.995833334,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.004166667,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.004166667,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.004166667,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.0125,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.0125,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.0125,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.020833334,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.020833334,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.020833334,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.029166667,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.029166667,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.029166667,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.029166667,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.0375,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.0375,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.0375,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.045833334,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.045833334,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.045833334,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.054166667,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.054166667,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.054166667,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.054166667,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.0625,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.0625,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.0625,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.070833334,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.070833334,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.070833334,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.079166667,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.079166667,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.079166667,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.079166667,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.0875,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.0875,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.0875,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.095833334,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.095833334,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.095833334,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.104166667,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.104166667,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.104166667,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.1125,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.1125,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.1125,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.1125,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.120833334,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.120833334,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.120833334,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.129166667,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.129166667,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.129166667,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.1375,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.1375,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.1375,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.1375,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.145833334,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.145833334,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.145833334,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.154166667,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.154166667,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.154166667,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.1625,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.1625,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.1625,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.1625,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.170833334,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.170833334,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.170833334,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.179166667,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.179166667,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.179166667,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.1875,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.1875,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.1875,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.195833334,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.195833334,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.195833334,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.195833334,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.204166667,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.204166667,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.204166667,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.2125,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.2125,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.2125,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.220833334,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.220833334,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.220833334,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.220833334,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.229166667,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.229166667,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.229166667,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.2375,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.2375,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.2375,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.245833334,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.245833334,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.245833334,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.254166667,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.254166667,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.2625,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.2625,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.270833334,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.270833334,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.270833334,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.279166667,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.279166667,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.2875,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.2875,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.295833334,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.295833334,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.295833334,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.304166667,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.304166667,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.3125,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.3125,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.320833334,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.320833334,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.320833334,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.329166667,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.329166667,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.3375,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.3375,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.345833334,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.345833334,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.345833334,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.354166667,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.354166667,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.3625,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.3625,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.370833334,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.370833334,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.370833334,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.379166667,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.379166667,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.3875,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.3875,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.395833334,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.395833334,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.395833334,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.404166667,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.404166667,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.4125,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.4125,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.420833334,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.420833334,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.420833334,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.429166667,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.429166667,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.4375,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.4375,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.445833334,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.445833334,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.445833334,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.454166667,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.454166667,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.4625,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.4625,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.470833334,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.470833334,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.470833334,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.479166667,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.479166667,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.4875,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.4875,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.495833334,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.495833334,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.511128794,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.518165698,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.533358666,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.543216362,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.550787514,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.5625,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.579166667,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.5875,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.595833334,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.6125,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.620833334,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.629166667,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.645833334,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.654166667,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.6625,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.679166667,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.6875,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.695833334,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.7125,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.720833334,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.729166667,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.744252874,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.775287357,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.792672414,0,PREVAIL,Placebo,Beer 2014,PREVAIL (Beer 2014) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.083333333,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
0.083333333,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
0.083333333,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
0.083333333,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
0.125,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
0.141666667,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
0.233333333,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
0.233333333,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
0.25,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
0.316666667,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
0.333333333,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
0.333333333,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
0.358333333,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
0.358333333,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
0.375,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
0.416666667,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
0.433333333,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
0.433333333,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
0.433333333,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
0.441666667,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
0.45,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
0.55,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
0.566666667,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
0.566666667,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
0.566666667,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
0.566666667,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
0.583333333,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
0.591666667,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
0.591666667,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
0.6,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
0.641666667,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
0.658333333,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
0.666666667,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
0.666666667,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
0.666666667,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
0.675,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
0.683333333,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
0.683333333,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
0.691666667,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
0.7,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
0.708333333,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
0.716666667,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
0.716666667,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
0.725,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
0.725,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
0.75,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
0.766666667,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
0.791666667,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
0.791666667,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
0.808333333,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
0.833333333,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
0.85,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
0.85,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
0.858333333,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
0.858333333,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
0.858333333,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
0.883333333,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
0.891666667,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
0.9,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
0.9,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
0.9,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
0.908333333,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
0.908333333,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
0.958333333,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
0.958333333,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
0.966666667,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
0.966666667,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
0.966666667,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
0.966666667,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
0.975,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
0.975,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
0.975,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
0.991666667,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.008333333,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.016666667,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.016666667,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.033333333,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.041666667,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.05,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.05,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.05,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.058333333,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.066666667,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.075,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.091666667,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.091666667,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.1,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.1,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.116666667,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.125,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.133333333,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.141666667,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.141666667,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.15,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.158333333,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.158333333,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.175,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.175,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.183333333,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.183333333,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.183333333,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.191666667,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.191666667,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.191666667,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.2,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.208333333,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.216666667,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.241666667,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.241666667,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.25,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.25,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.258333333,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.266666667,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.275,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.283333333,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.3,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.3,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.316666667,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.325,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.333333333,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.333333333,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.341666667,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.341666667,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.341666667,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.35,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.358333333,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.358333333,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.366666667,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.366666667,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.375,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.375,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.383333333,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.383333333,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.383333333,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.391666667,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.4,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.4,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.4,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.408333333,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.416666667,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.416666667,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.416666667,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.416666667,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.425,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.433333333,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.441666667,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.441666667,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.441666667,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.441666667,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.458333333,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.458333333,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.458333333,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.475,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.475,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.475,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.475,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.483333333,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.491666667,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.508333333,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.508333333,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.516666667,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.525,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.541666667,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.541666667,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.558333333,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.566666667,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.583333333,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.583333333,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.583333333,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.583333333,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.6,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.6,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.6,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.608333333,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.608333333,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.616666667,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.616666667,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.625,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.633333333,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.633333333,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.641666667,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.641666667,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.65,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.65,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.666666667,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.675,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.691666667,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.691666667,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.691666667,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.691666667,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.691666667,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.725,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.733333333,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.733333333,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.733333333,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.733333333,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.733333333,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.741666667,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.75,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.75,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.75,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.758333333,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.758333333,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.766666667,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.775,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.783333333,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.791666667,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.791666667,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.791666667,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.791666667,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.791666667,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.8,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.808333333,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.816666667,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.816666667,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.825,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.833333333,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.833333333,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.841666667,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.841666667,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.841666667,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.841666667,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.85,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.85,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.858333333,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.858333333,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.858333333,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.866666667,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.866666667,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.866666667,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.875,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.875,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.883333333,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.891666667,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.891666667,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.891666667,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.891666667,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.908333333,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.916666667,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.925,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.925,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.933333333,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.933333333,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.933333333,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.941666667,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.958333333,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.958333333,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.966666667,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.983333333,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.983333333,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.983333333,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.016666667,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.016666667,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.033333333,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.033333333,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.05,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.066666667,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.066666667,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.066666667,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.066666667,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.075,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.091666667,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.1,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.1,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.108333333,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.108333333,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.116666667,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.141666667,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.15,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.15,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.158333333,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.158333333,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.166666667,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.175,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.183333333,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.191666667,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.191666667,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.2,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.2,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.216666667,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.216666667,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.225,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.225,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.233333333,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.241666667,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.25,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.25,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.258333333,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.275,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.283333333,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.3,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.3,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.3,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.308333333,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.316666667,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.325,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.325,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.325,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.341666667,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.358333333,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.358333333,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.383333333,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.391666667,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.391666667,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.408333333,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.408333333,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.416666667,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.416666667,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.416666667,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.425,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.433333333,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.433333333,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.441666667,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.441666667,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.441666667,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.45,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.466666667,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.475,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.5,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.5,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.5,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.5,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.508333333,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.516666667,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.516666667,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.516666667,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.525,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.55,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.55,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.558333333,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.558333333,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.591666667,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.6,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.6,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.616666667,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.616666667,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.633333333,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.641666667,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.641666667,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.65,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.658333333,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.666666667,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.675,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.675,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.683333333,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.691666667,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.691666667,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.7,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.716666667,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.725,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.75,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.75,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.758333333,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.775,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.783333333,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.8,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.925,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.941666667,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.975,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
3.025,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
3.05,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
3.091666667,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
3.133333333,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
3.166666667,1,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
0.120833334,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
0.379166667,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.129166667,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.379166667,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.545833334,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.5875,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.629166667,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.670833334,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.7125,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.7625,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.779166667,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.795833334,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.8125,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.829166667,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.845833334,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.8625,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.870833334,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.8875,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.904166667,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.920833334,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.9375,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.954166667,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.970833334,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
1.9875,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.004166667,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.004166667,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.004166667,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.004166667,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.0125,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.0125,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.0125,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.0125,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.020833334,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.020833334,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.020833334,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.020833334,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.029166667,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.029166667,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.029166667,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.029166667,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.0375,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.0375,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.0375,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.0375,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.045833334,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.045833334,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.045833334,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.045833334,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.054166667,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.054166667,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.054166667,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.054166667,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.0625,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.0625,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.0625,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.0625,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.070833334,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.070833334,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.070833334,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.070833334,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.079166667,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.079166667,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.079166667,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.079166667,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.0875,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.0875,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.0875,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.0875,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.095833334,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.095833334,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.095833334,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.095833334,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.104166667,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.104166667,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.104166667,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.104166667,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.1125,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.1125,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.1125,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.1125,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.120833334,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.120833334,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.120833334,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.120833334,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.129166667,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.129166667,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.129166667,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.129166667,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.1375,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.1375,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.1375,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.1375,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.145833334,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.145833334,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.145833334,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.145833334,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.154166667,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.154166667,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.154166667,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.154166667,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.1625,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.1625,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.1625,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.1625,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.170833334,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.170833334,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.170833334,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.170833334,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.179166667,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.179166667,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.179166667,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.179166667,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.1875,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.1875,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.1875,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.1875,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.195833334,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.195833334,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.195833334,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.195833334,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.204166667,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.204166667,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.204166667,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.204166667,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.2125,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.2125,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.2125,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.2125,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.220833334,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.220833334,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.220833334,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.220833334,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.229166667,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.229166667,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.229166667,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.229166667,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.2375,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.2375,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.2375,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.2375,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.245833334,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.245833334,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.245833334,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.245833334,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.254166667,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.254166667,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.254166667,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.254166667,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.2625,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.2625,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.2625,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.2625,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.270833334,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.270833334,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.270833334,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.270833334,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.279166667,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.279166667,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.279166667,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.279166667,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.2875,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.2875,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.2875,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.2875,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.295833334,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.295833334,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.295833334,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.295833334,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.304166667,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.304166667,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.304166667,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.304166667,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.3125,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.3125,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.3125,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.3125,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.320833334,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.320833334,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.320833334,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.320833334,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.329166667,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.329166667,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.329166667,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.329166667,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.3375,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.3375,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.3375,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.3375,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.345833334,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.345833334,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.345833334,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.345833334,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.354166667,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.354166667,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.354166667,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.354166667,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.3625,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.3625,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.3625,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.3625,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.370833334,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.370833334,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.370833334,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.370833334,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.379166667,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.379166667,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.379166667,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.379166667,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.3875,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.3875,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.3875,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.3875,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.395833334,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.395833334,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.395833334,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.395833334,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.404166667,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.404166667,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.404166667,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.404166667,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.4125,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.4125,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.4125,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.4125,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.420833334,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.420833334,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.420833334,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.420833334,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.429166667,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.429166667,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.429166667,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.429166667,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.4375,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.4375,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.4375,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.4375,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.445833334,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.445833334,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.445833334,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.445833334,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.454166667,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.454166667,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.454166667,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.454166667,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.4625,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.4625,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.4625,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.4625,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.470833334,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.470833334,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.470833334,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.470833334,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.479166667,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.479166667,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.479166667,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.479166667,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.4875,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.4875,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.4875,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.4875,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.495833334,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.495833334,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.495833334,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.504166667,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.504166667,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.5125,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.5125,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.5125,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.520833334,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.520833334,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.520833334,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.529166667,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.529166667,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.529166667,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.5375,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.5375,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.5375,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.545833334,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.545833334,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.554166667,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.554166667,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.554166667,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.5625,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.5625,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.5625,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.570833334,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.570833334,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.570833334,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.579166667,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.579166667,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.579166667,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.5875,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.5875,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.595833334,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.595833334,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.595833334,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.604166667,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.604166667,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.604166667,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.6125,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.6125,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.6125,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.620833334,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.620833334,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.620833334,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.629166667,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.629166667,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.6375,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.6375,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.6375,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.645833334,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.645833334,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.645833334,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.654166667,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.654166667,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.654166667,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.6625,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.6625,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.6625,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.670833334,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.670833334,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.679166667,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.679166667,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.679166667,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.6875,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.6875,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.6875,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.695833334,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.695833334,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.695833334,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.704166667,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.704166667,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.704166667,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.7125,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.7125,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.720833334,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.720833334,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.720833334,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.729166667,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.729166667,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.729166667,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.7375,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.7375,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.7375,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.745833334,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.745833334,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.754166667,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.754166667,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.7625,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.7625,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.7625,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.770833334,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.770833334,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.770833334,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.779166667,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.779166667,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.7875,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.7875,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.7875,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.795833334,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.795833334,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.795833334,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.804166667,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.804166667,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.8125,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.8125,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.8125,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.820833334,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.820833334,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.820833334,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.829166667,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.829166667,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.8375,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.8375,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.8375,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.845833334,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.845833334,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.845833334,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.854166667,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.854166667,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.8625,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.8625,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.8625,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.870833334,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.870833334,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.870833334,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.879166667,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.879166667,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.8875,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.8875,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.8875,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.895833334,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.895833334,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.895833334,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.904166667,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.904166667,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.9125,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.9125,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.9125,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.920833334,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.920833334,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.920833334,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.929166667,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.929166667,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.9375,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.9375,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.9375,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.945833334,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.945833334,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.945833334,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.954166667,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.954166667,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.9625,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.9625,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.9625,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.970833334,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.970833334,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.970833334,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.979166667,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.979166667,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.9875,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.9875,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.9875,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.995833334,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
2.995833334,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
3.004166667,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
3.004166667,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
3.0125,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
3.0125,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
3.0125,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
3.020833334,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
3.020833334,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
3.029166667,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
3.029166667,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
3.029166667,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
3.0375,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
3.0375,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
3.045833334,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
3.045833334,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
3.045833334,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
3.054166667,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
3.054166667,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
3.0625,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
3.0625,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
3.0625,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
3.070833334,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
3.070833334,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
3.079166667,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
3.079166667,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
3.079166667,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
3.0875,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
3.0875,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
3.095833334,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
3.095833334,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
3.095833334,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
3.104166667,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
3.104166667,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
3.104166667,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
3.1125,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
3.1125,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
3.120833334,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
3.120833334,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
3.120833334,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
3.129166667,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
3.129166667,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
3.1375,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
3.1375,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
3.1375,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
3.145833334,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
3.145833334,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
3.154166667,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
3.154166667,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
3.154166667,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
3.1625,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
3.1625,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
3.170833334,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
3.170833334,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
3.170833334,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
3.179166667,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
3.179166667,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
3.1875,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
3.1875,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
3.1875,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
3.195833334,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
3.195833334,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
3.741666667,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
3.741666667,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
3.741666667,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
3.741666667,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
3.741666667,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
3.741666667,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
3.741666667,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
3.741666667,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
3.741666667,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
3.741666667,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
3.741666667,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
3.741666667,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
3.741666667,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
3.741666667,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
3.741666667,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
3.741666667,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
3.741666667,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
3.741666667,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
3.741666667,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
3.741666667,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
3.741666667,0,PREVAIL,Enzalutamide,Beer 2017,PREVAIL (Beer 2017) - Enzalutamide,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Enz-Bee
0.093187661,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.093187661,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.122107969,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.163881748,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.163881748,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.241002571,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.241002571,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.241002571,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.257069409,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.257069409,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.257069409,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.275,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.275,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.275,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.275,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.275,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.291666667,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.308333333,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.341666667,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.341666667,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.341666667,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.341666667,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.358333333,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.366666667,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.366666667,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.366666667,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.366666667,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.366666667,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.375,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.375,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.391666667,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.391666667,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.391666667,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.4,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.4,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.425,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.425,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.425,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.425,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.425,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.433333333,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.441666667,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.441666667,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.45,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.45,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.458333333,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.458333333,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.483333333,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.483333333,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.483333333,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.483333333,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.483333333,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.483333333,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.483333333,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.483333333,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.5,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.508333333,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.508333333,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.508333333,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.508333333,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.508333333,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.533333333,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.533333333,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.533333333,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.533333333,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.541666667,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.558333333,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.566666667,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.575,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.6,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.6,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.6,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.608333333,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.608333333,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.608333333,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.608333333,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.633333333,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.666666667,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.675,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.683333333,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.7,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.7,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.708333333,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.708333333,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.708333333,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.708333333,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.716666667,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.725,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.733333333,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.733333333,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.741666667,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.75,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.766666667,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.766666667,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.766666667,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.775,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.775,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.775,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.8,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.808333333,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.833333333,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.833333333,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.833333333,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.841666667,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.841666667,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.858333333,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.858333333,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.866666667,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.866666667,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.866666667,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.866666667,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.891666667,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.891666667,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.891666667,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.9,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.9,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.9,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.916666667,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.916666667,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.925,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.925,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.925,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.925,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.95,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.95,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.95,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.958333333,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.958333333,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.975,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.983333333,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.983333333,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.983333333,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.983333333,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.991666667,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.008333333,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.016666667,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.016666667,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.016666667,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.033333333,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.058333333,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.066666667,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.066666667,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.066666667,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.083333333,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.083333333,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.083333333,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.083333333,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.083333333,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.108333333,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.108333333,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.116666667,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.116666667,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.116666667,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.125,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.133333333,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.141666667,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.15,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.15,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.166666667,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.166666667,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.175,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.175,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.2,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.2,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.2,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.208333333,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.208333333,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.208333333,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.208333333,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.225,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.225,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.225,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.225,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.225,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.225,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.233333333,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.233333333,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.241666667,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.25,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.25,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.258333333,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.283333333,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.291666667,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.291666667,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.325,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.325,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.325,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.325,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.333333333,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.333333333,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.333333333,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.375,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.391666667,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.391666667,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.391666667,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.391666667,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.4,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.4,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.4,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.4,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.4,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.416666667,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.416666667,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.425,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.425,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.425,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.433333333,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.433333333,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.45,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.45,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.458333333,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.475,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.475,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.475,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.475,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.475,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.475,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.475,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.475,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.483333333,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.491666667,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.5,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.5,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.5,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.5,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.5,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.508333333,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.508333333,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.516666667,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.516666667,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.525,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.525,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.525,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.525,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.525,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.525,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.55,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.55,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.55,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.55,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.55,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.55,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.55,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.55,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.566666667,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.566666667,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.566666667,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.575,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.575,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.575,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.591666667,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.591666667,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.591666667,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.591666667,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.591666667,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.6,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.6,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.608333333,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.616666667,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.616666667,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.616666667,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.625,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.625,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.625,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.65,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.65,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.65,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.65,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.65,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.658333333,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.666666667,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.666666667,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.675,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.675,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.675,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.708333333,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.708333333,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.708333333,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.716666667,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.716666667,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.716666667,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.733333333,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.741666667,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.75,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.775,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.783333333,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.808333333,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.808333333,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.816666667,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.816666667,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.816666667,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.825,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.841666667,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.85,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.85,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.875,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.875,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.875,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.875,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.883333333,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.883333333,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.883333333,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.883333333,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.9,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.9,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.9,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.9,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.908333333,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.908333333,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.925,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.925,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.925,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.933333333,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.933333333,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.958333333,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.966666667,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.975,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.008333333,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.008333333,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.033333333,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.033333333,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.033333333,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.033333333,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.033333333,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.033333333,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.041666667,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.05,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.05,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.058333333,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.066666667,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.066666667,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.091666667,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.091666667,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.1,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.108333333,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.125,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.125,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.125,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.125,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.125,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.125,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.125,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.15,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.15,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.158333333,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.158333333,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.158333333,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.183333333,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.191666667,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.225,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.225,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.233333333,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.233333333,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.25,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.25,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.258333333,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.275,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.283333333,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.283333333,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.283333333,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.283333333,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.308333333,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.316666667,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.341666667,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.341666667,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.341666667,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.341666667,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.341666667,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.366666667,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.375,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.375,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.383333333,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.4,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.4,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.408333333,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.408333333,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.441666667,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.45,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.508333333,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.508333333,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.508333333,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.516666667,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.533333333,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.541666667,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.566666667,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.566666667,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.566666667,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.566666667,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.566666667,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.6,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.6,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.633333333,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.633333333,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.658333333,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.658333333,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.658333333,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.658333333,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.683333333,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.691666667,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.716666667,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.716666667,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.741666667,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.825,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.858333333,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.858333333,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.858333333,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.866666667,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.925,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.941666667,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.95,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
3.016666667,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
3.033333333,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
3.041666667,1,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.075514139,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.170308484,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.295833334,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.3375,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.379166667,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.420833334,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.4625,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.629166667,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.879166667,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.5875,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.670833334,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.770833334,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.7875,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.804166667,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.820833334,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.8375,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.854166667,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.870833334,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.895833334,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.9125,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.929166667,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.945833334,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.9625,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
1.979166667,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.004166667,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.004166667,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.004166667,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.0125,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.0125,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.0125,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.020833334,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.020833334,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.020833334,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.020833334,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.029166667,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.029166667,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.029166667,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.0375,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.0375,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.0375,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.0375,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.045833334,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.045833334,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.045833334,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.054166667,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.054166667,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.054166667,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.054166667,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.0625,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.0625,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.0625,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.070833334,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.070833334,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.070833334,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.079166667,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.079166667,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.079166667,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.079166667,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.0875,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.0875,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.0875,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.095833334,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.095833334,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.095833334,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.095833334,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.104166667,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.104166667,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.104166667,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.1125,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.1125,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.1125,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.1125,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.120833334,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.120833334,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.120833334,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.129166667,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.129166667,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.129166667,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.1375,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.1375,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.1375,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.1375,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.145833334,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.145833334,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.145833334,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.154166667,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.154166667,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.154166667,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.154166667,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.1625,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.1625,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.1625,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.170833334,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.170833334,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.170833334,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.170833334,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.179166667,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.179166667,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.179166667,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.1875,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.1875,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.1875,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.195833334,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.195833334,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.195833334,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.195833334,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.204166667,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.204166667,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.204166667,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.2125,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.2125,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.2125,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.2125,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.220833334,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.220833334,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.220833334,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.229166667,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.229166667,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.229166667,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.229166667,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.2375,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.2375,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.2375,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.245833334,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.245833334,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.245833334,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.254166667,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.254166667,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.2625,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.2625,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.2625,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.270833334,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.270833334,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.270833334,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.279166667,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.279166667,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.279166667,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.2875,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.2875,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.2875,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.295833334,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.295833334,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.295833334,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.304166667,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.304166667,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.304166667,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.3125,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.3125,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.3125,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.320833334,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.320833334,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.320833334,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.329166667,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.329166667,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.329166667,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.3375,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.3375,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.345833334,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.345833334,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.345833334,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.354166667,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.354166667,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.354166667,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.3625,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.3625,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.3625,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.370833334,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.370833334,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.370833334,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.379166667,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.379166667,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.379166667,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.3875,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.3875,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.3875,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.395833334,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.395833334,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.395833334,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.404166667,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.404166667,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.404166667,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.4125,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.4125,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.4125,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.420833334,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.420833334,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.429166667,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.429166667,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.429166667,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.4375,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.4375,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.4375,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.445833334,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.445833334,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.445833334,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.454166667,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.454166667,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.454166667,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.4625,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.4625,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.4625,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.470833334,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.470833334,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.470833334,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.479166667,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.479166667,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.479166667,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.4875,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.4875,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.4875,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.495833334,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.495833334,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.504166667,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.504166667,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.5125,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.5125,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.5125,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.520833334,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.520833334,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.529166667,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.529166667,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.529166667,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.5375,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.5375,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.5375,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.545833334,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.545833334,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.554166667,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.554166667,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.554166667,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.5625,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.5625,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.570833334,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.570833334,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.570833334,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.579166667,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.579166667,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.579166667,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.5875,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.5875,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.595833334,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.595833334,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.595833334,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.604166667,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.604166667,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.6125,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.6125,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.6125,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.620833334,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.620833334,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.620833334,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.629166667,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.629166667,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.6375,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.6375,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.6375,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.645833334,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.645833334,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.654166667,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.654166667,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.654166667,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.6625,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.6625,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.6625,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.670833334,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.670833334,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.679166667,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.679166667,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.679166667,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.6875,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.6875,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.695833334,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.695833334,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.695833334,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.704166667,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.704166667,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.704166667,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.7125,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.7125,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.720833334,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.720833334,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.720833334,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.729166667,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.729166667,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.7375,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.7375,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.7375,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.745833334,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.745833334,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.754166667,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.754166667,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.7625,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.7625,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.770833334,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.770833334,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.770833334,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.779166667,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.779166667,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.7875,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.7875,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.7875,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.795833334,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.795833334,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.804166667,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.804166667,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.804166667,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.8125,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.8125,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.820833334,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.820833334,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.820833334,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.829166667,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.829166667,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.8375,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.8375,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.8375,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.845833334,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.845833334,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.854166667,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.854166667,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.854166667,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.8625,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.8625,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.870833334,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.870833334,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.870833334,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.879166667,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.879166667,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.8875,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.8875,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.895833334,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.895833334,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.895833334,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.904166667,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.904166667,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.9125,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.9125,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.9125,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.920833334,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.920833334,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.929166667,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.929166667,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.929166667,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.9375,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.9375,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.945833334,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.945833334,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.945833334,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.954166667,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.954166667,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.9625,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.9625,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.9625,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.970833334,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.970833334,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.979166667,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.979166667,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.979166667,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.9875,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.9875,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.995833334,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
2.995833334,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
3.004166667,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
3.0125,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
3.0125,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
3.020833334,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
3.020833334,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
3.029166667,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
3.029166667,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
3.0375,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
3.0375,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
3.045833334,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
3.054166667,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
3.054166667,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
3.0625,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
3.0625,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
3.070833334,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
3.070833334,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
3.079166667,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
3.079166667,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
3.0875,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
3.095833334,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
3.095833334,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
3.104166667,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
3.104166667,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
3.1125,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
3.1125,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
3.120833334,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
3.120833334,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
3.129166667,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
3.1375,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
3.1375,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
3.145833334,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
3.145833334,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
3.154166667,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
3.154166667,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
3.1625,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
3.1625,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
3.170833334,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
3.179166667,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
3.179166667,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
3.1875,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
3.1875,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
3.195833334,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
3.195833334,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
3.204166667,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
3.204166667,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
3.2125,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
3.220833334,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
3.220833334,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
3.229166667,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
3.229166667,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
3.2375,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
3.2375,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
3.245833334,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
3.279166667,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
3.3125,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
3.345833334,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
3.379166667,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
3.4125,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
3.445833334,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
3.479166667,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
3.733333333,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
3.733333333,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
3.733333333,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
3.733333333,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
3.733333333,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
3.733333333,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
3.733333333,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
3.733333333,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
3.733333333,0,PREVAIL,Placebo,Beer 2017,PREVAIL (Beer 2017) - Placebo,metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,PRE-Pla-Bee
0.234509301,1,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
0.234509301,1,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
0.234509301,1,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
0.313489277,1,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
0.313489277,1,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
0.344782818,1,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
0.344782818,1,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
0.344782818,1,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
0.344782818,1,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
0.608015435,1,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
0.63434452,1,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
0.705084374,1,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
0.780781403,1,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
0.831787181,1,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
0.951894979,1,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
0.978231344,1,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.007857934,1,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.007857934,1,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.032556465,1,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.032556465,1,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.050674544,1,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.050674544,1,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.077032746,1,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.077032746,1,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.077032746,1,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.123110465,1,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.213598952,1,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.230071918,1,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.251494782,1,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.251494782,1,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.251494782,1,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.267967749,1,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.267967749,1,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.300913681,1,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.300913681,1,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.300913681,1,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.300913681,1,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.343701175,1,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.361811975,1,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.376654387,1,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.376654387,1,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.376654387,1,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.391474961,1,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.445770965,1,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.532983785,1,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.549442193,1,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.574140723,1,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.590599131,1,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.653127979,1,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.683333333,1,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.683333333,1,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.683333333,1,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.7,1,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.766666667,1,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.783333333,1,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.783333333,1,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.8,1,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.833333333,1,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.85,1,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.866666667,1,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.916666667,1,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.933333333,1,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2,1,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2,1,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.016666667,1,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.033333333,1,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.066666667,1,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.083333333,1,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.083333333,1,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.1,1,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.133333333,1,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.15,1,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.166666667,1,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.166666667,1,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.2,1,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.216666667,1,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.25,1,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.266666667,1,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.3,1,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.383333333,1,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.383333333,1,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.4,1,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.433333333,1,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.45,1,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.466666667,1,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.483333333,1,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.5,1,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.516666667,1,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.516666667,1,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.516666667,1,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.533333333,1,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.533333333,1,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.566666667,1,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.616666667,1,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.633333333,1,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.65,1,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.716666667,1,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.733333333,1,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.783333333,1,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.816666667,1,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.833333333,1,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.883333333,1,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.95,1,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
3,1,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
0.0136,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
0.0136,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
0.038702853,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
0.038702853,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
0.038702853,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
0.066656834,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
0.066656834,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
0.066656834,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
0.093801196,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
0.093801196,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
0.117655332,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
0.117655332,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
0.117655332,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
0.134950855,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
0.149778709,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
0.149778709,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
0.171168816,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
0.171168816,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
0.195849149,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
0.195849149,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
0.195849149,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
0.222170955,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
0.222170955,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
0.244379978,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
0.244379978,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
0.267411558,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
0.267411558,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
0.267411558,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
0.267411558,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
0.297030869,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
0.297030869,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
0.297030869,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
0.297030869,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
0.297030869,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
0.329136048,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
0.329136048,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
0.329136048,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
0.329136048,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
0.329136048,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
0.35136327,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
0.35136327,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
0.368636955,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
0.368636955,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
0.368636955,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
0.368636955,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
0.389200865,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
0.389200865,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
0.389200865,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
0.407297107,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
0.407297107,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
0.407297107,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
0.425393348,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
0.425393348,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
0.425393348,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
0.452537711,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
0.452537711,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
0.452537711,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
0.452537711,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
0.452537711,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
0.484617412,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
0.484617412,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
0.484617412,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
0.484617412,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
0.484617412,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
0.515874556,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
0.515874556,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
0.515874556,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
0.515874556,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
0.515874556,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
0.547131701,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
0.547131701,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
0.547131701,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
0.547131701,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
0.547131701,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
0.547131701,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
0.547131701,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
0.547131701,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
0.547131701,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
0.571812033,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
0.571812033,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
0.571812033,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
0.571812033,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
0.571812033,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
0.571812033,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
0.594850893,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
0.594850893,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
0.594850893,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
0.594850893,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
0.594850893,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
0.594850893,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
0.594850893,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
0.594850893,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
0.621179978,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
0.621179978,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
0.621179978,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
0.621179978,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
0.621179978,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
0.621179978,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
0.621179978,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
0.621179978,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
0.621179978,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
0.645037754,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
0.645037754,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
0.645037754,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
0.645037754,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
0.645037754,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
0.645037754,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
0.672182117,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
0.672182117,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
0.672182117,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
0.672182117,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
0.672182117,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
0.672182117,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
0.672182117,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
0.672182117,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
0.672182117,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
0.672182117,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
0.672182117,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
0.69685881,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
0.69685881,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
0.69685881,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
0.69685881,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
0.69685881,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
0.715781247,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
0.715781247,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
0.715781247,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
0.715781247,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
0.715781247,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
0.715781247,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
0.715781247,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
0.733884768,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
0.733884768,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
0.733884768,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
0.733884768,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
0.74951698,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
0.74951698,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
0.74951698,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
0.74951698,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
0.74951698,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
0.769261974,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
0.769261974,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
0.769261974,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
0.769261974,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
0.769261974,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
0.789829524,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
0.789829524,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
0.789829524,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
0.789829524,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
0.789829524,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
0.80710321,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
0.80710321,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
0.80710321,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
0.80710321,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
0.823557978,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
0.823557978,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
0.823557978,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
0.823557978,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
0.845770641,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
0.845770641,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
0.845770641,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
0.845770641,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
0.845770641,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
0.845770641,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
0.845770641,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
0.872092447,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
0.872092447,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
0.872092447,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
0.872092447,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
0.872092447,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
0.872092447,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
0.897591696,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
0.897591696,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
0.897591696,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
0.897591696,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
0.897591696,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
0.897591696,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
0.897591696,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
0.931323789,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
0.931323789,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
0.931323789,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
0.931323789,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
0.931323789,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
0.931323789,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
0.931323789,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
0.931323789,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
0.931323789,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
0.931323789,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
0.965063162,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
0.965063162,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
0.965063162,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
0.965063162,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
0.965063162,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
0.965063162,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
0.965063162,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
0.993044639,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
0.993044639,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
0.993044639,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
0.993044639,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
0.993044639,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
0.993044639,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
0.993044639,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.0202072,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.0202072,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.0202072,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.0202072,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.0202072,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.041615505,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.041615505,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.041615505,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.041615505,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.041615505,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.063853645,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.063853645,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.063853645,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.063853645,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.063853645,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.063853645,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.08526195,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.08526195,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.08526195,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.08526195,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.10830081,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.10830081,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.10830081,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.10830081,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.10830081,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.10830081,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.132158586,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.132158586,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.132158586,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.132158586,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.132158586,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.158480392,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.158480392,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.158480392,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.158480392,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.158480392,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.158480392,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.158480392,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.158480392,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.189737537,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.189737537,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.189737537,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.189737537,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.189737537,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.189737537,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.208659974,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.208659974,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.208659974,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.221835435,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.221835435,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.221835435,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.24078335,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.24078335,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.24078335,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.24078335,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.24078335,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.259731266,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.259731266,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.259731266,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.284440715,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.284440715,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.284440715,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.284440715,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.284440715,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.284440715,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.284440715,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.308320329,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.308320329,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.308320329,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.329714076,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.329714076,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.329714076,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.329714076,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.329714076,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.329714076,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.352756575,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.352756575,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.352756575,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.352756575,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.369233181,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.369233181,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.369233181,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.384064674,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.384064674,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.384064674,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.403813308,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.403813308,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.403813308,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.403813308,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.403813308,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.403813308,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.43096131,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.43096131,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.43096131,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.43096131,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.43096131,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.43096131,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.459758064,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.459758064,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.459758064,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.459758064,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.459758064,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.459758064,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.491841405,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.491841405,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.491841405,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.491841405,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.491841405,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.491841405,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.491841405,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.521460716,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.521460716,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.521460716,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.521460716,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.521460716,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.521460716,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.541212989,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.541212989,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.541212989,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.541212989,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.541212989,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.561791458,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.561791458,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.561791458,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.561791458,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.561791458,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.561791458,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.561791458,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.582369927,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.582369927,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.582369927,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.582369927,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.582369927,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.602941118,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.602941118,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.602941118,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.602941118,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.602941118,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.602941118,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.602941118,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.634205542,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.634205542,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.634205542,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.634205542,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.634205542,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.634205542,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.634205542,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.634205542,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.634205542,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.634205542,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.634205542,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.668230656,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.668230656,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.668230656,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.668230656,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.668230656,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.668230656,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.668230656,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.668230656,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.668230656,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.691666667,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.691666667,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.691666667,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.691666667,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.691666667,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.708333334,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.708333334,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.708333334,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.708333334,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.708333334,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.725,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.725,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.725,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.725,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.725,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.741666667,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.741666667,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.741666667,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.741666667,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.741666667,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.758333334,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.758333334,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.758333334,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.758333334,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.775,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.775,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.775,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.775,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.791666667,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.791666667,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.791666667,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.791666667,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.791666667,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.808333334,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.808333334,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.808333334,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.808333334,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.808333334,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.825,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.825,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.825,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.825,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.841666667,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.841666667,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.841666667,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.841666667,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.841666667,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.858333334,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.858333334,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.858333334,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.858333334,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.858333334,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.875,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.875,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.875,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.875,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.875,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.891666667,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.891666667,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.891666667,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.891666667,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.908333334,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.908333334,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.908333334,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.908333334,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.908333334,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.925,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.925,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.925,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.925,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.925,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.941666667,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.941666667,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.941666667,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.941666667,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.941666667,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.958333334,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.958333334,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.958333334,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.958333334,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.975,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.975,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.975,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.975,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.975,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.991666667,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.991666667,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.991666667,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.991666667,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
1.991666667,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.008333334,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.008333334,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.008333334,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.008333334,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.025,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.025,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.025,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.025,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.025,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.041666667,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.041666667,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.041666667,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.041666667,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.041666667,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.058333334,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.058333334,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.058333334,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.058333334,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.058333334,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.075,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.075,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.075,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.075,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.075,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.091666667,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.091666667,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.091666667,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.091666667,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.091666667,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.091666667,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.108333334,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.108333334,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.108333334,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.108333334,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.108333334,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.125,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.125,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.125,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.125,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.125,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.141666667,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.141666667,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.141666667,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.141666667,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.141666667,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.158333334,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.158333334,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.158333334,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.158333334,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.158333334,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.175,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.175,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.175,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.175,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.175,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.175,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.191666667,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.191666667,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.191666667,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.191666667,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.191666667,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.208333334,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.208333334,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.208333334,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.208333334,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.208333334,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.225,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.225,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.225,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.225,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.225,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.241666667,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.241666667,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.241666667,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.241666667,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.241666667,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.258333334,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.258333334,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.258333334,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.258333334,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.258333334,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.275,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.275,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.275,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.275,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.291666667,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.291666667,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.291666667,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.291666667,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.291666667,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.308333334,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.308333334,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.308333334,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.308333334,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.308333334,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.325,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.325,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.325,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.325,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.325,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.341666667,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.341666667,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.341666667,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.341666667,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.341666667,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.358333334,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.358333334,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.358333334,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.358333334,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.375,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.375,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.375,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.375,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.375,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.391666667,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.391666667,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.391666667,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.391666667,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.391666667,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.408333334,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.408333334,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.408333334,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.408333334,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.408333334,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.425,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.425,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.425,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.425,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.425,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.441666667,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.441666667,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.441666667,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.441666667,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.458333334,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.458333334,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.458333334,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.458333334,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.458333334,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.475,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.475,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.475,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.475,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.475,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.491666667,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.491666667,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.491666667,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.491666667,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.491666667,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.508333334,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.508333334,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.508333334,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.508333334,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.525,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.525,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.525,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.525,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.525,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.541666667,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.541666667,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.541666667,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.541666667,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.541666667,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.541666667,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.558333334,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.558333334,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.558333334,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.558333334,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.558333334,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.558333334,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.575,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.575,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.575,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.575,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.575,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.591666667,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.591666667,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.591666667,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.591666667,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.591666667,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.591666667,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.608333334,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.608333334,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.608333334,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.608333334,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.608333334,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.608333334,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.625,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.625,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.625,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.625,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.625,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.625,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.641666667,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.641666667,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.641666667,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.641666667,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.641666667,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.658333334,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.658333334,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.658333334,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.658333334,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.658333334,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.658333334,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.675,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.675,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.675,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.675,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.675,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.675,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.691666667,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.691666667,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.691666667,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.691666667,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.691666667,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.691666667,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.708333334,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.708333334,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.708333334,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.708333334,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.708333334,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.725,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.725,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.725,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.725,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.725,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.725,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.741666667,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.741666667,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.741666667,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.741666667,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.741666667,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.741666667,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.758333334,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.758333334,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.758333334,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.758333334,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.758333334,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.775,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.775,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.775,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.775,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.791666667,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.791666667,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.791666667,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.791666667,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.808333334,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.808333334,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.808333334,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.808333334,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.808333334,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.825,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.825,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.825,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.825,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.841666667,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.841666667,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.841666667,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.841666667,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.841666667,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.858333334,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.858333334,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.858333334,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.858333334,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.875,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.875,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.875,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.875,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.875,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.891666667,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.891666667,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.891666667,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.891666667,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.908333334,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.908333334,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.908333334,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.908333334,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.908333334,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.925,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.925,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.925,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.925,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.941666667,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.941666667,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.941666667,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.941666667,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.941666667,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.958333334,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.958333334,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.958333334,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.958333334,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.975,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.975,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.975,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.975,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.975,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.991666667,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.991666667,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.991666667,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
2.991666667,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
3.008333334,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
3.008333334,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
3.008333334,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
3.008333334,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
3.025,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
3.025,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
3.025,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
3.041666667,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
3.041666667,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
3.041666667,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
3.041666667,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
3.058333334,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
3.058333334,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
3.058333334,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
3.058333334,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
3.075,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
3.075,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
3.075,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
3.075,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
3.091666667,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
3.091666667,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
3.091666667,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
3.091666667,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
3.108333334,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
3.108333334,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
3.108333334,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
3.108333334,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
3.125,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
3.125,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
3.125,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
3.125,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
3.141666667,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
3.141666667,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
3.141666667,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
3.141666667,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
3.158333334,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
3.158333334,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
3.158333334,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
3.158333334,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
3.175,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
3.175,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
3.175,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
3.175,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
3.191666667,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
3.191666667,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
3.191666667,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
3.191666667,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
3.208333334,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
3.208333334,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
3.208333334,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
3.208333334,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
3.225,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
3.225,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
3.225,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
3.225,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
3.241666667,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
3.241666667,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
3.241666667,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
3.258333334,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
3.275,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
3.275,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
3.291666667,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
3.308333334,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
3.308333334,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
3.325,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
3.341666667,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
3.341666667,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
3.358333334,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
3.358333334,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
3.375,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
3.391666667,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
3.391666667,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
3.408333334,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
3.425,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
3.425,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
3.441666667,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
3.458333334,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
3.458333334,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
3.475,0,PROSPER,Enzalutamide,"NICE report, IA1","PROSPER (NICE report, IA1) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-NIC
0.605299765,1,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
0.624361486,1,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
0.639615076,1,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
0.677704817,1,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
0.709142966,1,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
0.716666667,1,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
0.733333333,1,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
0.933333333,1,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
0.95,1,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
0.983333333,1,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
1,1,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
1.033333333,1,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
1.066666667,1,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
1.116666667,1,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
1.216666667,1,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
1.25,1,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
1.283333333,1,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
1.3,1,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
1.316666667,1,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
1.333333333,1,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
1.360721029,1,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
1.375974618,1,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
1.45,1,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
1.5,1,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
1.533333333,1,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
1.566666667,1,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
1.583333333,1,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
1.6,1,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
1.616666667,1,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
1.616666667,1,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
1.65,1,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
1.666666667,1,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
1.716666667,1,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
1.716666667,1,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
1.716666667,1,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
1.733333333,1,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
1.766666667,1,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
1.833333333,1,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
1.9,1,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
1.95,1,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
1.983333333,1,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
2.05,1,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
2.066666667,1,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
2.066666667,1,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
2.166666667,1,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
2.166666667,1,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
2.25,1,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
2.283333333,1,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
2.416666667,1,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
2.45,1,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
2.5,1,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
2.516666667,1,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
2.516666667,1,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
2.516666667,1,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
2.533333333,1,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
2.566666667,1,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
2.7,1,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
2.783333333,1,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
2.816666667,1,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
2.833333333,1,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
2.866666667,1,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
2.9,1,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
3.067956151,1,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
0.021666988,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
0.035946173,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
0.067367471,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
0.08640813,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
0.106876837,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
0.128297577,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
0.128297577,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
0.150194334,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
0.171615075,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
0.200182381,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
0.222081244,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
0.246358083,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
0.265398742,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
0.285395646,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
0.285395646,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
0.285395646,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
0.302536451,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
0.320149059,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
0.320149059,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
0.320149059,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
0.341093783,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
0.341093783,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
0.358230376,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
0.358230376,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
0.375842984,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
0.375842984,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
0.396311692,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
0.396311692,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
0.416780399,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
0.416780399,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
0.436297074,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
0.436297074,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
0.454861716,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
0.454861716,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
0.474854407,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
0.474854407,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
0.474854407,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
0.493895065,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
0.511507674,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
0.511507674,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
0.527216217,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
0.527216217,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
0.545306948,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
0.545306948,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
0.545306948,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
0.57006191,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
0.57006191,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
0.57006191,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
0.588626552,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
0.600057266,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
0.600057266,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
0.614830626,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
0.614830626,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
0.631988281,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
0.631988281,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
0.646755323,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
0.646755323,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
0.65865784,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
0.670562464,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
0.670562464,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
0.685797097,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
0.685797097,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
0.701516171,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
0.701516171,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
0.712904817,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
0.725,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
0.725,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
0.75,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
0.75,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
0.75,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
0.75,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
0.775,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
0.775,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
0.791666667,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
0.791666667,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
0.808333334,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
0.808333334,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
0.808333334,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
0.825,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
0.825,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
0.841666667,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
0.841666667,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
0.841666667,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
0.858333334,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
0.858333334,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
0.875,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
0.875,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
0.891666667,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
0.891666667,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
0.891666667,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
0.908333334,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
0.908333334,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
0.925,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
0.925,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
0.925,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
0.941666667,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
0.941666667,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
0.958333334,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
0.958333334,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
0.975,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
0.975,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
0.975,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
0.991666667,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
0.991666667,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
1.008333334,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
1.008333334,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
1.025,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
1.025,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
1.041666667,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
1.041666667,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
1.058333334,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
1.058333334,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
1.075,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
1.075,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
1.091666667,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
1.091666667,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
1.108333334,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
1.108333334,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
1.125,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
1.125,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
1.141666667,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
1.141666667,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
1.158333334,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
1.158333334,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
1.175,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
1.175,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
1.191666667,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
1.191666667,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
1.208333334,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
1.208333334,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
1.225,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
1.225,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
1.241666667,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
1.241666667,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
1.258333334,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
1.275,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
1.275,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
1.291666667,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
1.291666667,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
1.308333334,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
1.308333334,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
1.325,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
1.325,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
1.339876403,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
1.353570251,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
1.353570251,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
1.368347824,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
1.368347824,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
1.387987309,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
1.387987309,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
1.387987309,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
1.408333334,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
1.408333334,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
1.425,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
1.425,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
1.441666667,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
1.441666667,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
1.458333334,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
1.458333334,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
1.475,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
1.475,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
1.491666667,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
1.491666667,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
1.508333334,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
1.525,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
1.525,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
1.541666667,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
1.541666667,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
1.558333334,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
1.558333334,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
1.558333334,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
1.575,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
1.575,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
1.591666667,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
1.591666667,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
1.591666667,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
1.608333334,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
1.608333334,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
1.625,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
1.625,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
1.641666667,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
1.641666667,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
1.641666667,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
1.658333334,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
1.658333334,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
1.675,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
1.675,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
1.675,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
1.691666667,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
1.691666667,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
1.708333334,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
1.708333334,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
1.725,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
1.725,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
1.725,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
1.741666667,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
1.741666667,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
1.758333334,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
1.758333334,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
1.775,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
1.775,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
1.791666667,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
1.791666667,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
1.808333334,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
1.808333334,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
1.808333334,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
1.825,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
1.825,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
1.841666667,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
1.841666667,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
1.858333334,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
1.858333334,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
1.858333334,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
1.875,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
1.875,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
1.891666667,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
1.891666667,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
1.908333334,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
1.908333334,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
1.908333334,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
1.925,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
1.925,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
1.941666667,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
1.941666667,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
1.958333334,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
1.958333334,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
1.958333334,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
1.975,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
1.975,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
1.991666667,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
1.991666667,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
2.008333334,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
2.008333334,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
2.025,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
2.025,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
2.041666667,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
2.041666667,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
2.041666667,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
2.058333334,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
2.058333334,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
2.075,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
2.075,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
2.075,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
2.091666667,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
2.091666667,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
2.108333334,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
2.108333334,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
2.108333334,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
2.125,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
2.125,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
2.141666667,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
2.141666667,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
2.141666667,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
2.158333334,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
2.158333334,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
2.175,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
2.175,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
2.175,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
2.191666667,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
2.191666667,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
2.208333334,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
2.208333334,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
2.208333334,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
2.225,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
2.225,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
2.241666667,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
2.241666667,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
2.241666667,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
2.258333334,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
2.258333334,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
2.275,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
2.275,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
2.291666667,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
2.291666667,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
2.308333334,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
2.308333334,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
2.308333334,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
2.325,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
2.325,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
2.341666667,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
2.341666667,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
2.358333334,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
2.358333334,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
2.358333334,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
2.375,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
2.375,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
2.391666667,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
2.391666667,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
2.408333334,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
2.408333334,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
2.408333334,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
2.425,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
2.425,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
2.441666667,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
2.441666667,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
2.458333334,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
2.458333334,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
2.458333334,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
2.475,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
2.475,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
2.491666667,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
2.491666667,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
2.508333334,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
2.508333334,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
2.525,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
2.525,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
2.541666667,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
2.541666667,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
2.541666667,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
2.558333334,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
2.558333334,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
2.558333334,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
2.575,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
2.575,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
2.591666667,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
2.591666667,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
2.591666667,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
2.608333334,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
2.608333334,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
2.608333334,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
2.625,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
2.625,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
2.625,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
2.641666667,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
2.641666667,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
2.658333334,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
2.658333334,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
2.658333334,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
2.675,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
2.675,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
2.675,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
2.691666667,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
2.691666667,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
2.691666667,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
2.708333334,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
2.708333334,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
2.725,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
2.725,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
2.725,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
2.741666667,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
2.741666667,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
2.741666667,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
2.758333334,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
2.758333334,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
2.775,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
2.775,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
2.791666667,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
2.791666667,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
2.808333334,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
2.808333334,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
2.825,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
2.825,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
2.841666667,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
2.841666667,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
2.858333334,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
2.858333334,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
2.875,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
2.875,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
2.891666667,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
2.891666667,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
2.891666667,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
2.908333334,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
2.908333334,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
2.925,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
2.925,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
2.941666667,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
2.941666667,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
2.958333334,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
2.958333334,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
2.975,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
2.975,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
2.991666667,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
2.991666667,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
3.008333334,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
3.008333334,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
3.025,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
3.041666667,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
3.054613889,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
3.062947223,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
3.075644742,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
3.091666667,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
3.091666667,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
3.108333334,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
3.125,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
3.125,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
3.141666667,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
3.158333334,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
3.175,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
3.175,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
3.191666667,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
3.208333334,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
3.208333334,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
3.225,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
3.241666667,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
3.275,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
3.308333334,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
3.325,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
3.358333334,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
3.375,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
3.408333334,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
3.425,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
3.458333334,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
3.475,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
3.533049503,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
3.548758046,0,PROSPER,Placebo,"NICE report, IA1","PROSPER (NICE report, IA1) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-NIC
0.166666667,1,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
0.25,1,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
0.341666667,1,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
0.425,1,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
0.5,1,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
0.525,1,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
0.7,1,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
0.7,1,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
0.9,1,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
0.941666667,1,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
0.966666667,1,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
1.083333333,1,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
1.1,1,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
1.141666667,1,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
1.225,1,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
1.241666667,1,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
1.266666667,1,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
1.283333333,1,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
1.291666667,1,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
1.316666667,1,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
1.358333333,1,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
1.375,1,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
1.408333333,1,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
1.516666667,1,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
1.533333333,1,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
1.55,1,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
1.575,1,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
1.65,1,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
1.658333333,1,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
1.683333333,1,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
1.716666667,1,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
1.75,1,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
1.766666667,1,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
1.8,1,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
1.858333333,1,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
1.908333333,1,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
1.916666667,1,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
1.933333333,1,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
2.008333333,1,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
2.066666667,1,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
2.091666667,1,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
2.116666667,1,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
2.15,1,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
2.166666667,1,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
2.191666667,1,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
2.225,1,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
2.258333333,1,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
2.266666667,1,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
2.291666667,1,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
2.375,1,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
2.383333333,1,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
2.45,1,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
2.491666667,1,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
2.516666667,1,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
2.525,1,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
2.533333333,1,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
2.583333333,1,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
2.641666667,1,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
2.65,1,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
2.733333333,1,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
2.766666667,1,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
2.791666667,1,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
2.825,1,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
2.85,1,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
2.866666667,1,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
2.958333333,1,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
3,1,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
3.041666667,1,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
3.075,1,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
3.141666667,1,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
3.183333333,1,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
3.241666667,1,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
3.275,1,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
3.3,1,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
3.35,1,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
3.375,1,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
3.408333333,1,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
3.525,1,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
3.575,1,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
3.6,1,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
3.641666667,1,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
3.683333333,1,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
3.75,1,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
3.8,1,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
3.941666667,1,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
4.158909122,1,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
0.420833334,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
0.508333334,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
0.5875,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
0.695833334,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
0.720833334,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
0.7375,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
0.7625,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
0.7875,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
0.804166667,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
0.829166667,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
0.854166667,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
0.870833334,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
0.895833334,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
0.920833334,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
0.9375,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
0.9625,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
0.9875,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
1.020833334,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
1.029166667,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
1.05,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
1.05,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
1.05,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
1.079166667,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
1.0875,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
1.095833334,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
1.125,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
1.125,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
1.125,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
1.145833334,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
1.154166667,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
1.1625,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
1.179166667,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
1.1875,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
1.195833334,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
1.208333334,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
1.220833334,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
1.229166667,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
1.254166667,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
1.254166667,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
1.254166667,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
1.279166667,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
1.2875,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
1.295833334,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
1.308333334,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
1.325,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
1.3375,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
1.345833334,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
1.354166667,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
1.3625,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
1.370833334,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
1.379166667,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
1.3875,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
1.395833334,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
1.404166667,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
1.4125,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
1.420833334,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
1.429166667,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
1.4375,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
1.445833334,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
1.454166667,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
1.4625,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
1.470833334,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
1.479166667,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
1.4875,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
1.495833334,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
1.508333334,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
1.508333334,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
1.520833334,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
1.529166667,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
1.5375,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
1.545833334,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
1.554166667,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
1.5625,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
1.570833334,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
1.579166667,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
1.5875,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
1.595833334,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
1.604166667,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
1.6125,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
1.625,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
1.625,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
1.6375,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
1.645833334,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
1.654166667,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
1.6625,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
1.675,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
1.675,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
1.6875,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
1.695833334,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
1.704166667,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
1.7125,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
1.725,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
1.725,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
1.725,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
1.741666667,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
1.741666667,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
1.758333334,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
1.758333334,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
1.770833334,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
1.779166667,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
1.779166667,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
1.7875,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
1.795833334,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
1.804166667,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
1.8125,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
1.820833334,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
1.829166667,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
1.829166667,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
1.8375,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
1.845833334,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
1.854166667,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
1.8625,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
1.870833334,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
1.879166667,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
1.8875,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
1.8875,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
1.895833334,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
1.904166667,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
1.9125,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
1.920833334,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
1.929166667,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
1.9375,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
1.945833334,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
1.945833334,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
1.954166667,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
1.9625,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
1.970833334,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
1.979166667,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
1.9875,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
1.995833334,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
2.0125,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
2.020833334,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
2.029166667,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
2.0375,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
2.045833334,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
2.054166667,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
2.0625,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
2.079166667,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
2.0875,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
2.095833334,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
2.104166667,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
2.1125,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
2.120833334,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
2.129166667,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
2.145833334,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
2.154166667,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
2.1625,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
2.170833334,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
2.179166667,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
2.1875,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
2.195833334,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
2.2125,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
2.220833334,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
2.229166667,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
2.2375,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
2.245833334,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
2.254166667,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
2.2625,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
2.279166667,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
2.2875,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
2.295833334,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
2.304166667,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
2.3125,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
2.320833334,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
2.3375,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
2.345833334,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
2.354166667,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
2.3625,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
2.370833334,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
2.379166667,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
2.391666667,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
2.391666667,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
2.404166667,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
2.4125,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
2.420833334,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
2.429166667,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
2.4375,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
2.445833334,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
2.445833334,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
2.454166667,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
2.4625,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
2.470833334,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
2.479166667,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
2.4875,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
2.495833334,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
2.504166667,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
2.5125,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
2.520833334,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
2.529166667,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
2.5375,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
2.545833334,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
2.554166667,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
2.554166667,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
2.5625,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
2.575,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
2.575,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
2.5875,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
2.595833334,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
2.604166667,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
2.6125,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
2.620833334,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
2.629166667,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
2.6375,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
2.645833334,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
2.654166667,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
2.6625,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
2.675,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
2.675,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
2.6875,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
2.7,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
2.7,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
2.7125,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
2.725,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
2.725,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
2.725,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
2.7375,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
2.745833334,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
2.754166667,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
2.7625,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
2.770833334,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
2.779166667,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
2.779166667,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
2.7875,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
2.795833334,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
2.804166667,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
2.8125,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
2.820833334,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
2.829166667,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
2.829166667,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
2.8375,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
2.845833334,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
2.854166667,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
2.8625,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
2.870833334,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
2.879166667,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
2.8875,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
2.8875,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
2.895833334,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
2.904166667,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
2.9125,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
2.920833334,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
2.929166667,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
2.945833333,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
2.945833333,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
2.945833333,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
2.945833333,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
2.9625,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
2.970833334,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
2.979166667,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
2.9875,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
2.995833334,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
3.004166667,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
3.0125,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
3.020833334,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
3.029166667,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
3.0375,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
3.045833334,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
3.054166667,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
3.0625,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
3.0625,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
3.070833334,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
3.079166667,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
3.0875,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
3.095833334,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
3.104166667,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
3.1125,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
3.120833334,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
3.129166667,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
3.129166667,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
3.1375,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
3.145833334,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
3.154166667,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
3.1625,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
3.170833334,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
3.179166667,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
3.1875,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
3.195833334,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
3.195833334,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
3.204166667,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
3.2125,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
3.220833334,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
3.229166667,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
3.2375,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
3.245833334,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
3.254166667,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
3.2625,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
3.2625,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
3.270833334,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
3.279166667,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
3.2875,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
3.295833334,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
3.304166667,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
3.3125,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
3.320833334,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
3.329166667,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
3.345833334,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
3.354166667,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
3.3625,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
3.370833334,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
3.379166667,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
3.3875,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
3.395833334,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
3.404166667,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
3.4125,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
3.420833334,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
3.429166667,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
3.4375,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
3.445833334,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
3.454166667,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
3.4625,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
3.470833334,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
3.479166667,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
3.4875,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
3.495833334,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
3.504166667,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
3.5125,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
3.520833334,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
3.529166667,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
3.5375,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
3.545833334,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
3.554166667,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
3.5625,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
3.570833334,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
3.579166667,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
3.5875,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
3.595833334,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
3.604166667,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
3.6125,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
3.620833334,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
3.629166667,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
3.6375,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
3.645833334,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
3.654166667,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
3.679166667,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
3.6875,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
3.695833334,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
3.7125,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
3.720833334,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
3.729166667,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
3.745833334,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
3.7625,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
3.7625,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
3.779166667,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
3.7875,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
3.795833334,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
3.8125,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
3.820833334,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
3.829166667,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
3.845833334,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
3.854166667,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
3.8625,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
3.879166667,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
3.8875,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
3.895833334,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
3.916666667,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
3.916666667,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
3.933333334,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
3.945833334,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
3.954166667,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
3.9625,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
3.979166667,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
3.9875,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
4,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
4.029166667,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
4.045833334,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
4.070833334,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
4.0875,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
4.1125,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
4.129166667,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
4.154166667,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
4.174024965,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
4.185613778,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
4.2125,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
4.229166667,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
4.254166667,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
4.270833334,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
4.29596427,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
4.313735195,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
4.345833334,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
4.3625,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
4.379451435,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
4.395833334,0,PROSPER,Enzalutamide,"TLV report, IA2","PROSPER (TLV report, IA2) - Enzalutamide",hormone-relapsed non-metastatic prostate cancer,PRO-Enz-TLV
0.504906042,1,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
0.504906042,1,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
0.633333333,1,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
0.65,1,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
0.666666667,1,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
0.7,1,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
0.7,1,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
0.7,1,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
0.716666667,1,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
0.733333333,1,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
0.766666667,1,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
0.8,1,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
0.85,1,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
0.85,1,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
0.906987462,1,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
0.936211425,1,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
0.936211425,1,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
0.960396773,1,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
0.960396773,1,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
0.960396773,1,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
0.960396773,1,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
1.003728856,1,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
1.016829253,1,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
1.016829253,1,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
1.016829253,1,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
1.016829253,1,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
1.033333333,1,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
1.05,1,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
1.066666667,1,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
1.196203922,1,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
1.196203922,1,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
1.221396993,1,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
1.241551451,1,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
1.241551451,1,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
1.259690462,1,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
1.259690462,1,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
1.282868088,1,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
1.310076605,1,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
1.310076605,1,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
1.310076605,1,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
1.344339182,1,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
1.373563145,1,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
1.373563145,1,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
1.373563145,1,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
1.373563145,1,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
1.400771662,1,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
1.400771662,1,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
1.492474442,1,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
1.508598008,1,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
1.524721573,1,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
1.524721573,1,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
1.547899199,1,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
1.547899199,1,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
1.547899199,1,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
1.559991873,1,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
1.582161776,1,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
1.582161776,1,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
1.596269896,1,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
1.596269896,1,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
1.610378016,1,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
1.610378016,1,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
1.610378016,1,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
1.610378016,1,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
1.610378016,1,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
1.610378016,1,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
1.616666667,1,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
1.616666667,1,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
1.616666667,1,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
1.616666667,1,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
1.616666667,1,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
1.633333333,1,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
1.65,1,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
1.666666667,1,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
1.666666667,1,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
1.716666667,1,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
1.716666667,1,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
1.716666667,1,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
1.733333333,1,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
1.733333333,1,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
1.733333333,1,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
1.733333333,1,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
1.733333333,1,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
1.75,1,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
1.75,1,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
1.75,1,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
1.766666667,1,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
1.766666667,1,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
1.783333333,1,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
1.783333333,1,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
1.8,1,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
1.866666667,1,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
1.883333333,1,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
1.916666667,1,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
1.916666667,1,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
1.916666667,1,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
1.916666667,1,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
1.933333333,1,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
1.95,1,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
1.95,1,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
1.966666667,1,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
1.966666667,1,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
1.966666667,1,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
1.983333333,1,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
1.983333333,1,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2,1,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2,1,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.016666667,1,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.016666667,1,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.05,1,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.05,1,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.1,1,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.116666667,1,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.116666667,1,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.116666667,1,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.133333333,1,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.166666667,1,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.166666667,1,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.183333333,1,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.183333333,1,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.216666667,1,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.266666667,1,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.283333333,1,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.283333333,1,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.3,1,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.3,1,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.3,1,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.35,1,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.35,1,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.416666667,1,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.45,1,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.466666667,1,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.5,1,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.516666667,1,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.516666667,1,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.516666667,1,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.533333333,1,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.533333333,1,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.533333333,1,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.55,1,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.55,1,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.55,1,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.55,1,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.55,1,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.55,1,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.55,1,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.55,1,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.55,1,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.55,1,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.566666667,1,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.566666667,1,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.566666667,1,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.6,1,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.6,1,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.6,1,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.616666667,1,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.65,1,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.65,1,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.666666667,1,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.666666667,1,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.666666667,1,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.683333333,1,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.683333333,1,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.716666667,1,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.733333333,1,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.733333333,1,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.75,1,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.783333333,1,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.783333333,1,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.8,1,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.816666667,1,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.816666667,1,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.833333333,1,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.833333333,1,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.85,1,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.85,1,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.85,1,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.866666667,1,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.9,1,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.9,1,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.916666667,1,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.916666667,1,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.916666667,1,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.916666667,1,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.916666667,1,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.933333333,1,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.933333333,1,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.933333333,1,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.966666667,1,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.966666667,1,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.983333333,1,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3,1,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.033333333,1,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.05,1,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.066666667,1,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.066666667,1,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.083333333,1,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.083333333,1,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.083333333,1,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.083333333,1,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.083333333,1,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.1,1,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.116666667,1,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.116666667,1,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.166666667,1,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.183333333,1,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.2,1,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.25,1,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.333333333,1,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.35,1,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.45,1,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.483333333,1,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.483333333,1,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.6,1,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.616666667,1,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.616666667,1,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.930156033,1,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.930156033,1,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
4.111546147,1,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
4.111546147,1,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
0.046392142,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
0.093251255,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
0.129529278,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
0.167822747,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
0.223247504,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
0.263556418,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
0.310415531,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
0.378436824,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
0.397079697,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
0.431342274,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
0.448977424,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
0.471147327,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
0.491805645,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
0.530099114,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
0.545592033,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
0.575,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
0.591666667,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
0.625,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
0.641666667,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
0.841666667,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
1.010279055,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
1.025081293,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
1.025081293,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
1.025081293,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
1.041666667,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
1.041666667,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
1.058333334,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
1.058333334,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
1.058333334,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
1.075002815,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
1.075002815,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
1.093416191,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
1.093416191,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
1.093416191,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
1.108028172,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
1.125663322,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
1.125663322,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
1.125663322,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
1.125663322,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
1.150856394,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
1.150856394,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
1.150856394,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
1.179576495,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
1.179576495,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
1.179576495,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
1.179576495,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
1.179576495,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
1.208800458,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
1.208800458,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
1.208800458,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
1.208800458,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
1.231474222,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
1.231474222,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
1.231474222,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
1.250620957,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
1.250620957,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
1.271279275,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
1.271279275,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
1.271279275,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
1.271279275,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
1.296472347,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
1.296472347,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
1.296472347,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
1.296472347,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
1.327207894,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
1.327207894,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
1.327207894,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
1.327207894,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
1.358951164,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
1.358951164,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
1.358951164,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
1.358951164,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
1.387167404,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
1.387167404,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
1.387167404,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
1.387167404,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
1.410345029,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
1.410345029,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
1.410345029,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
1.410345029,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
1.432514932,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
1.432514932,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
1.432514932,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
1.432514932,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
1.455692558,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
1.455692558,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
1.455692558,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
1.479374045,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
1.479374045,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
1.479374045,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
1.479374045,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
1.500536225,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
1.500536225,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
1.500536225,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
1.516659791,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
1.516659791,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
1.536310386,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
1.536310386,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
1.536310386,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
1.536310386,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
1.553945536,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
1.553945536,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
1.571076825,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
1.571076825,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
1.571076825,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
1.589215836,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
1.589215836,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
1.589215836,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
1.603323956,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
1.603323956,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
1.613522342,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
1.625,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
1.625,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
1.625,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
1.641666667,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
1.641666667,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
1.658333334,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
1.658333334,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
1.658333334,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
1.675,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
1.675,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
1.691666667,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
1.691666667,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
1.691666667,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
1.708333334,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
1.708333334,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
1.708333334,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
1.708333334,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
1.725,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
1.725,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
1.725,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
1.741666667,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
1.741666667,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
1.741666667,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
1.741666667,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
1.758333334,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
1.758333334,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
1.758333334,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
1.775,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
1.775,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
1.775,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
1.775,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
1.791666667,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
1.791666667,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
1.791666667,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
1.808333334,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
1.808333334,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
1.808333334,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
1.808333334,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
1.825,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
1.825,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
1.825,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
1.841666667,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
1.841666667,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
1.841666667,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
1.841666667,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
1.858333334,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
1.858333334,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
1.858333334,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
1.858333334,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
1.875,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
1.875,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
1.875,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
1.891666667,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
1.891666667,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
1.891666667,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
1.891666667,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
1.908333334,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
1.908333334,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
1.908333334,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
1.925,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
1.925,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
1.925,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
1.925,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
1.941666667,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
1.941666667,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
1.941666667,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
1.958333334,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
1.958333334,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
1.958333334,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
1.958333334,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
1.975,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
1.975,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
1.975,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
1.991666667,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
1.991666667,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
1.991666667,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
1.991666667,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.008333334,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.008333334,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.008333334,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.025,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.025,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.025,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.025,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.041666667,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.041666667,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.041666667,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.041666667,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.058333334,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.058333334,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.058333334,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.058333334,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.075,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.075,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.075,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.075,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.091666667,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.091666667,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.091666667,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.091666667,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.108333334,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.108333334,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.108333334,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.108333334,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.125,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.125,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.125,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.125,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.141666667,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.141666667,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.141666667,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.141666667,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.158333334,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.158333334,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.158333334,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.158333334,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.175,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.175,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.175,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.175,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.191666667,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.191666667,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.191666667,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.191666667,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.208333334,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.208333334,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.208333334,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.208333334,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.225,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.225,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.225,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.225,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.241666667,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.241666667,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.241666667,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.241666667,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.258333334,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.258333334,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.258333334,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.258333334,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.275,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.275,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.275,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.275,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.291666667,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.291666667,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.291666667,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.291666667,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.308333334,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.308333334,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.308333334,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.308333334,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.325,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.325,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.325,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.341666667,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.341666667,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.341666667,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.358333334,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.358333334,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.358333334,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.358333334,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.375,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.375,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.375,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.391666667,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.391666667,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.391666667,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.391666667,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.408333334,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.408333334,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.408333334,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.408333334,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.425,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.425,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.425,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.441666667,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.441666667,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.441666667,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.441666667,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.458333334,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.458333334,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.458333334,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.475,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.475,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.475,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.475,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.491666667,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.491666667,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.491666667,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.491666667,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.508333334,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.508333334,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.508333334,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.525,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.525,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.525,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.525,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.541666667,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.541666667,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.541666667,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.541666667,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.558333334,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.558333334,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.558333334,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.575,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.575,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.575,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.575,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.591666667,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.591666667,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.591666667,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.608333334,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.608333334,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.608333334,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.608333334,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.625,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.625,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.625,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.625,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.641666667,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.641666667,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.641666667,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.658333334,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.658333334,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.658333334,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.658333334,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.675,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.675,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.675,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.691666667,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.691666667,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.691666667,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.708333334,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.708333334,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.708333334,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.725,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.725,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.725,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.725,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.741666667,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.741666667,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.741666667,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.758333334,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.758333334,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.758333334,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.758333334,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.775,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.775,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.775,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.791666667,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.791666667,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.791666667,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.808333334,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.808333334,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.808333334,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.808333334,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.825,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.825,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.825,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.841666667,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.841666667,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.841666667,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.841666667,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.858333334,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.858333334,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.858333334,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.875,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.875,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.875,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.891666667,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.891666667,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.891666667,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.891666667,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.908333334,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.908333334,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.908333334,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.925,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.925,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.925,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.925,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.941666667,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.941666667,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.941666667,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.958333334,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.958333334,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.958333334,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.975,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.975,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.975,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.975,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.991666667,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.991666667,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
2.991666667,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.008333334,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.008333334,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.008333334,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.025,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.025,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.025,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.025,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.041666667,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.041666667,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.041666667,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.041666667,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.041666667,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.058333334,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.058333334,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.058333334,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.058333334,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.058333334,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.075,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.075,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.075,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.075,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.075,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.091666667,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.091666667,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.091666667,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.091666667,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.091666667,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.108333334,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.108333334,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.108333334,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.108333334,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.108333334,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.125,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.125,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.125,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.125,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.125,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.141666667,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.141666667,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.141666667,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.141666667,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.141666667,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.158333334,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.158333334,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.158333334,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.158333334,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.158333334,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.175,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.175,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.175,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.175,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.191666667,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.191666667,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.191666667,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.191666667,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.191666667,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.208333334,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.208333334,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.208333334,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.208333334,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.208333334,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.225,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.225,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.225,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.225,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.225,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.241666667,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.241666667,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.241666667,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.241666667,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.241666667,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.258333334,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.258333334,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.258333334,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.258333334,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.258333334,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.275,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.275,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.275,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.275,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.275,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.291666667,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.291666667,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.291666667,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.291666667,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.291666667,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.308333334,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.308333334,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.308333334,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.308333334,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.308333334,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.325,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.325,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.325,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.325,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.341666667,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.341666667,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.341666667,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.341666667,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.358333334,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.358333334,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.358333334,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.358333334,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.358333334,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.375,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.375,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.375,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.375,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.375,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.391666667,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.391666667,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.391666667,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.391666667,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.391666667,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.408333334,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.408333334,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.408333334,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.408333334,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.408333334,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.425,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.425,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.425,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.425,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.425,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.441666667,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.441666667,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.441666667,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.441666667,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.441666667,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.458333334,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.458333334,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.458333334,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.458333334,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.458333334,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.475,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.475,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.475,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.475,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.475,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.491666667,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.491666667,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.491666667,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.491666667,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.491666667,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.508333334,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.508333334,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.508333334,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.508333334,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.508333334,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.525,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.525,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.525,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.525,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.525,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.541666667,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.541666667,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.541666667,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.541666667,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.558333334,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.558333334,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.558333334,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.558333334,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.558333334,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.575,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.575,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.575,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.575,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.575,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.591666667,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.591666667,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.591666667,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.591666667,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.591666667,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.608333334,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.608333334,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.608333334,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.608333334,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.608333334,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.625,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.625,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.625,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.625,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.625,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.641666667,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.641666667,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.641666667,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.641666667,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.641666667,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.661089491,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.661089491,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.661089491,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.661089491,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.661089491,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.661089491,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.677721458,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.677721458,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.692333439,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.692333439,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.692333439,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.692333439,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.712991758,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.712991758,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.712991758,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.712991758,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.712991758,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.712991758,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.735665522,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.735665522,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.735665522,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.735665522,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.735665522,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.760858593,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.760858593,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.760858593,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.760858593,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.760858593,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.760858593,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.760858593,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.785547803,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.785547803,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.785547803,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.785547803,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.785547803,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.804694538,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.804694538,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.804694538,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.804694538,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.826864441,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.826864441,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.826864441,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.826864441,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.826864441,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.826864441,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.826864441,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.849034343,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.849034343,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.849034343,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.849034343,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.863646325,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.863646325,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.880777614,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.880777614,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.880777614,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.880777614,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.880777614,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.880777614,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.900428209,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.900428209,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.900428209,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.900428209,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.917559498,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.917559498,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.917559498,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.917559498,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.928140588,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.941240985,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.941240985,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.941240985,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.941240985,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.941240985,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.957364551,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.957364551,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.957364551,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.965930195,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.973488116,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.973488116,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.980542176,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.980542176,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.991782673,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.991782673,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
3.991782673,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
4.008333334,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
4.025,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
4.025,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
4.041666667,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
4.041666667,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
4.058333334,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
4.058333334,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
4.075,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
4.091666667,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
4.091666667,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
4.105773074,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
4.114065455,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
4.12666199,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
4.141273972,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
4.141273972,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
4.159916845,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
4.159916845,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
4.180071302,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
4.180071302,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
4.199218036,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
4.199218036,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
4.217860909,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
4.217860909,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
4.235999921,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
4.235999921,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
4.249100318,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
4.26421616,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
4.26421616,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
4.279065292,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
4.291666667,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
4.291666667,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
4.308333334,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
4.308333334,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
4.325,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
4.374645132,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
4.407816668,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
4.458333334,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
4.491666667,0,PROSPER,Placebo,"TLV report, IA2","PROSPER (TLV report, IA2) - Placebo",hormone-relapsed non-metastatic prostate cancer,PRO-Pla-TLV
0.09,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
0.09,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
0.12,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
0.12,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
0.12,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
0.15,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
0.15,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
0.18,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
0.21,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
0.21,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
0.21,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
0.21,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
0.24,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
0.24,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
0.27,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
0.27,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
0.33,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
0.33,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
0.33,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
0.36,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
0.36,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
0.39,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
0.39,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
0.39,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
0.42,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
0.42,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
0.42,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
0.42,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
0.42,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
0.42,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
0.42,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
0.42,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
0.42,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
0.42,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
0.45,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
0.48,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
0.48,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
0.48,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
0.51,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
0.51,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
0.57,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
0.6,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
0.6,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
0.6,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
0.6,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
0.63,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
0.63,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
0.63,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
0.66,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
0.66,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
0.69,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
0.69,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
0.72,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
0.72,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
0.72,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
0.75,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
0.75,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
0.75,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
0.75,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
0.78,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
0.78,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
0.78,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
0.78,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
0.81,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
0.81,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
0.81,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
0.81,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
0.84,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
0.84,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
0.84,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
0.84,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
0.87,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
0.87,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
0.9,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
0.9,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
0.9,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
0.9,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
0.9,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
0.9,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
0.9,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
0.93,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
0.93,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
0.93,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
0.93,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
0.96,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
0.96,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
0.96,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
0.99,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
0.99,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
0.99,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
1.02,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
1.02,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
1.05,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
1.05,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
1.05,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
1.08,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
1.08,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
1.08,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
1.11,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
1.11,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
1.11,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
1.11,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
1.11,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
1.14,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
1.14,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
1.14,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
1.17,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
1.17,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
1.17,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
1.17,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
1.2,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
1.2,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
1.2,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
1.2,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
1.23,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
1.23,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
1.23,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
1.23,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
1.23,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
1.23,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
1.26,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
1.26,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
1.26,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
1.26,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
1.29,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
1.29,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
1.29,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
1.29,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
1.32,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
1.32,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
1.32,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
1.35,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
1.35,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
1.35,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
1.38,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
1.38,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
1.38,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
1.41,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
1.41,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
1.41,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
1.44,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
1.44,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
1.44,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
1.44,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
1.44,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
1.47,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
1.47,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
1.47,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
1.47,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
1.5,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
1.5,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
1.53,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
1.53,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
1.53,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
1.56,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
1.56,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
1.56,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
1.56,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
1.56,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
1.59,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
1.59,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
1.59,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
1.59,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
1.59,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
1.62,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
1.62,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
1.62,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
1.62,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
1.62,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
1.62,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
1.65,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
1.65,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
1.65,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
1.65,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
1.68,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
1.68,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
1.68,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
1.74,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
1.74,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
1.74,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
1.77,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
1.77,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
1.77,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
1.8,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
1.8,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
1.8,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
1.8,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
1.8,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
1.83,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
1.83,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
1.83,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
1.86,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
1.86,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
1.86,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
1.86,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
1.89,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
1.89,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
1.89,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
1.89,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
1.89,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
1.92,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
1.92,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
1.92,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
1.92,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
1.95,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
1.95,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
1.95,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
1.98,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
1.98,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
1.98,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
1.98,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
2.01,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
2.01,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
2.01,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
2.01,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
2.04,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
2.04,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
2.04,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
2.07,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
2.07,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
2.1,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
2.1,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
2.1,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
2.13,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
2.13,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
2.16,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
2.16,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
2.16,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
2.16,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
2.19,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
2.19,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
2.22,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
2.25,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
2.31,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
2.34,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
2.34,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
2.37,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
2.4,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
2.4,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
2.4,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
2.4,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
2.43,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
2.43,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
2.43,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
2.43,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
2.43,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
2.46,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
2.46,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
2.49,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
2.49,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
2.52,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
2.55,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
2.55,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
2.58,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
2.61,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
2.61,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
2.64,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
2.7,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
2.7,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
2.73,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
2.76,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
2.76,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
2.76,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
2.79,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
2.85,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
2.88,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
2.91,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
2.91,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
2.97,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
3,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
3.03,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
3.06,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
3.09,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
3.24,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
3.24,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
3.27,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
3.27,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
3.3,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
3.3,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
3.33,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
3.36,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
3.42,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
3.45,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
3.45,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
3.48,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
3.48,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
3.6,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
3.63,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
3.69,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
3.72,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
3.75,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
3.75,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
3.75,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
3.78,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
3.84,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
3.96,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
3.99,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
3.99,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
4.02,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
4.11,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
4.2,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
4.2,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
4.23,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
4.56,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
4.59,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
4.59,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
4.62,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
4.62,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
4.65,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
4.74,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
4.74,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
4.89,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
4.92,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
4.98,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
5.01,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
5.04,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
5.1,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
5.1,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
5.61,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
5.61,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
5.61,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
5.61,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
5.61,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
5.61,1,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
6,0,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
6,0,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
6,0,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
6,0,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
6,0,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
6,0,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
6,0,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
6,0,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
6,0,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
6,0,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
6,0,TAX 327,Docetaxel every 3 wk,Berthold 2008,TAX 327 (Berthold 2008) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Ber
0.03,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
0.09,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
0.09,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
0.12,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
0.15,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
0.15,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
0.15,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
0.15,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
0.21,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
0.24,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
0.24,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
0.24,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
0.27,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
0.27,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
0.3,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
0.33,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
0.33,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
0.33,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
0.33,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
0.33,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
0.36,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
0.36,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
0.36,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
0.39,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
0.39,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
0.42,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
0.42,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
0.42,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
0.42,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
0.45,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
0.45,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
0.45,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
0.48,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
0.48,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
0.48,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
0.48,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
0.48,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
0.51,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
0.51,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
0.51,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
0.54,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
0.54,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
0.54,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
0.57,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
0.57,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
0.57,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
0.6,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
0.6,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
0.6,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
0.6,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
0.6,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
0.6,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
0.6,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
0.63,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
0.63,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
0.63,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
0.63,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
0.66,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
0.66,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
0.66,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
0.66,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
0.670225989,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
0.670225989,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
0.670225989,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
0.670225989,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
0.670225989,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
0.72,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
0.72,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
0.72,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
0.75,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
0.75,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
0.75,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
0.78,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
0.81,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
0.81,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
0.81,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
0.81,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
0.81,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
0.84,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
0.84,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
0.84,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
0.84,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
0.843691149,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
0.843691149,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
0.843691149,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
0.87,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
0.87,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
0.9,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
0.9,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
0.9,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
0.9,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
0.9,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
0.9,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
0.9,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
0.9,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
0.913521657,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
0.913521657,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
0.913521657,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
0.913521657,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
0.913521657,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
0.929378531,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
0.929378531,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
0.929378531,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
0.929378531,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
0.929378531,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
0.96,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
0.96,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
0.963634652,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
0.963634652,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
0.963634652,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
0.963634652,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
0.963634652,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
0.993634652,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
0.993634652,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
0.993634652,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
0.993634652,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
0.993634652,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
0.993634652,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
1.02693032,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
1.02693032,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
1.02693032,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
1.02693032,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
1.02693032,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
1.034839925,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
1.034839925,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
1.034839925,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
1.034839925,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
1.05693032,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
1.05693032,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
1.05693032,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
1.061205273,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
1.061205273,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
1.061205273,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
1.061205273,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
1.080979284,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
1.080979284,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
1.080979284,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
1.080979284,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
1.11,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
1.11,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
1.11,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
1.11,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
1.14,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
1.14,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
1.14,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
1.2,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
1.2,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
1.2,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
1.2,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
1.2,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
1.23,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
1.23,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
1.23,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
1.23,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
1.26,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
1.26,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
1.26,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
1.26,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
1.29,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
1.29,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
1.29,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
1.29,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
1.32,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
1.35,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
1.35,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
1.357815443,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
1.357815443,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
1.357815443,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
1.357815443,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
1.357815443,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
1.38,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
1.38,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
1.38,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
1.38,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
1.41,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
1.41,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
1.41,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
1.41,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
1.44,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
1.44,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
1.44,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
1.47,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
1.47,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
1.47,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
1.5,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
1.53,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
1.53,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
1.59,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
1.59,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
1.59,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
1.62,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
1.62,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
1.62,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
1.62,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
1.647834275,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
1.647834275,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
1.647834275,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
1.65,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
1.65,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
1.65,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
1.68,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
1.68,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
1.693973635,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
1.693973635,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
1.693973635,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
1.693973635,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
1.71,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
1.71,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
1.71,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
1.71,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
1.720338983,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
1.720338983,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
1.74,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
1.74,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
1.74,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
1.74,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
1.74,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
1.77,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
1.850112994,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
1.850112994,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
1.850112994,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
1.850112994,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
1.850112994,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
1.873521657,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
1.873521657,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
1.873521657,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
1.887043315,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
1.887043315,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
1.887043315,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
1.913747646,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
1.913747646,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
1.943747646,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
1.943747646,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
1.943747646,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
1.983634652,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
2.003747646,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
2.003747646,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
2.003747646,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
2.043634652,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
2.043634652,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
2.043634652,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
2.1,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
2.1,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
2.1,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
2.1,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
2.13,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
2.13,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
2.13,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
2.16,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
2.16,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
2.16,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
2.16,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
2.19,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
2.19,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
2.22,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
2.22,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
2.22,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
2.28,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
2.31,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
2.34,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
2.37,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
2.4,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
2.4,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
2.43,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
2.46,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
2.46,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
2.55,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
2.58,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
2.61,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
2.64,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
2.64,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
2.64,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
2.64,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
2.67,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
2.7,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
2.73,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
2.76,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
2.76,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
2.82,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
2.82,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
2.82,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
2.82,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
2.85,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
2.88,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
2.91,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
2.94,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
2.97,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
2.97,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
3,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
3,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
3.03,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
3.03,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
3.09,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
3.12,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
3.15,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
3.18,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
3.24,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
3.279887006,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
3.3,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
3.3,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
3.36,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
3.36,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
3.42,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
3.42,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
3.45,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
3.45,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
3.48,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
3.48,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
3.51,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
3.51,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
3.57,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
3.57,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
3.57,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
3.75,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
3.78,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
3.78,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
3.81,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
3.99,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
3.99,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
4.29,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
4.32,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
4.71,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
4.74,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
4.77,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
4.8,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
4.8,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
4.8,1,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
5.25,0,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
5.25,0,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
5.25,0,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
5.25,0,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
5.25,0,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
5.25,0,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
5.25,0,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
5.25,0,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
5.25,0,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
5.25,0,TAX 327,Mitoxantrone,Berthold 2008,TAX 327 (Berthold 2008) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Ber
0.12,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
0.12,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
0.15,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
0.18,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
0.18,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
0.18,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
0.18,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
0.21,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
0.21,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
0.27,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
0.27,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
0.27,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
0.3,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
0.33,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
0.33,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
0.33,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
0.33,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
0.33,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
0.33,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
0.33,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
0.33,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
0.39,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
0.39,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
0.42,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
0.42,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
0.42,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
0.45,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
0.45,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
0.45,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
0.45,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
0.48,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
0.48,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
0.48,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
0.48,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
0.51,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
0.51,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
0.54,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
0.54,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
0.54,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
0.54,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
0.54,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
0.54,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
0.54,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
0.57,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
0.6,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
0.6,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
0.6,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
0.6,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
0.6,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
0.6,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
0.63,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
0.63,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
0.63,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
0.63,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
0.63,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
0.63,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
0.66,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
0.66,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
0.69,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
0.69,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
0.69,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
0.69,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
0.69,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
0.69,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
0.75,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
0.75,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
0.75,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
0.75,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
0.75,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
0.75,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
0.75,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
0.75,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
0.81,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
0.81,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
0.81,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
0.81,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
0.81,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
0.81,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
0.81,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
0.87,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
0.87,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
0.87,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
0.87,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
0.87,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
0.87,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
0.87,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
0.9,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
0.9,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
0.93,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
0.93,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
0.93,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
0.93,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
0.93,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
0.96,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
0.96,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
0.96,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
0.96,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
0.96,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
0.99,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
0.99,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
0.99,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
1.02,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
1.02,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
1.02,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
1.02,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
1.02,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
1.02,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
1.02,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
1.05,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
1.05,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
1.05,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
1.08,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
1.08,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
1.08,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
1.08,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
1.08,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
1.08,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
1.11,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
1.11,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
1.11,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
1.14,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
1.17,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
1.17,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
1.17,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
1.2,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
1.2,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
1.2,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
1.2,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
1.23,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
1.23,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
1.23,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
1.23,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
1.23,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
1.26,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
1.26,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
1.26,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
1.26,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
1.29,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
1.29,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
1.29,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
1.29,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
1.29,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
1.32,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
1.32,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
1.32,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
1.32,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
1.35,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
1.35,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
1.35,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
1.35,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
1.38,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
1.38,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
1.38,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
1.41,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
1.41,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
1.41,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
1.44,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
1.44,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
1.44,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
1.47,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
1.47,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
1.47,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
1.47,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
1.47,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
1.5,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
1.5,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
1.5,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
1.53,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
1.53,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
1.53,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
1.53,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
1.53,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
1.53,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
1.56,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
1.56,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
1.56,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
1.56,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
1.56,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
1.56,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
1.59,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
1.59,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
1.59,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
1.59,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
1.62,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
1.62,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
1.62,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
1.62,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
1.62,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
1.62,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
1.65,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
1.68,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
1.68,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
1.71,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
1.74,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
1.74,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
1.77,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
1.77,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
1.77,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
1.77,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
1.8,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
1.8,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
1.8,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
1.8,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
1.83,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
1.83,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
1.83,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
1.86,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
1.86,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
1.86,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
1.89,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
1.89,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
1.89,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
1.89,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
1.89,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
1.92,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
1.92,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
1.92,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
1.95,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
1.95,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
1.95,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
1.98,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
1.98,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
1.98,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
2.01,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
2.01,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
2.01,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
2.04,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
2.04,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
2.07,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
2.07,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
2.13,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
2.13,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
2.16,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
2.16,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
2.16,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
2.19,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
2.19,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
2.22,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
2.25,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
2.28,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
2.28,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
2.28,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
2.28,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
2.31,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
2.31,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
2.31,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
2.34,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
2.37,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
2.37,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
2.4,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
2.4,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
2.43,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
2.43,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
2.46,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
2.46,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
2.49,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
2.49,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
2.52,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
2.52,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
2.55,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
2.55,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
2.55,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
2.55,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
2.58,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
2.58,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
2.58,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
2.64,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
2.67,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
2.7,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
2.73,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
2.76,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
2.79,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
2.79,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
2.88,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
3,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
3,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
3.03,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
3.03,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
3.06,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
3.12,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
3.18,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
3.18,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
3.18,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
3.21,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
3.21,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
3.24,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
3.24,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
3.27,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
3.27,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
3.3,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
3.3,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
3.3,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
3.3,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
3.33,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
3.51,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
3.57,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
3.6,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
3.6,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
3.63,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
3.66,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
3.66,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
3.69,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
3.78,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
3.78,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
3.9,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
3.9,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
4.02,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
4.32,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
4.32,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
4.38,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
4.41,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
4.41,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
4.68,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
4.68,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
4.71,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
4.71,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
5.13,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
5.16,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
5.16,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
5.48,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
5.48,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
5.48,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
5.48,1,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
6.45,0,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
6.45,0,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
6.45,0,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
6.45,0,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
6.45,0,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
6.45,0,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
6.45,0,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
6.45,0,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
6.45,0,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
6.45,0,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
6.45,0,TAX 327,Weekly docetaxel,Berthold 2008,TAX 327 (Berthold 2008) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Ber
0.033333333,1,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
0.091666667,1,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
0.125,1,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
0.141666667,1,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
0.15,1,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
0.166666667,1,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
0.191666667,1,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
0.2,1,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
0.241666667,1,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
0.241666667,1,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
0.241666667,1,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
0.25,1,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
0.258333333,1,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
0.308333333,1,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
0.308333333,1,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
0.325,1,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
0.325,1,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
0.333333333,1,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
0.341666667,1,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
0.35,1,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
0.358333333,1,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
0.366666667,1,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
0.375,1,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
0.383333333,1,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
0.391666667,1,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
0.4,1,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
0.408333333,1,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
0.416666667,1,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
0.425,1,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
0.433333333,1,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
0.441666667,1,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
0.441666667,1,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
0.45,1,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
0.458333333,1,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
0.466666667,1,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
0.475,1,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
0.5,1,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
0.508333333,1,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
0.516666667,1,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
0.533333333,1,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
0.541666667,1,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
0.55,1,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
0.558333333,1,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
0.566666667,1,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
0.6,1,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
0.608333333,1,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
0.616666667,1,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
0.616666667,1,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
0.633333333,1,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
0.675,1,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
0.683333333,1,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
0.7,1,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
0.708333333,1,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
0.725,1,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
0.733333333,1,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
0.733333333,1,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
0.75,1,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
0.758333333,1,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
0.766666667,1,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
0.766666667,1,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
0.775,1,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
0.783333333,1,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
0.783333333,1,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
0.808333333,1,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
0.825,1,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
0.833333333,1,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
0.833333333,1,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
0.841666667,1,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
0.866666667,1,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
0.875,1,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
0.875,1,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
0.883333333,1,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
0.891666667,1,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
0.891666667,1,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
0.9,1,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
0.908333333,1,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
0.916666667,1,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
0.916666667,1,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
0.916666667,1,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
0.925,1,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
0.933333333,1,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
0.933333333,1,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
0.941666667,1,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
0.958333333,1,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
0.966666667,1,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
1,1,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
1.008333333,1,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
1.016666667,1,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
1.058333333,1,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
1.066666667,1,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
1.075,1,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
1.083333333,1,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
1.091666667,1,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
1.091666667,1,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
1.1,1,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
1.116666667,1,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
1.158333333,1,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
1.166666667,1,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
1.166666667,1,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
1.175,1,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
1.191666667,1,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
1.2,1,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
1.2,1,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
1.208333333,1,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
1.208333333,1,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
1.208333333,1,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
1.208333333,1,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
1.216666667,1,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
1.233333333,1,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
1.241666667,1,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
1.25,1,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
1.25,1,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
1.258333333,1,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
1.283333333,1,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
1.291666667,1,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
1.291666667,1,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
1.3,1,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
1.308333333,1,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
1.316666667,1,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
1.325,1,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
1.333333333,1,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
1.333333333,1,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
1.366666667,1,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
1.383333333,1,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
1.391666667,1,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
1.4,1,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
1.4,1,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
1.416666667,1,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
1.416666667,1,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
1.425,1,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
1.433333333,1,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
1.441666667,1,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
1.458333333,1,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
1.458333333,1,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
1.466666667,1,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
1.525,1,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
1.533333333,1,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
1.566666667,1,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
1.575,1,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
1.583333333,1,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
1.591666667,1,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
1.608333333,1,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
1.625,1,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
1.633333333,1,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
1.641666667,1,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
1.65,1,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
1.658333333,1,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
1.683333333,1,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
1.733333333,1,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
1.75,1,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
1.766666667,1,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
1.791666667,1,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
1.816666667,1,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
1.841666667,1,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
1.866666667,1,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
1.895407677,1,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
1.895407677,1,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
1.95,1,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
1.983333333,1,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
2.008333333,1,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
2.033333333,1,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
2.066666667,1,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
0.120833334,0,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
0.245833334,0,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
0.370833334,0,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
0.5125,0,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
0.529166667,0,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
0.545833334,0,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
0.5625,0,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
0.579166667,0,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
0.595833334,0,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
0.6125,0,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
0.629166667,0,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
0.645833334,0,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
0.6625,0,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
0.679166667,0,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
0.695833334,0,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
0.7125,0,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
0.729166667,0,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
0.745833334,0,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
0.754166667,0,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
0.770833334,0,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
0.7875,0,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
0.804166667,0,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
0.820833334,0,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
0.8375,0,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
0.854166667,0,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
0.870833334,0,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
0.8875,0,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
0.904166667,0,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
0.920833334,0,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
0.9375,0,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
0.954166667,0,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
0.970833334,0,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
0.9875,0,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
1.004166667,0,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
1.0125,0,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
1.020833334,0,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
1.029166667,0,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
1.0375,0,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
1.045833334,0,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
1.054166667,0,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
1.0625,0,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
1.070833334,0,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
1.079166667,0,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
1.0875,0,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
1.095833334,0,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
1.104166667,0,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
1.1125,0,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
1.120833334,0,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
1.120833334,0,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
1.129166667,0,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
1.1375,0,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
1.145833334,0,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
1.154166667,0,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
1.1625,0,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
1.170833334,0,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
1.179166667,0,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
1.1875,0,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
1.195833334,0,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
1.204166667,0,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
1.2125,0,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
1.220833334,0,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
1.229166667,0,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
1.2375,0,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
1.245833334,0,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
1.245833334,0,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
1.254166667,0,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
1.2625,0,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
1.270833334,0,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
1.279166667,0,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
1.2875,0,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
1.295833334,0,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
1.304166667,0,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
1.3125,0,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
1.320833334,0,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
1.329166667,0,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
1.3375,0,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
1.345833334,0,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
1.354166667,0,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
1.3625,0,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
1.370833334,0,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
1.370833334,0,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
1.379166667,0,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
1.3875,0,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
1.395833334,0,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
1.404166667,0,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
1.4125,0,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
1.420833334,0,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
1.429166667,0,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
1.4375,0,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
1.445833334,0,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
1.454166667,0,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
1.4625,0,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
1.470833334,0,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
1.479166667,0,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
1.4875,0,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
1.495833334,0,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
1.5125,0,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
1.520833334,0,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
1.5375,0,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
1.545833334,0,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
1.554166667,0,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
1.570833334,0,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
1.579166667,0,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
1.5875,0,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
1.604166667,0,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
1.6125,0,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
1.620833334,0,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
1.6375,0,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
1.645833334,0,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
1.6625,0,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
1.670833334,0,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
1.679166667,0,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
1.695833334,0,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
1.704166667,0,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
1.7125,0,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
1.729166667,0,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
1.7375,0,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
1.745833334,0,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
1.7625,0,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
1.770833334,0,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
1.7875,0,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
1.795833334,0,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
1.804166667,0,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
1.820833334,0,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
1.829166667,0,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
1.8375,0,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
1.854166667,0,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
1.8625,0,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
1.870833334,0,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
1.88854371,0,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
1.901870505,0,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
1.9125,0,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
1.920833334,0,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
1.929166667,0,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
1.945833334,0,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
1.954166667,0,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
1.9625,0,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
1.979166667,0,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
1.9875,0,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
2.0125,0,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
2.029166667,0,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
2.045833334,0,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
2.0625,0,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
2.079166667,0,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
2.095833334,0,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
2.1125,0,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
2.129166667,0,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
2.145833334,0,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
2.1625,0,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
2.179166667,0,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
2.195833334,0,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
2.2125,0,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
2.229166667,0,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
2.245833334,0,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
2.2625,0,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
2.279166667,0,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
2.295833334,0,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
2.3125,0,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
2.329166667,0,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
2.345833334,0,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
2.3625,0,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
2.379166667,0,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
2.395833334,0,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
2.4125,0,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
2.429166667,0,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
2.445833334,0,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
2.4625,0,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
2.479166667,0,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
2.5375,0,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
2.579166667,0,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
2.620833334,0,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
2.704166667,0,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
2.704166667,0,TAX 327,Docetaxel every 3 wk,Tannock 2004,TAX 327 (Tannock 2004) - Docetaxel every 3 wk,hormone-refractory metastatic prostate cancer,TAX-Doc-Tan
0.025,1,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
0.091666667,1,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
0.1,1,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
0.1,1,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
0.1,1,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
0.108333333,1,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
0.116666667,1,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
0.141666667,1,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
0.175,1,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
0.2,1,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
0.216666667,1,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
0.241666667,1,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
0.241666667,1,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
0.283333333,1,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
0.291666667,1,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
0.308333333,1,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
0.308333333,1,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
0.308333333,1,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
0.316666667,1,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
0.341666667,1,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
0.341666667,1,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
0.358333333,1,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
0.366666667,1,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
0.366666667,1,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
0.375,1,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
0.375,1,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
0.383333333,1,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
0.4,1,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
0.408333333,1,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
0.416666667,1,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
0.425,1,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
0.433333333,1,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
0.441666667,1,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
0.441666667,1,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
0.45,1,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
0.458333333,1,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
0.475,1,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
0.491666667,1,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
0.491666667,1,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
0.508333333,1,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
0.516666667,1,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
0.533333333,1,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
0.541666667,1,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
0.55,1,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
0.55,1,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
0.55,1,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
0.566666667,1,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
0.591666667,1,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
0.591666667,1,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
0.6,1,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
0.608333333,1,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
0.608333333,1,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
0.608333333,1,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
0.616666667,1,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
0.616666667,1,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
0.633333333,1,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
0.633333333,1,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
0.633333333,1,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
0.641666667,1,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
0.641666667,1,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
0.641666667,1,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
0.658333333,1,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
0.658333333,1,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
0.666666667,1,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
0.683333333,1,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
0.683333333,1,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
0.691666667,1,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
0.7,1,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
0.733333333,1,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
0.741666667,1,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
0.741666667,1,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
0.75,1,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
0.758333333,1,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
0.766666667,1,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
0.766666667,1,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
0.783333333,1,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
0.791666667,1,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
0.8,1,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
0.8,1,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
0.808333333,1,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
0.825,1,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
0.833333333,1,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
0.841666667,1,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
0.85,1,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
0.858333333,1,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
0.866666667,1,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
0.875,1,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
0.883333333,1,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
0.883333333,1,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
0.891666667,1,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
0.891666667,1,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
0.891666667,1,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
0.9,1,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
0.9,1,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
0.9,1,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
0.908333333,1,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
0.916666667,1,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
0.925,1,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
0.933333333,1,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
0.941666667,1,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
0.941666667,1,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
0.95,1,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
0.95,1,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
0.966666667,1,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
0.966666667,1,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
0.966666667,1,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
0.975,1,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
0.975,1,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
0.983333333,1,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
0.991666667,1,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
0.991666667,1,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
1,1,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
1.008333333,1,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
1.016666667,1,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
1.016666667,1,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
1.033333333,1,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
1.033333333,1,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
1.041666667,1,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
1.041666667,1,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
1.05,1,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
1.05,1,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
1.066666667,1,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
1.066666667,1,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
1.083333333,1,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
1.083333333,1,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
1.091666667,1,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
1.091666667,1,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
1.1,1,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
1.116666667,1,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
1.125,1,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
1.141666667,1,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
1.141666667,1,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
1.15,1,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
1.158333333,1,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
1.175,1,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
1.183333333,1,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
1.191666667,1,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
1.191666667,1,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
1.2,1,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
1.208333333,1,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
1.225,1,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
1.241666667,1,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
1.25,1,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
1.25,1,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
1.258333333,1,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
1.266666667,1,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
1.275,1,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
1.291666667,1,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
1.308333333,1,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
1.358333333,1,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
1.366666667,1,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
1.366666667,1,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
1.375,1,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
1.391666667,1,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
1.4,1,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
1.408333333,1,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
1.408333333,1,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
1.416666667,1,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
1.416666667,1,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
1.425,1,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
1.433333333,1,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
1.466666667,1,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
1.5,1,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
1.533333333,1,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
1.541666667,1,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
1.558333333,1,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
1.566666667,1,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
1.583333333,1,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
1.591666667,1,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
1.6,1,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
1.625,1,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
1.65,1,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
1.658333333,1,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
1.675,1,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
1.691666667,1,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
1.708333333,1,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
1.708333333,1,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
1.725,1,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
1.725,1,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
1.741666667,1,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
1.75,1,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
1.758333333,1,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
1.775,1,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
1.833333333,1,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
1.841666667,1,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
1.866666667,1,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
1.891666667,1,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
1.908333333,1,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
1.933333333,1,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
1.975,1,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
1.991666667,1,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
2.075,1,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
2.1,1,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
2.166666667,1,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
2.175,1,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
2.3,1,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
2.316666667,1,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
0.254166667,0,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
0.520833334,0,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
0.5375,0,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
0.554166667,0,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
0.570833334,0,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
0.5875,0,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
0.595833334,0,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
0.6125,0,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
0.629166667,0,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
0.645833334,0,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
0.6625,0,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
0.670833334,0,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
0.6875,0,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
0.704166667,0,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
0.720833334,0,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
0.7375,0,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
0.754166667,0,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
0.7625,0,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
0.779166667,0,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
0.795833334,0,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
0.8125,0,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
0.829166667,0,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
0.8375,0,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
0.854166667,0,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
0.870833334,0,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
0.8875,0,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
0.904166667,0,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
0.920833334,0,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
0.929166667,0,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
0.945833334,0,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
0.9625,0,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
0.979166667,0,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
0.995833334,0,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
1.020833334,0,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
1.029166667,0,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
1.0375,0,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
1.054166667,0,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
1.0625,0,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
1.070833334,0,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
1.079166667,0,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
1.095833334,0,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
1.104166667,0,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
1.1125,0,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
1.129166667,0,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
1.1375,0,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
1.145833334,0,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
1.154166667,0,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
1.170833334,0,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
1.179166667,0,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
1.1875,0,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
1.195833334,0,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
1.2125,0,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
1.220833334,0,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
1.229166667,0,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
1.245833334,0,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
1.254166667,0,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
1.2625,0,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
1.270833334,0,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
1.2875,0,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
1.295833334,0,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
1.304166667,0,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
1.320833334,0,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
1.329166667,0,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
1.3375,0,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
1.345833334,0,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
1.3625,0,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
1.370833334,0,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
1.379166667,0,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
1.3875,0,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
1.404166667,0,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
1.4125,0,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
1.420833334,0,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
1.4375,0,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
1.445833334,0,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
1.454166667,0,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
1.4625,0,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
1.479166667,0,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
1.4875,0,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
1.495833334,0,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
1.520833334,0,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
1.5375,0,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
1.545833334,0,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
1.5625,0,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
1.570833334,0,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
1.5875,0,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
1.595833334,0,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
1.6125,0,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
1.620833334,0,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
1.6375,0,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
1.645833334,0,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
1.6625,0,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
1.670833334,0,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
1.6875,0,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
1.695833334,0,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
1.7125,0,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
1.720833334,0,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
1.7375,0,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
1.745833334,0,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
1.7625,0,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
1.770833334,0,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
1.7875,0,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
1.795833334,0,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
1.8125,0,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
1.820833334,0,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
1.8375,0,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
1.845833334,0,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
1.8625,0,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
1.870833334,0,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
1.8875,0,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
1.895833334,0,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
1.9125,0,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
1.920833334,0,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
1.9375,0,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
1.945833334,0,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
1.9625,0,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
1.970833334,0,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
1.9875,0,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
2.020833334,0,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
2.045833334,0,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
2.070833334,0,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
2.095833334,0,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
2.120833334,0,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
2.145833334,0,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
2.1625,0,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
2.1875,0,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
2.2125,0,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
2.2375,0,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
2.2625,0,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
2.2875,0,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
2.3125,0,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
2.329166667,0,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
2.354166667,0,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
2.379166667,0,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
2.404166667,0,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
2.429166667,0,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
2.454166667,0,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
2.479166667,0,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
2.545833334,0,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
2.595833334,0,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
2.645833334,0,TAX 327,Mitoxantrone,Tannock 2004,TAX 327 (Tannock 2004) - Mitoxantrone,hormone-refractory metastatic prostate cancer,TAX-Mit-Tan
0.025,1,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
0.066666667,1,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
0.1,1,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
0.108333333,1,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
0.125,1,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
0.166666667,1,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
0.166666667,1,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
0.2,1,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
0.2,1,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
0.216666667,1,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
0.241666667,1,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
0.25,1,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
0.258333333,1,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
0.308333333,1,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
0.308333333,1,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
0.316666667,1,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
0.325,1,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
0.333333333,1,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
0.341666667,1,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
0.391666667,1,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
0.4,1,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
0.408333333,1,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
0.416666667,1,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
0.425,1,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
0.45,1,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
0.45,1,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
0.45,1,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
0.45,1,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
0.458333333,1,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
0.458333333,1,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
0.458333333,1,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
0.458333333,1,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
0.458333333,1,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
0.458333333,1,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
0.466666667,1,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
0.475,1,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
0.491666667,1,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
0.508333333,1,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
0.508333333,1,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
0.525,1,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
0.533333333,1,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
0.55,1,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
0.55,1,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
0.55,1,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
0.558333333,1,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
0.583333333,1,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
0.6,1,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
0.6,1,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
0.6,1,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
0.6,1,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
0.608333333,1,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
0.608333333,1,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
0.616666667,1,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
0.633333333,1,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
0.65,1,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
0.65,1,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
0.65,1,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
0.65,1,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
0.658333333,1,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
0.658333333,1,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
0.658333333,1,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
0.666666667,1,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
0.691666667,1,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
0.7,1,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
0.708333333,1,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
0.708333333,1,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
0.741666667,1,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
0.741666667,1,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
0.75,1,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
0.75,1,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
0.758333333,1,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
0.766666667,1,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
0.766666667,1,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
0.791666667,1,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
0.808333333,1,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
0.825,1,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
0.833333333,1,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
0.833333333,1,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
0.841666667,1,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
0.841666667,1,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
0.858333333,1,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
0.858333333,1,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
0.875,1,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
0.883333333,1,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
0.9,1,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
0.9,1,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
0.908333333,1,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
0.916666667,1,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
0.925,1,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
0.933333333,1,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
0.941666667,1,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
0.941666667,1,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
0.95,1,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
0.95,1,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
0.958333333,1,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
0.966666667,1,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
0.975,1,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
0.983333333,1,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
0.991666667,1,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
1,1,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
1.008333333,1,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
1.008333333,1,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
1.008333333,1,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
1.025,1,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
1.025,1,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
1.05,1,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
1.05,1,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
1.066666667,1,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
1.066666667,1,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
1.075,1,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
1.083333333,1,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
1.091666667,1,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
1.091666667,1,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
1.1,1,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
1.116666667,1,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
1.141666667,1,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
1.166666667,1,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
1.191666667,1,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
1.191666667,1,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
1.191666667,1,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
1.191666667,1,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
1.208333333,1,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
1.216666667,1,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
1.233333333,1,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
1.233333333,1,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
1.233333333,1,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
1.233333333,1,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
1.25,1,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
1.25,1,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
1.258333333,1,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
1.266666667,1,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
1.266666667,1,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
1.291666667,1,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
1.308333333,1,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
1.316666667,1,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
1.333333333,1,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
1.333333333,1,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
1.333333333,1,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
1.35,1,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
1.358333333,1,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
1.375,1,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
1.383333333,1,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
1.383333333,1,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
1.4,1,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
1.416666667,1,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
1.433333333,1,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
1.441666667,1,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
1.45,1,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
1.45,1,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
1.475,1,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
1.508333333,1,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
1.516666667,1,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
1.516666667,1,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
1.533333333,1,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
1.533333333,1,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
1.541666667,1,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
1.558333333,1,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
1.558333333,1,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
1.566666667,1,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
1.575,1,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
1.591666667,1,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
1.6,1,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
1.616666667,1,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
1.633333333,1,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
1.641666667,1,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
1.658333333,1,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
1.666666667,1,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
1.708333333,1,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
1.716666667,1,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
1.733333333,1,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
1.75,1,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
1.758333333,1,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
1.808333333,1,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
1.808333333,1,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
1.833333333,1,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
1.85,1,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
1.858333333,1,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
1.883333333,1,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
1.908333333,1,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
1.941666667,1,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
1.95,1,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
2.008333333,1,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
2.191666667,1,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
2.191666667,1,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
2.258333333,1,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
2.291666667,1,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
2.3,1,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
2.408333333,1,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
2.416666667,1,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
2.681927657,1,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
2.681927657,1,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
0.520833334,0,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
0.5375,0,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
0.554166667,0,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
0.5625,0,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
0.579166667,0,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
0.595833334,0,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
0.604166667,0,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
0.620833334,0,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
0.6375,0,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
0.654166667,0,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
0.6625,0,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
0.679166667,0,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
0.695833334,0,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
0.704166667,0,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
0.720833334,0,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
0.7375,0,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
0.754166667,0,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
0.7625,0,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
0.779166667,0,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
0.795833334,0,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
0.804166667,0,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
0.820833334,0,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
0.8375,0,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
0.854166667,0,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
0.8625,0,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
0.879166667,0,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
0.895833334,0,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
0.904166667,0,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
0.920833334,0,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
0.9375,0,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
0.954166667,0,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
0.9625,0,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
0.979166667,0,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
0.995833334,0,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
1.020833334,0,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
1.029166667,0,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
1.0375,0,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
1.054166667,0,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
1.0625,0,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
1.070833334,0,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
1.0875,0,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
1.095833334,0,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
1.104166667,0,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
1.120833334,0,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
1.129166667,0,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
1.1375,0,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
1.145833334,0,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
1.1625,0,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
1.170833334,0,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
1.179166667,0,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
1.195833334,0,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
1.204166667,0,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
1.2125,0,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
1.229166667,0,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
1.2375,0,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
1.245833334,0,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
1.254166667,0,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
1.270833334,0,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
1.279166667,0,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
1.2875,0,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
1.304166667,0,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
1.3125,0,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
1.320833334,0,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
1.3375,0,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
1.345833334,0,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
1.354166667,0,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
1.370833334,0,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
1.379166667,0,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
1.3875,0,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
1.395833334,0,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
1.4125,0,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
1.420833334,0,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
1.429166667,0,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
1.445833334,0,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
1.454166667,0,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
1.4625,0,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
1.479166667,0,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
1.4875,0,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
1.495833334,0,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
1.520833334,0,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
1.529166667,0,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
1.5375,0,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
1.554166667,0,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
1.5625,0,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
1.570833334,0,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
1.579166667,0,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
1.595833334,0,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
1.604166667,0,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
1.6125,0,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
1.629166667,0,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
1.6375,0,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
1.645833334,0,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
1.654166667,0,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
1.670833334,0,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
1.679166667,0,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
1.6875,0,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
1.704166667,0,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
1.7125,0,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
1.720833334,0,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
1.729166667,0,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
1.745833334,0,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
1.754166667,0,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
1.7625,0,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
1.779166667,0,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
1.7875,0,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
1.795833334,0,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
1.804166667,0,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
1.820833334,0,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
1.829166667,0,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
1.8375,0,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
1.854166667,0,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
1.8625,0,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
1.870833334,0,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
1.879166667,0,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
1.895833334,0,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
1.904166667,0,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
1.9125,0,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
1.929166667,0,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
1.9375,0,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
1.945833334,0,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
1.954166667,0,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
1.970833334,0,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
1.979166667,0,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
1.9875,0,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
2.0375,0,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
2.079166667,0,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
2.1125,0,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
2.154166667,0,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
2.1875,0,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
2.229166667,0,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
2.2625,0,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
2.304166667,0,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
2.3375,0,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
2.379166667,0,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
2.549297162,0,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
2.549297162,0,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
2.549297162,0,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
2.549297162,0,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
2.549297162,0,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
2.549297162,0,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
2.549297162,0,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
2.714908884,0,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
2.714908884,0,TAX 327,Weekly docetaxel,Tannock 2004,TAX 327 (Tannock 2004) - Weekly docetaxel,hormone-refractory metastatic prostate cancer,TAX-Wee-Tan
0.040019759,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
0.102084744,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
0.102084744,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
0.102084744,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
0.172346992,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
0.188155997,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
0.195182222,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
0.202793966,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
0.202793966,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
0.207478115,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
0.212162265,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
0.212162265,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
0.212162265,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
0.242609239,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
0.242609239,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
0.2789114,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
0.2789114,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
0.2789114,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
0.2789114,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
0.2789114,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
0.283333333,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
0.333333333,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
0.336877755,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
0.336877755,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
0.336877755,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
0.336877755,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
0.341666667,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
0.362640579,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
0.366666667,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
0.379035103,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
0.379035103,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
0.379035103,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
0.379035103,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
0.405383446,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
0.408333333,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
0.431731789,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
0.433333333,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
0.433333333,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
0.443130463,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
0.443130463,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
0.455738057,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
0.455738057,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
0.458333333,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
0.466666667,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
0.475,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
0.491666667,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
0.493211255,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
0.493211255,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
0.5,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
0.5,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
0.50492163,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
0.508333333,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
0.525,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
0.530098935,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
0.533333333,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
0.534783085,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
0.534783085,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
0.541666667,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
0.55,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
0.558333333,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
0.583333333,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
0.591666667,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
0.591666667,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
0.616666667,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
0.616666667,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
0.616666667,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
0.625,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
0.625,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
0.625,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
0.65,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
0.658333333,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
0.658333333,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
0.675,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
0.675,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
0.683333333,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
0.683333333,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
0.683333333,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
0.691666667,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
0.691666667,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
0.691666667,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
0.7,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
0.7,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
0.7,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
0.716666667,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
0.725,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
0.733333333,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
0.741666667,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
0.75,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
0.775,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
0.791666667,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
0.791666667,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
0.791666667,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
0.8,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
0.8,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
0.8,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
0.8,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
0.808333333,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
0.808333333,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
0.808333333,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
0.808333333,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
0.825,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
0.833333333,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
0.85,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
0.85,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
0.858333333,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
0.858333333,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
0.875,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
0.875,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
0.883333333,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
0.891666667,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
0.891666667,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
0.9,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
0.9,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
0.9,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
0.95,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
0.95,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
0.95,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
0.95,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
0.958333333,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
0.958333333,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
0.958333333,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
0.966666667,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
0.966666667,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
0.966666667,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
1,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
1,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
1,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
1,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
1.008333333,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
1.008333333,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
1.008333333,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
1.008333333,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
1.016666667,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
1.033333333,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
1.033333333,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
1.033333333,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
1.033333333,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
1.05,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
1.05,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
1.058333333,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
1.066666667,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
1.066666667,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
1.066666667,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
1.075,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
1.083333333,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
1.1,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
1.108333333,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
1.116666667,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
1.116666667,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
1.116666667,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
1.125,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
1.125,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
1.125,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
1.133333333,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
1.141666667,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
1.141666667,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
1.15,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
1.15,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
1.158333333,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
1.158333333,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
1.158333333,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
1.166666667,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
1.175,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
1.183333333,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
1.183333333,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
1.191666667,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
1.191666667,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
1.191666667,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
1.2,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
1.2,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
1.208333333,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
1.208333333,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
1.208333333,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
1.208333333,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
1.216666667,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
1.216666667,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
1.233333333,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
1.233333333,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
1.241666667,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
1.241666667,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
1.25,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
1.266666667,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
1.266666667,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
1.266666667,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
1.275,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
1.283333333,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
1.283333333,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
1.3,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
1.308333333,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
1.308333333,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
1.308333333,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
1.316666667,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
1.325,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
1.333333333,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
1.341666667,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
1.341666667,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
1.358333333,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
1.360950013,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
1.379686612,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
1.379686612,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
1.379686612,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
1.379686612,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
1.379686612,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
1.380272131,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
1.380272131,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
1.408962548,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
1.408962548,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
1.414817736,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
1.430626741,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
1.430626741,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
1.430626741,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
1.433333333,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
1.458333333,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
1.475,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
1.491666667,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
1.491666667,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
1.5,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
1.5,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
1.521382145,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
1.521382145,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
1.525,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
1.525,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
1.533333333,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
1.556513268,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
1.558333333,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
1.558333333,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
1.558333333,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
1.591666667,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
1.625,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
1.65,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
1.65,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
1.658333333,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
1.683333333,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
1.683333333,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
1.683333333,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
1.716666667,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
1.716666667,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
1.716666667,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
1.716666667,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
1.741666667,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
1.75,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
1.75,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
1.775,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
1.808333333,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
1.841666667,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
1.866666667,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
1.9,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
1.908333333,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
1.908333333,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
1.941666667,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
1.941666667,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
1.95,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
1.991666667,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
1.991666667,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
2.010290284,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
2.066666667,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
2.083333333,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
2.1,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
2.108333333,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
2.266666667,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
2.358333333,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
2.391666667,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
2.408333333,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
2.433333333,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
2.469336968,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
2.469336968,1,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
0.063733268,0,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
0.126091013,0,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
0.189034276,0,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
0.249049945,0,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
0.3125,0,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
0.377017552,0,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
0.441529757,0,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
0.670833334,0,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
0.8375,0,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
1.0375,0,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
1.070833334,0,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
1.104166667,0,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
1.1375,0,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
1.170833334,0,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
1.204166667,0,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
1.2375,0,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
1.270833334,0,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
1.304166667,0,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
1.3375,0,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
1.376759018,0,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
1.405742196,0,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
1.4375,0,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
1.470833334,0,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
1.519024406,0,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
1.529166667,0,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
1.545833334,0,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
1.553256634,0,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
1.570833334,0,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
1.579166667,0,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
1.5875,0,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
1.604166667,0,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
1.6125,0,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
1.629166667,0,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
1.6375,0,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
1.645833334,0,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
1.6625,0,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
1.670833334,0,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
1.6875,0,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
1.695833334,0,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
1.704166667,0,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
1.720833334,0,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
1.729166667,0,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
1.745833334,0,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
1.754166667,0,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
1.7625,0,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
1.779166667,0,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
1.7875,0,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
1.804166667,0,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
1.8125,0,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
1.829166667,0,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
1.8375,0,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
1.845833334,0,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
1.8625,0,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
1.870833334,0,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
1.8875,0,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
1.895833334,0,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
1.904166667,0,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
1.920833334,0,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
1.929166667,0,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
1.945833334,0,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
1.954166667,0,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
1.9625,0,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
1.979166667,0,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
1.987443509,0,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
2.017645142,0,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
2.0375,0,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
2.054166667,0,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
2.070833334,0,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
2.0875,0,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
2.104166667,0,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
2.120833334,0,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
2.1375,0,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
2.154166667,0,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
2.170833334,0,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
2.1875,0,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
2.204166667,0,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
2.220833334,0,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
2.2375,0,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
2.254166667,0,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
2.270833334,0,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
2.2875,0,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
2.304166667,0,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
2.320833334,0,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
2.3375,0,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
2.354166667,0,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
2.370833334,0,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
2.3875,0,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
2.404166667,0,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
2.420833334,0,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
2.4375,0,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
2.453520537,0,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
2.464652818,0,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
2.482803899,0,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
2.5,0,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
2.5,0,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
2.5,0,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
2.5,0,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
2.5,0,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
2.5,0,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
2.5,0,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
2.5,0,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
2.5,0,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
2.5,0,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
2.5,0,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
2.5,0,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
2.5,0,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
2.5,0,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
2.5,0,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
2.5,0,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
2.5,0,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
2.5,0,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
2.5,0,TROPIC,Cabazitaxel,Bahl 2012,TROPIC (Bahl 2012) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-Bah
0.031705393,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
0.031705393,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
0.031705393,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
0.058333333,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
0.1,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
0.103372885,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
0.103372885,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
0.108333333,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
0.116666667,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
0.133333333,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
0.133333333,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
0.175,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
0.183333333,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
0.225,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
0.242492136,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
0.242492136,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
0.274110147,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
0.274110147,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
0.274110147,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
0.274110147,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
0.274110147,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
0.3,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
0.3,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
0.3,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
0.3,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
0.308333333,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
0.325,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
0.325,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
0.325,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
0.341666667,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
0.341666667,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
0.341666667,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
0.341666667,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
0.366666667,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
0.366666667,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
0.366666667,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
0.383333333,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
0.383333333,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
0.383333333,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
0.383333333,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
0.4,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
0.4,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
0.4,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
0.4,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
0.408333333,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
0.416666667,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
0.416666667,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
0.433333333,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
0.441666667,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
0.441666667,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
0.441666667,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
0.458333333,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
0.458333333,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
0.458333333,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
0.458333333,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
0.466666667,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
0.466666667,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
0.466666667,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
0.466666667,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
0.491666667,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
0.491666667,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
0.508333333,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
0.508333333,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
0.508333333,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
0.508333333,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
0.516666667,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
0.525,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
0.525,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
0.525,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
0.527054238,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
0.527054238,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
0.527054238,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
0.527054238,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
0.527054238,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
0.533333333,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
0.55,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
0.566666667,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
0.566666667,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
0.575,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
0.575,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
0.575,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
0.583333333,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
0.583333333,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
0.583333333,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
0.602937465,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
0.602937465,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
0.608333333,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
0.608333333,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
0.608333333,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
0.625421385,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
0.625421385,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
0.625421385,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
0.625421385,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
0.625421385,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
0.633333333,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
0.641666667,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
0.65,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
0.65,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
0.658333333,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
0.658333333,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
0.666666667,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
0.666666667,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
0.675,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
0.683333333,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
0.7,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
0.7,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
0.7,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
0.7,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
0.725,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
0.725,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
0.725,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
0.741666667,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
0.741666667,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
0.75,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
0.75,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
0.758333333,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
0.766666667,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
0.766666667,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
0.766666667,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
0.775,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
0.783333333,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
0.791666667,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
0.796861269,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
0.796861269,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
0.796861269,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
0.796861269,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
0.796861269,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
0.796861269,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
0.796861269,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
0.796861269,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
0.796861269,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
0.798266514,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
0.798266514,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
0.798266514,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
0.798266514,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
0.808333333,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
0.808333333,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
0.825,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
0.825,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
0.85,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
0.858333333,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
0.866666667,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
0.866666667,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
0.866666667,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
0.866666667,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
0.875,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
0.875,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
0.883333333,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
0.883333333,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
0.883333333,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
0.891666667,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
0.891666667,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
0.933333333,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
0.941666667,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
0.941666667,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
0.941666667,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
0.966666667,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
0.966666667,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
0.975,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
0.983333333,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
0.983333333,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
0.983333333,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
1,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
1,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
1.008333333,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
1.025,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
1.025,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
1.033333333,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
1.033333333,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
1.033333333,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
1.033333333,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
1.05,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
1.05,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
1.05,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
1.05,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
1.05,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
1.083333333,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
1.083333333,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
1.083333333,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
1.091666667,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
1.091666667,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
1.091666667,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
1.1,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
1.1,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
1.1,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
1.108333333,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
1.108333333,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
1.108333333,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
1.133333333,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
1.141666667,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
1.141666667,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
1.141666667,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
1.141666667,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
1.141666667,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
1.15,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
1.15,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
1.158333333,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
1.158333333,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
1.166666667,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
1.175,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
1.183333333,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
1.191666667,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
1.2,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
1.208333333,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
1.216666667,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
1.216666667,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
1.225,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
1.233333333,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
1.233333333,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
1.247944898,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
1.247944898,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
1.247944898,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
1.247944898,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
1.247944898,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
1.247944898,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
1.247944898,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
1.258333333,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
1.266666667,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
1.266666667,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
1.3,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
1.3,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
1.308333333,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
1.308333333,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
1.308333333,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
1.321720258,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
1.321720258,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
1.321720258,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
1.321720258,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
1.321720258,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
1.321720258,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
1.325,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
1.325,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
1.333333333,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
1.358333333,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
1.358333333,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
1.358333333,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
1.370201209,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
1.370201209,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
1.375,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
1.383333333,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
1.383333333,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
1.383333333,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
1.391666667,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
1.391666667,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
1.4,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
1.416666667,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
1.416666667,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
1.416666667,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
1.425,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
1.45,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
1.45,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
1.475,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
1.491666667,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
1.5,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
1.5,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
1.5,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
1.55,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
1.55,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
1.55,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
1.55,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
1.575,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
1.575,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
1.575,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
1.575,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
1.583333333,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
1.583333333,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
1.583333333,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
1.608333333,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
1.641666667,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
1.641666667,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
1.641666667,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
1.666666667,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
1.675,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
1.675,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
1.7,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
1.7,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
1.708333333,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
1.783333333,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
1.783333333,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
1.791666667,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
1.808333333,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
1.841666667,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
1.866666667,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
1.875,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
1.875,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
1.941666667,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
1.941666667,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
1.983333333,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
1.984995875,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
1.984995875,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
1.984995875,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
2.066666667,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
2.075,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
2.116666667,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
2.158333333,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
2.233333333,1,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
0.020017697,0,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
0.054166667,0,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
0.0875,0,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
0.1125,0,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
0.1375,0,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
0.170833334,0,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
0.195833334,0,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
0.229881644,0,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
0.254166667,0,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
0.279424363,0,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
0.3125,0,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
0.3375,0,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
0.370833334,0,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
0.395833334,0,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
0.420833334,0,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
0.454166667,0,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
0.479166667,0,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
0.754166667,0,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
1.054166667,0,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
1.104166667,0,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
1.154166667,0,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
1.204166667,0,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
1.254166667,0,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
1.304166667,0,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
1.354166667,0,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
1.404166667,0,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
1.454166667,0,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
1.529166667,0,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
1.545833334,0,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
1.5625,0,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
1.579166667,0,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
1.595833334,0,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
1.6125,0,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
1.629166667,0,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
1.645833334,0,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
1.6625,0,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
1.679166667,0,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
1.695833334,0,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
1.7125,0,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
1.729166667,0,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
1.745833334,0,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
1.7625,0,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
1.779166667,0,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
1.795833334,0,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
1.8125,0,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
1.829166667,0,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
1.845833334,0,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
1.8625,0,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
1.879166667,0,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
1.904166667,0,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
1.920833334,0,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
1.9375,0,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
1.954166667,0,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
1.970833334,0,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
1.988331271,0,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
2.029166667,0,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
2.054166667,0,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
2.0875,0,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
2.1125,0,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
2.1375,0,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
2.170833334,0,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
2.195833334,0,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
2.220833334,0,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
2.254166667,0,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
2.279166667,0,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
2.304166667,0,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
2.3375,0,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
2.3625,0,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
2.3875,0,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
2.420833334,0,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
2.445833334,0,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
2.470833334,0,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
2.501423394,0,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
2.501423394,0,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
2.501423394,0,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
2.501423394,0,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
2.501423394,0,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
2.501423394,0,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
2.501423394,0,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
2.501423394,0,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
2.501423394,0,TROPIC,Mitoxantrone,Bahl 2012,TROPIC (Bahl 2012) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-Bah
0.033143215,1,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
0.041383815,1,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
0.041383815,1,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
0.041383815,1,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
0.05,1,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
0.058333333,1,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
0.058333333,1,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
0.075,1,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
0.075,1,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
0.116666667,1,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
0.125,1,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
0.125,1,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
0.158333333,1,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
0.216666667,1,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
0.225,1,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
0.233333333,1,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
0.241666667,1,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
0.25,1,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
0.258333333,1,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
0.275,1,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
0.3,1,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
0.3,1,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
0.308333333,1,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
0.308333333,1,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
0.316666667,1,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
0.325,1,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
0.333333333,1,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
0.333333333,1,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
0.333333333,1,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
0.341666667,1,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
0.358333333,1,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
0.358333333,1,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
0.383333333,1,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
0.391666667,1,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
0.4,1,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
0.4,1,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
0.408333333,1,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
0.416666667,1,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
0.416666667,1,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
0.425,1,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
0.425,1,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
0.433333333,1,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
0.45,1,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
0.466666667,1,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
0.466666667,1,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
0.466666667,1,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
0.475,1,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
0.475,1,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
0.475,1,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
0.475,1,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
0.483333333,1,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
0.483333333,1,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
0.508333333,1,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
0.508333333,1,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
0.508333333,1,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
0.508333333,1,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
0.516666667,1,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
0.533333333,1,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
0.541666667,1,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
0.541666667,1,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
0.55,1,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
0.558333333,1,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
0.575,1,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
0.583333333,1,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
0.591666667,1,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
0.591666667,1,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
0.6,1,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
0.608333333,1,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
0.616666667,1,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
0.633333333,1,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
0.641666667,1,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
0.641666667,1,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
0.65,1,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
0.65,1,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
0.65,1,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
0.658333333,1,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
0.675,1,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
0.675,1,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
0.675,1,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
0.683333333,1,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
0.683333333,1,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
0.7,1,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
0.7,1,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
0.708333333,1,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
0.708333333,1,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
0.716666667,1,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
0.725,1,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
0.733333333,1,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
0.75,1,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
0.766666667,1,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
0.766666667,1,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
0.775,1,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
0.775,1,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
0.775,1,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
0.783333333,1,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
0.783333333,1,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
0.783333333,1,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
0.791666667,1,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
0.791666667,1,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
0.808333333,1,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
0.808333333,1,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
0.825,1,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
0.841666667,1,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
0.841666667,1,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
0.85,1,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
0.85,1,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
0.866666667,1,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
0.866666667,1,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
0.875,1,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
0.875,1,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
0.883333333,1,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
0.891666667,1,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
0.908333333,1,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
0.925,1,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
0.925,1,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
0.933333333,1,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
0.933333333,1,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
0.933333333,1,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
0.933333333,1,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
0.933333333,1,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
0.933333333,1,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
0.941666667,1,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
0.95,1,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
0.958333333,1,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
0.958333333,1,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
0.975,1,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
0.975,1,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
0.975,1,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
0.983333333,1,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
0.991666667,1,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
0.991666667,1,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
0.991666667,1,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
1.008333333,1,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
1.016666667,1,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
1.016666667,1,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
1.025,1,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
1.025,1,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
1.041666667,1,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
1.041666667,1,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
1.041666667,1,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
1.05,1,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
1.058333333,1,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
1.066666667,1,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
1.066666667,1,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
1.091666667,1,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
1.091666667,1,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
1.091666667,1,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
1.1,1,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
1.108333333,1,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
1.108333333,1,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
1.125,1,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
1.125,1,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
1.141666667,1,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
1.141666667,1,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
1.15,1,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
1.15,1,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
1.158333333,1,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
1.158333333,1,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
1.158333333,1,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
1.166666667,1,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
1.175,1,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
1.175,1,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
1.183333333,1,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
1.191666667,1,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
1.191666667,1,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
1.191666667,1,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
1.191666667,1,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
1.191666667,1,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
1.2,1,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
1.2,1,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
1.2,1,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
1.208333333,1,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
1.216666667,1,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
1.225,1,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
1.225,1,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
1.233333333,1,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
1.25,1,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
1.258333333,1,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
1.266666667,1,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
1.266666667,1,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
1.275,1,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
1.275,1,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
1.275,1,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
1.283333333,1,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
1.283333333,1,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
1.3,1,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
1.3,1,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
1.308333333,1,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
1.308333333,1,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
1.316666667,1,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
1.316666667,1,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
1.35,1,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
1.35,1,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
1.358333333,1,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
1.375,1,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
1.383333333,1,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
1.387088556,1,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
1.387088556,1,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
1.387088556,1,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
1.4,1,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
1.408333333,1,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
1.416666667,1,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
1.433333333,1,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
1.45,1,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
1.45,1,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
1.466666667,1,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
1.491666667,1,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
1.5,1,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
1.516666667,1,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
1.525,1,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
1.525,1,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
1.533333333,1,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
1.55,1,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
1.566666667,1,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
1.591666667,1,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
1.6,1,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
1.641666667,1,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
1.683333333,1,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
1.7,1,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
1.716666667,1,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
1.716666667,1,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
1.75,1,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
1.875,1,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
1.9,1,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
1.916666667,1,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
1.958333333,1,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
2.077381789,1,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
2.082305703,1,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
2.37622043,1,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
2.383333333,1,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
2.389954763,1,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
2.472360762,1,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
0.0875,0,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
0.170833334,0,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
0.254166667,0,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
0.3375,0,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
0.420833334,0,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
0.554166667,0,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
0.595833334,0,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
0.645833334,0,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
0.6875,0,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
0.7375,0,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
0.779166667,0,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
0.829166667,0,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
0.870833334,0,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
0.920833334,0,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
0.9625,0,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
1.0125,0,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
1.020833334,0,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
1.029166667,0,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
1.0375,0,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
1.045833334,0,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
1.054166667,0,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
1.0625,0,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
1.070833334,0,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
1.079166667,0,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
1.0875,0,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
1.0875,0,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
1.095833334,0,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
1.104166667,0,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
1.1125,0,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
1.120833334,0,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
1.129166667,0,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
1.1375,0,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
1.145833334,0,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
1.154166667,0,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
1.1625,0,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
1.170833334,0,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
1.170833334,0,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
1.179166667,0,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
1.1875,0,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
1.195833334,0,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
1.204166667,0,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
1.2125,0,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
1.220833334,0,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
1.229166667,0,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
1.2375,0,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
1.245833334,0,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
1.254166667,0,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
1.254166667,0,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
1.2625,0,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
1.270833334,0,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
1.279166667,0,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
1.2875,0,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
1.295833334,0,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
1.304166667,0,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
1.3125,0,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
1.320833334,0,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
1.329166667,0,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
1.3375,0,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
1.3375,0,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
1.345833334,0,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
1.354166667,0,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
1.3625,0,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
1.370833334,0,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
1.379166667,0,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
1.393544278,0,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
1.393544278,0,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
1.404166667,0,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
1.4125,0,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
1.420833334,0,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
1.420833334,0,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
1.429166667,0,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
1.4375,0,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
1.445833334,0,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
1.454166667,0,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
1.4625,0,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
1.470833334,0,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
1.479166667,0,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
1.4875,0,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
1.495833334,0,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
1.504166667,0,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
1.520833334,0,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
1.529166667,0,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
1.5375,0,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
1.554166667,0,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
1.5625,0,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
1.570833334,0,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
1.5875,0,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
1.595833334,0,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
1.604166667,0,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
1.620833334,0,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
1.629166667,0,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
1.6375,0,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
1.654166667,0,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
1.6625,0,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
1.670833334,0,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
1.679166667,0,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
1.695833334,0,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
1.704166667,0,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
1.7125,0,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
1.729166667,0,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
1.7375,0,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
1.745833334,0,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
1.7625,0,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
1.770833334,0,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
1.779166667,0,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
1.795833334,0,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
1.804166667,0,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
1.8125,0,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
1.829166667,0,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
1.8375,0,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
1.845833334,0,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
1.854166667,0,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
1.870833334,0,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
1.879166667,0,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
1.8875,0,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
1.904166667,0,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
1.9125,0,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
1.920833334,0,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
1.9375,0,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
1.945833334,0,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
1.954166667,0,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
1.970833334,0,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
1.979166667,0,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
1.9875,0,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
2.029166667,0,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
2.054166667,0,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
2.080474459,0,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
2.104166667,0,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
2.129166667,0,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
2.154166667,0,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
2.1875,0,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
2.2125,0,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
2.2375,0,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
2.2625,0,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
2.2875,0,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
2.3125,0,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
2.345833334,0,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
2.370833334,0,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
2.395833334,0,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
2.420833334,0,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
2.445833334,0,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
2.474138192,0,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
2.5,0,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
2.5,0,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
2.5,0,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
2.5,0,TROPIC,Cabazitaxel,de Bono 2010,TROPIC (de Bono 2010) - Cabazitaxel,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Cab-de 
0.016666667,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
0.016666667,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
0.075,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
0.091666667,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
0.116666667,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
0.158333333,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
0.175,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
0.183333333,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
0.183333333,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
0.191666667,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
0.191666667,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
0.2,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
0.216666667,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
0.216666667,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
0.225,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
0.241666667,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
0.266666667,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
0.266666667,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
0.266666667,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
0.266666667,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
0.266666667,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
0.275,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
0.283333333,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
0.283333333,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
0.283333333,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
0.291666667,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
0.291666667,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
0.291666667,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
0.291666667,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
0.308333333,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
0.316666667,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
0.316666667,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
0.325,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
0.333333333,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
0.333333333,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
0.341666667,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
0.341666667,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
0.35,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
0.358333333,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
0.366666667,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
0.366666667,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
0.375,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
0.375,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
0.375,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
0.383333333,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
0.383333333,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
0.383333333,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
0.391666667,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
0.4,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
0.408333333,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
0.408333333,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
0.416666667,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
0.433333333,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
0.433333333,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
0.433333333,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
0.441666667,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
0.441666667,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
0.441666667,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
0.45,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
0.458333333,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
0.458333333,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
0.458333333,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
0.475,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
0.475,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
0.483333333,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
0.483333333,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
0.483333333,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
0.483333333,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
0.491666667,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
0.5,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
0.5,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
0.5,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
0.5,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
0.5,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
0.525,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
0.525,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
0.533333333,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
0.533333333,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
0.533333333,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
0.533333333,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
0.566666667,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
0.566666667,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
0.566666667,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
0.575,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
0.575,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
0.583333333,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
0.583333333,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
0.591666667,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
0.591666667,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
0.591666667,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
0.591666667,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
0.6,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
0.6,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
0.608333333,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
0.616666667,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
0.616666667,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
0.625,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
0.625,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
0.633333333,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
0.633333333,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
0.633333333,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
0.633333333,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
0.641666667,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
0.65,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
0.65,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
0.658333333,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
0.666666667,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
0.675,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
0.675,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
0.691666667,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
0.7,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
0.7,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
0.708333333,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
0.708333333,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
0.708333333,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
0.716666667,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
0.725,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
0.725,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
0.725,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
0.725,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
0.733333333,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
0.733333333,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
0.75,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
0.75,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
0.758333333,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
0.758333333,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
0.758333333,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
0.766666667,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
0.766666667,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
0.775,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
0.775,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
0.775,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
0.775,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
0.783333333,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
0.783333333,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
0.783333333,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
0.783333333,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
0.791666667,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
0.816666667,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
0.825,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
0.825,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
0.833333333,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
0.841666667,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
0.841666667,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
0.85,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
0.85,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
0.85,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
0.85,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
0.858333333,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
0.858333333,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
0.866666667,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
0.875,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
0.875,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
0.883333333,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
0.891666667,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
0.891666667,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
0.9,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
0.908333333,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
0.908333333,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
0.933333333,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
0.941666667,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
0.95,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
0.95,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
0.958333333,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
0.975,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
0.983333333,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
0.983333333,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
0.983333333,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
0.991666667,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
0.991666667,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
0.991666667,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
0.991666667,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
1.016666667,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
1.016666667,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
1.016666667,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
1.025,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
1.025,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
1.033333333,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
1.033333333,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
1.041666667,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
1.05,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
1.058333333,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
1.066666667,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
1.066666667,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
1.066666667,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
1.075,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
1.083333333,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
1.083333333,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
1.091666667,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
1.091666667,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
1.1,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
1.108333333,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
1.116666667,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
1.125,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
1.133333333,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
1.133333333,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
1.133333333,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
1.141666667,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
1.141666667,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
1.141666667,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
1.158333333,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
1.158333333,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
1.166666667,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
1.166666667,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
1.166666667,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
1.175,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
1.183333333,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
1.191666667,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
1.2,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
1.2,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
1.208333333,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
1.216666667,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
1.225,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
1.225,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
1.225,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
1.233333333,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
1.25,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
1.258333333,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
1.258333333,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
1.266666667,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
1.275,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
1.283333333,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
1.283333333,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
1.291666667,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
1.291666667,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
1.291666667,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
1.3,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
1.308333333,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
1.308333333,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
1.316666667,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
1.316666667,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
1.333333333,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
1.333333333,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
1.333333333,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
1.333333333,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
1.341666667,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
1.358333333,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
1.358333333,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
1.366666667,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
1.366666667,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
1.375,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
1.383333333,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
1.425,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
1.433333333,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
1.441666667,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
1.458333333,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
1.466666667,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
1.475,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
1.491666667,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
1.5,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
1.516666667,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
1.533333333,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
1.541666667,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
1.558333333,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
1.566666667,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
1.566666667,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
1.575,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
1.583333333,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
1.583333333,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
1.625,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
1.625,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
1.625,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
1.633333333,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
1.65,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
1.675,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
1.7,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
1.758333333,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
1.766666667,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
1.825,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
1.85,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
1.875,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
1.891666667,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
1.916666667,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
1.958333333,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
1.958333333,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
1.966666667,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
2.008333333,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
2.25,1,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
0.129166667,0,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
0.254166667,0,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
0.379166667,0,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
0.5375,0,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
0.570833334,0,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
0.604166667,0,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
0.6375,0,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
0.670833334,0,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
0.704166667,0,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
0.7375,0,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
0.770833334,0,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
0.804166667,0,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
0.8375,0,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
0.870833334,0,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
0.904166667,0,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
0.9375,0,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
0.970833334,0,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
1.020833334,0,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
1.029166667,0,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
1.045833334,0,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
1.054166667,0,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
1.0625,0,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
1.079166667,0,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
1.0875,0,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
1.095833334,0,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
1.1125,0,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
1.120833334,0,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
1.129166667,0,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
1.145833334,0,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
1.154166667,0,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
1.170833334,0,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
1.179166667,0,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
1.1875,0,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
1.204166667,0,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
1.2125,0,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
1.220833334,0,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
1.2375,0,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
1.245833334,0,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
1.254166667,0,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
1.270833334,0,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
1.279166667,0,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
1.295833334,0,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
1.304166667,0,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
1.3125,0,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
1.329166667,0,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
1.3375,0,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
1.345833334,0,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
1.3625,0,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
1.370833334,0,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
1.379166667,0,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
1.395833334,0,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
1.404166667,0,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
1.420833334,0,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
1.429166667,0,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
1.4375,0,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
1.454166667,0,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
1.4625,0,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
1.470833334,0,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
1.4875,0,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
1.495833334,0,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
1.520833334,0,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
1.5375,0,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
1.554166667,0,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
1.570833334,0,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
1.5875,0,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
1.604166667,0,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
1.620833334,0,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
1.6375,0,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
1.654166667,0,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
1.670833334,0,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
1.679166667,0,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
1.695833334,0,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
1.7125,0,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
1.729166667,0,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
1.745833334,0,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
1.7625,0,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
1.779166667,0,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
1.795833334,0,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
1.8125,0,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
1.829166667,0,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
1.8375,0,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
1.854166667,0,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
1.870833334,0,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
1.8875,0,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
1.904166667,0,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
1.920833334,0,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
1.9375,0,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
1.954166667,0,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
1.970833334,0,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
1.9875,0,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
2.054166667,0,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
2.1125,0,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
2.1625,0,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
2.220833334,0,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
2.279166667,0,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
2.329166667,0,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
2.3875,0,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
2.445833334,0,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
2.5,0,TROPIC,Mitoxantrone,de Bono 2010,TROPIC (de Bono 2010) - Mitoxantrone,castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,TRO-Mit-de 
